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Abstract 
 
Cyclopropanes and carbohydrates have long been used in the field of drug 
development. Previous work has shown that 1,2-cyclopropyl carbohydrates display 
bioactivity in both HeLa cancer cell lines1 and in yeast2 with a tentatively proposed 
mechanism of inhibition occurring through an enzymatic cyclopropane ring opening 
reaction and subsequent formation of a covalent bond with a target enzyme.2 
 
A small library of 1,2-cyclopropyl carbohydrate derivatives were synthesised based 
on known pharmacophores to examine further the potential mechanism of inhibition 
of such compounds and confirm the occurrence of enzyme-catalysed cyclopropane 
ring-opening reactions. Initial synthetic efforts were focused on the synthesis of the 
1,2-dichlorocyclopropyl carbohydrate 23, which, through the optimisation of an 
essential C-6 detritylation reaction, was achieved in moderate yields of 32% over 7 
steps. Following this, the ethoxycarbonyl substituted 1,2-cyclopropyl carbohydrate 54 
was synthesised over 7 steps in a 22% yield through a rhodium acetate-catalysed 
addition of ethyl diazoacetate (49) to the glucal substrate 40. It was envisioned that if 
enzymatic cyclopropane ring-opening was occurring to form a C-7 carbanion, this 
would in turn be stabilised through the potential enolate formation of 54. Use of N,N-
ditosylhydrazine in the synthesis of propargyl diazoacetate (58) followed by a 
rhodium acetate-catalysed cyclopropanation of 58 with substrate 40 resulted in the 
successful synthesis of 61 over 7 steps in a total yield of 9%. The incorporation of the 
propargyl substituent in 61 was introduced as a molecular probe in an attempt to 
isolate the target protein through an affinity purification procedure. The bioactivity of 
the propargyl derivative 61 was consistent with the synthesised compounds 23 and 54. 
It was proposed that these compounds undergo an enzymatic cyclopropane 
ring-opening reaction accompanied with a clear diastereoselective preference for the 
α-stereoisomer of the cyclopropane ring, consistent with a target-based activation of 
the compounds. 
 
Chemical genetic analysis of the resulting bioactive compounds was undertaken using 
a deletion mutant array of Saccharomyces cerevisiae to elucidate a potential 
mechanism of action. Analysis of the results showed that, of the 4800 homozygous 
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deletion strains tested in the high-throughput screens, a total of 122 strains were found 
following validation to sensitise and 68 to give resistance against 23 and 54. These 
sensitive and resistant mutants were subjected to a validation assay. Following 
validation, genes whose deletion led to sensitivity or resistance were then subjected to 
gene ontology term enrichment analysis which showed enrichment in the cytosolic 
ribosome, SNARE complex and SNAP receptor activity for resistant strains and 
enrichment in endoplasmic reticulum and endomembrane systems was found for the 
sensitive strain. Genes whose deletion sensitised to both compounds showed strong 
enrichment in cellular protein localisation, intra-golgi vesicale-mediated transport and 
the endomembrane system.  
 
Target identification and isolation were attempted through an affinity purification 
procedure using compound 61 and an azide-modified agarose resin. However, this 
was without success, either through inaccessibility of the alkyne of the target probe or 
because the target resides in the membrane-associated fraction which was discarded 
prior to treatment with the probe.  
 
This study suggests that the 1,2-cyclopropyl carbohydrates synthesised function 
through a cyclopropane ring-opening reaction, assisted by an enzymatic nucleophile. 
Chemical genetic analysis showed that the target of these compounds is involved in 
protein transport and protein localisation most likely relating to the vesicle tethering. 
Although many aspects of this work still need further investigation, either through the 
synthesis of new 1,2-cyclopropyl carbohydrates to increase bioactivity and better 
understand the enzymatic target, or through further biological procedures to better 
understand the mechanism of action, the use of 1,2-cyclopropyl carbohydrates as a 
potential pharmaceuticals or probes of protein trafficking shows much promise.  
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Chapter 1 
Introduction 
 
Carbohydrates and cyclopropanes have long been used in the field of pharmacology 
for their respective reactivity and structural properties. The high stereochemical 
information contained within carbohydrates and their ability to mimic the structure 
and function of naturally occurring compounds have made them powerful tools in 
drug design. Organic chemists have also utilised the ability of cyclopropanes to 
undergo ring-opening and ring-expansion reactions.3 These investigations have raised 
the question as to whether cyclopropyl carbohydrates can mimic natural compounds 
and undergo such reactions via enzymatic processes within cells, which could 
potentially lead to the discovery of a new covalent bioactive compound.2 
 
This thesis aims to explore these ideas through the synthesis of a variety of potentially 
bioactive 1,2-cyclopropyl carbohydrate structures. A small library of compounds will 
be synthesised to undergo both yeast and mammalian cell assays where they will be 
screened for potential bioactivity. Bioactive compounds will then be subjected to both 
chemical and genetic techniques in order to identify the molecular target and elucidate 
their mechanism of action. This will be achieved through the synthesis of a molecular 
probe to bind any potential targets to an affinity purification resin and through 
chemical genetic analysis utilising activity screening against yeast deletion set.  
 
1.1  History of drug discovery 
 
The modern era of drug research and drug development as we know it dates back 
more than a century, when chemical concepts and principles were applied to problems 
outside the field of chemistry. This application began around the mid-19th century 
when the periodic table had been established and the atomic hypothesis proposed by 
Avogadro had been confirmed.4 The development of the modern field of 
chemotherapeutics coincided with the industrial revolution and the move from 
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biofuels to coal and tar. The use of these new fuels created sizable quantities of by-
products that were found to contain large amounts of aromatic and aliphatic 
compounds. The discovery of the aromatic and aliphatic compounds and their use as 
dyes in the mid-19th century prompted chemist, Paul Ehrlich, to investigate their 
affinity with biological tissue. From his work, he postulated the existence of chemo-
receptors, and that pathogens contained chemo-receptors with slight structural 
variation to our own, allowing therapeutic exploitation of these sites.4 This became 
the basis of medicinal chemistry and the birth of modern chemotherapeutics.  
 
Comparatively, the use of plants as herbal medicine far outdates that of medicinal 
chemistry. The use of plants in traditional Chinese and North American medicine is 
an ancient practice that is still used currently. Additionally, the isolation and 
purification of the active compounds from traditional plant-based remedies have also 
played a role in the advancement of medicinal chemistry in the 19th century. 
Morphine was first isolated from Papaver somniferum, a species of opium poppy 
plants, in 1815 by F. W. Sertürner.4,5,6 The discovery of morphine and its medicinal 
properties led to an increased pharmaceutical interest in the field of natural products, 
resulting in the discovery of many more natural bioactive products such as paclitaxel 
(Taxol), a commonly used anticancer drug.7 Later in the 20th century, the accidental 
contamination of an agar plate containing Staphylococcus variants with a white fluffy 
mould led to the discovery of the natural product penicillin by Alexander Fleming 
which greatly influenced the field of medicinal chemistry.6 Penicillin was found to be 
a very effective antibiotic and quickly became the most widely used antibiotic due to 
its lack of toxicity and high efficacy. This led the way to a new era of antibiotics, with 
the majority of pharmaceutical companies establishing microbiology and fermentation 
departments in the hope of discovering similar natural products.4  
 
1.2  Approaches to drug design 
 
The processes of drug design have come a long way since the major findings of both 
Paul Ehrlich and Alexander Fleming. Several new approaches have been developed 
which are more systematic rather than serendipitous, although a certain element of 
serendipity still remains. These new approaches have been made possible due to the 
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corresponding advancements made in many other aspects of biological, physical and 
chemical sciences. The most notable approaches to drug design can be split into three 
categories.  
 
1.2.1 Structure-based drug design 
 
As the name implies, structure-based drug design relies on the 3D structural 
knowledge of the biological target. This method of drug design had been very limited 
until the early 1990s when technological advancements were made in the fields of X-
ray crystallography, homology modelling and nuclear magnetic resonance (NMR) 
spectroscopy, providing methods to better determine the structure of the biological 
targets.8 In 1990, Roberts and colleagues9 released the first publication utilising 
structure-based drug design in the synthesis of small peptide-derived molecules that 
mimicked the protease activity of the human immunodeficiency virus (HIV). Once a 
biological target is found and its structure is elucidated, compounds and fragments in 
a computer data system are typically screened against the target in the search for the 
best fitting compound, which utilises as many non-covalent interactions as possible. 
Based on the steric and electronic effects, the compounds of best fit are then 
synthesised and tested against the target to determine their IC50 concentrations. The 
lead compounds are normally altered in attempts to heighten their potency by 
increasing the amount of interactions they can establish.10 Identifying a biological 
target can be the most difficult and lengthy process, as extensive research must be 
carried out to confirm that the target is involved in the pathophysiology of the 
disease.10  
 
1.2.2 Ligand-based drug design 
 
The second method of drug design, ligand-based design, is most commonly employed 
when the 3D structure of the biological target remains unknown. Ligand-based drug 
design, also known as indirect drug design, relies on the structural knowledge of the 
compound that produces a desired pharmacological response. This allows for 
subsequent chemical modification of the lead compound, which will establish the 
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pharmacophores necessary for the molecular recognition of both the active compound 
and the biological target.11 This is primarily achieved in two ways: structure-activity 
relationship (SAR) assays and quantitative structure-activity relationship (QSAR) 
assays.  
 
SAR assays involve small chemical modifications of the lead compound in an attempt 
to better utilise the steric and electronic interactions within the biological binding site. 
This in turn can have both positive and negative effects on the affinity of the 
compound with the biological binding site. If the structural changes to the ligand 
cause undesirable steric and/or electronic effects, a decrease in binding affinity will 
result which will be marked by a reduced potency of the compound (higher IC50). The 
opposite is true for favourable steric and electronic interactions, leading to a higher 
binding affinity and in turn a lower IC50.12 Knowing both the favourable and 
unfavourable interactions paints a picture of the shape and electronic effects within 
the binding pocket.  
 
QSAR is similar to SAR assays, though it involves a computational method that finds 
a quantitative relationship between steric and electronic features of structurally related 
compounds and their biological activity.13 Pharmacophores are identified in a small 
library of molecules and correlations between the pharmacophores and the biological 
activity are calculated which then allow for the prediction of the bioactivity of 
untested compounds, inevitably directing future synthesis. However, for QSAR to be 
effective, a large amount of structural information is required on previously known 
molecules that activate the targeted binding site.12,14 
 
1.2.3 Mechanism-based drug design 
 
The term mechanism-based refers to the process of an enzyme catalysing its own 
inactivation.15 This typically occurs through an addition reaction, where an active 
nucleophilic residue located within the enzyme’s binding site attacks an electrophilic 
centre on an inhibitor compound,16 forming a covalent bond.16,17,18 Mechanism-based 
drug design is therefore the design of a drug that will utilise the enzyme’s catalytic 
mechanism to inactivate itself.19 Mechanism-based drug design can be approached in 
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two manners: when the biological targets structure is known, much like structure-
based drug design, or when the structural information about the target remains 
unknown.  
 
The first approach is the synthesis of a covalently binding drug through prior 
structural knowledge of the target binding site, similar to structure-based drug design. 
For example, a study conducted by Vavricka and colleagues20 examined the 
possibilities of designing covalent inhibitors to target the influenza virus based on the 
knowledge of the active site of the viral neuraminidase (NA) enzyme. They found that 
the active site of the NA in influenza shared very few similarities with other 
organisms. Previous research indicated that a conserved tyrosine residue (Tyr406) 
within the NA active site could play an important role in the influenza NA 
mechanism.20 Using a fluorescence-based kinetic analysis of wild type influenza and 
Tyr406-deficient strains, Vavricka and colleagues showed a hundred-fold reduction in 
kcat (catalytic constant of the conversion from a substrate to a product21) indicating 
that Tyr406 is essential for the catalytic activity in influenza NA. Based on this, they 
hypothesised that Tyr406 was acting as a catalytic nucleophile and would be able to 
initiate a nucleophilic attack of a covalent inhibitor. Using previous knowledge that 
influenza NA is a glycosidase, Vavricka and colleagues utilised structural and 
mechanism-based knowledge to develop 2α,3ax-difluoro-Neu5Ac (1) as a 
carbohydrate-derived covalent inhibitor of influenza NA as shown in scheme 1.1.20 It 
was envisaged that in order for 1 to undergo a nucleophilic attack at the anomeric 
carbon within the influenza NA enzyme, there needed to be several essential 
structural characteristics of the ligand. Firstly, a good leaving group is required at the 
C-2 position and a highly electronegative group at the C-3 position to prevent the 
formation of a potential oxocarbenium ion transition state. From the structural 
analysis of the binding pocket, it was also proposed that the leaving group should 
ideally be in the α-position and therefore facing the outside of the binding pocket, 
allowing it to leave more readily.20 This led to a dramatic increase in potency of 1 
compared to other influenza NA inhibitors.  
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The second approach is not so well precedent. It involves prior knowledge of how the 
compound of interest would react when exposed to a nucleophile within an 
enzymatic-binding site. The expected reaction of the compounds are normally well 
understood within a chemically controlled environment. The question is then posed, 
whether it is possible to replicate these reactions within a cell through enzymatic 
activation, forming a covalent bond between the compound and the enzyme.2 This is a 
concept that will be explored throughout this thesis and covered furthered in section 
1.4.1 Cyclopropyl carbohydrates. 
 
1.3  Covalent inhibitors 
 
Covalently binding drugs have long been exploited throughout medicine for many 
different uses, from analgesics to anti-cancer agents.22 Approximately 30% of drugs 
currently on the market act through covalent interactions with their target.22 However, 
more recently, the development of covalent drugs has declined due to the perceived 
lack of selectivity and off-target reactivity, which led to consequences such as 
hepatotoxicity and neurotoxicity. These fears arose from several studies undertaken in 
the 1970’s and 80’s, which reported that chemically inert drugs were metabolised to 
form reactive metabolites that covalently bound to a wide array of unrelated proteins 
 
 
Scheme 1.1: Proposed mechanism-based inhibition of influenza NA through the covalent binding 
drug 1.20 
O
HO
OH COO
F
F
OH
OH
AcHN
OH
O
O
O
H H
Tyr406
Glu277
1
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in the liver.23 The key to overcoming this problem of non-selectivity is to alter the 
drugs’ chemical and physical properties. 
  
As shown in scheme 1.2, the formation of a covalent complex with the target 
molecule occurs in two steps. Firstly a non-covalent complex is formed involving 
non-covalent interactions such as hydrogen bonds, hydrophobic interactions and van 
der Waals forces. This reversible binding positions the ligand in the correct 
orientation within the binding site. This then allows for the second step to occur, 
which is the subsequent formation of the covalent bond via attack of the ligand by the 
enzyme.  
 
 
Scheme 1.2: General mechanism for covalent binding drugs, E denotes enzyme and I denotes inhibitor. 
 
 
The selectivity of a covalently binding drug can be greatly increased by altering both 
the covalent and the non-covalent interactions. A high affinity for the enzyme’s 
binding site, which is indicated by a low dissociation constant, Ki, drives the 
formation of the non-covalent complex through utilisation of as many non-covalent 
interactions as possible. The increase in non-covalent interactions better positions the 
drug within the binding pocket, bringing the electrophile within close proximity of the 
nucleophile and increasing the residence time of the ligand within the binding pocket. 
This increased residence time in turn facilitates enzymatic nucleophilic attack. 
Increases in both the residence time and the amount of non-covalent interactions 
allow for reduced reactivity of the electrophilic covalent drug. The nucleophilic 
reaction then occurs due to the close proximity of the electrophile to the nucleophile 
rather than the presence of highly reactive moieties, thus reducing the chances of off-
E + I E I E - I
k2
k-2Ki
E I = Initial non-covalent complex
E - I = Final covalent complex
	8	
target binding and increasing the drugs selectivity.24 Therefore, selectivity is 
enhanced when the inherent reactivity of the covalent inhibitor is low, ensuring 
covalent attachment is highly dependent on the long lifetime of the E•I complex 
(scheme 1.2).  
 
1.4  Cyclopropane chemistry 
 
Cyclopropanes (C3H6) are the smallest and simplest ring structures possible, 
consisting of only three carbon atoms. From the first reported synthesis of 
cyclopropanes in 1881 by August Freund,25 to their first commercial use as an 
anesthetic for dogs,26 thousands of cyclopropanated compounds have since been 
synthesised and discovered. Due to the interesting reactivity of the three-membered 
carbocycles, cyclopropyl moieties have become an important aspect in many 
pharmaceutical compounds. So much so that, as of April 2003, there were more than 
200 patented pharmaceutical compounds containing cyclopropane functional groups 
in the literature.27 Cyclopropane-containing compounds have not only been found to 
have biological activity in humans but also in plants and microorganisms, interacting 
mainly with enzymes in enzyme-catalysed reactions.  
 
Cyclopropane ring opening is a very important reaction in many active 
pharmaceutical agents. The physical and chemical properties of the cyclopropane ring 
greatly aid in its ability to undergo ring opening reactions. As shown in figure 1.0A, 
cyclopropanes contain bond angles of 60°, which is a substantial deviation from the 
preferred tetrahedral bond angle of approximately 109°. This decreased bond angle 
greatly increases the ring strain within the cyclopropane, increasing the 
cyclopropane’s potential energy and providing the driving force of ring opening 
reactions.28 Additionally, the bonds within the molecule are bent. Although molecular 
orbital theory describes the cyclopropane’s bonds as sp3-hybridised, drastic deviation 
away from the ideal tetrahedral angle results in bent bonds leading to an increased 
degree of p character29 (figure 1.0B), and consequently increased reactivity. 
Cyclopropanes also have a high torsional strain due to the eclipsing interactions of 
vicinal substituents. The combination of both the high ring and torsional strain results 
in the ability of the cyclopropane to easily undergo ring opening reactions.  
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Cyclopropane moieties are often added as substituents to compounds, which due to 
their p-like characteristics provides an electrophilic centre, which can be subjected to 
nucleophilic attack resulting in ring opening or expansion reactions and the formation 
of a covalent bond. This can lead to irreversible attachment of the nucleophile to the 
original cyclopropane-containing compound.  
 
Inhibition of dihydrofolate reductase (DHFR) by a pyrimidine (scheme 1.3) occurs in 
this manner.30 Through a combination of both structure-based and mechanism-based 
drug design, Haddow and colleagues30 proposed that the mechanism of action of 
DHFR occurred through a proton transfer from an aspartatic acid residue to 
dihydrofolate within the active site of the enzyme. From this, they hypothesised that 
the proton transfer from the aspartatic acid residue could activate a cyclopropyl 
substituent on pyrimidine (2) initiating a nucleophilic attack on the cyclopropane 
moieties from the enzymatic nucleophile. This in turn would cause a ring opening 
reaction to occur and, simultaneously, the formation of a covalent bond leading to the 
inhibition of the enzyme.30 This study showed the first mechanism-based approach to 
the development of DHFR inhibitors.30  
 
Figure 1.0: (A) Cyclopropane showing bond angle at 60°, (B) Molecular orbitals of cyclopropane 
showing bent bonds. 
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However, not all bioactive cyclopropyl compounds go through either a ring-opening 
or ring-expansion reaction to have an effect. Cyclopropanes have been used to 
constitute novel rigidity to oligopeptide ligands in order to mimic peptide secondary 
structures, increasing their binding affinity for the enzymes active site, in attempts to 
outcompete the natural peptide. Although pseudopeptides are commonly designed to 
mimic the turns and helices of peptides, Martain and colleagues31 aimed to 
incorporate cyclopropanes into an oligopeptide in order to rigidify the structure into a 
locked β-strand conformation, which was known to be an essential characteristic for 
the activation of HIV-1 proteases (figure 1.1). Following the synthesis of compounds 
6 and 7 it was reported that when the substituents on the cyclopropane were in the 
trans position, this caused locking of the Φ angle (angle corresponding to the N-Cα on 
the unmodified peptide backbone 5) at approximately -120° resulting in the locked β-
strand conformation. Although the conformation of 6 was only determined in solution 
it was reported as almost identical to the conformation of 7 of which Martain and 
colleagues31 were able to get an X-ray crystal structure of the ligand (7) within the 
HIV-1 protease binding site. This indicated that the preferred structural conformation 
 
Scheme 1.3: Inhibition of DHFR via a ring-opening mechanism of a spirocyclopropane-containing 
pyrimidine.30 
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of these compounds in solution closely matches that of the conformation needed in 
the enzyme’s active site.32 Both compounds 6 and 7 were found to be bioactive in the 
low nanomolar range, indicating potent inhibition of the HIV-1 protease. Therefore, 
Martain and colleagues31 results show compelling evidence that the trans-substituted 
cyclopropanes introduced into the oliopeptide are able to rigidify the structure locking 
it into a β-strand conformation.  
 
 
 
1.4.1 Cyclopropyl carbohydrates 
 
Carbohydrates are polyhydroxylated compounds with numerous chiral centres, which 
have made them an area of great interest in organic chemistry, with the synthesis of 
novel carbohydrate derivatives being used in different scientific disciplines such as 
glycobiology, glycomics and chemical synthesis. Cyclopropanes are commonly 
incorporated into carbohydrates through their installment at the 1,2-position of the 
sugar. The synthesis of 1,2-cyclopropyl carbohydrates commonly results from the 
addition of a carbene to a glucal. Though several protected glucals are commercially 
available, it is also possible to synthesise them from their corresponding parent 
sugars. The combination of both cyclopropanes and carbohydrates provides an 
 
Figure 1.1: Trans substituents on the cyclopropane provide structural rigidity locking 6 and 7 into a 
locked β-strand conformation. 
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interesting area of research, with the chemical and physical properties of 
cyclopropanes such as ring and torsional strain as well as the numerous chiral centres 
of carbohydrate molecules. For example, a lot of research has been done around 
pyranoside-based cyclopropanes in ring expansion reactions to form seven-membered 
oxepines (schemes 1.5 and 1.6).33,34,35  
 
Ring opening reactions of 1,2-cyclopropanated pyranose sugars have been 
demonstrated to form 2-C-branched pyranosides34, 36 with the proposed mechanism 
involving the selective nucleophilic addition at the anomeric position resulting in the 
formation of a carbanion, which is stabilised by the electron-withdrawing substituent 
on C-7 (scheme 1.4). Under basic conditions, C-2 deprotonation occurs, causing the 
loss of a C-7 substituent formation of the 2-C-branched pyranoside. However, this 
mechanism has only been shown to occur in the presence of electron-withdrawing 
substituents on the cyclopropane.3,35 
 
 
 
 
Scheme 1.4: A plausible mechanism for ring opening forming C-2-branched pyranosides. 
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Formation of oxepines can occur through two different pathways as shown in 
schemes 1.5 and 1.6. Ring expansion to form the oxepine readily occurs in the 
presence of a nucleophile under basic conditions or in the presence of a Lewis acid.2, 
34 Nucleophilic attack at the C-1 position, promoted by a Lewis acid or an 
electrophile, can result in the ejection of the substituent on either the C-7 position 
(scheme 1.5) or the C-3 position (scheme 1.6) depending on which position has the 
superior leaving group. Under the correct conditions, ring opening or expansion 
(schemes 1.4, 1.5 and 1.6) of 1,2-cyclopropanated sugars have characteristics 
susceptible to catalysis by enzymes. The enzyme would require a nucleophilic moiety 
and a correct spatial configuration in its binding site to accommodate the 
cyclopropanated sugar, along with the ability to stabilise a transition state during the 
subsequent reaction. Given theses properties, nucleophilic attack on the 
cyclopropanated sugar could lead to the formation of a covalent bond resulting in 
irreversible binding. Depending on the target this might then result in biological 
activity, which is the starting process of mechanism-based drug design. 
 
 
 
 
Scheme 1.5: A proposed mechanism for ring expansion through loss of a C-7 leaving group. 
 
Scheme 1.6: A proposed mechanism for ring expansion through the loss of a C-3 substituent. 
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1.5  Target identification and mechanism of action 
 
 The identification of drug targets have been made possible due to the vast 
advancements made in the research field. To this end, methods for identifying 
molecular targets can be roughly split into three groups: computational approaches, 
genetic-based approaches and biochemical approaches. Computational approaches are 
used to predict drug targets based on the chemical similarities of known inhibitors; 
genetic-based approaches utilise gene deletion and over-expression sets as a tool to 
determine pathways, which the compound may act upon;37 and biochemical 
approaches employ chemical proteomics and affinity purification methods for target 
identification.  
 
Before target identification can occur, however, the discovery of small bioactive 
compounds that are able to elicit a desired response either against a cell or organism is 
required. Whilst cytotoxicity is often perceived as an end-point, addressing the 
phenotypic response can be carried out through two processes, namely reverse 
chemical genetics or forward chemical genetics screening, respectively.38,39,40,41  
 
Developments made in the fields of biochemistry and molecular biology makes 
screening a library of compounds against specifically selected proteins a readily 
accessible method for identifying new bioactive small molecules. This is known as 
reverse chemical genetics or target-based screening. The specifically selected proteins 
are normally involved in the pathophysiology of diseases such as G-protein coupled 
receptors and kinases. However, target selection and validation can be time-
consuming processes. Selection of the target is based on its therapeutic potential and 
its accessibility in a high-throughput screen (HTS).41 When the biochemical target is 
identified, it must first be validated, typically through molecular biological 
approaches. Once validated, a library of small molecules is then screened to identify 
functional ligands that are able to induce or suppress the target’s activity. When a 
small bioactive molecule is identified, it is then introduced into a cell or organism in 
attempts to study its mechanism of action.38 However, although reverse chemical 
genetics may result in the identification of a highly specific bioactive small molecule, 
targeting a specific protein may prevent identification of potential off-target effects 
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that can arise in more complex systems as well as the activation of multiple signalling 
pathways.42 Additionally, targeting a specific protein involved in the pathophysiology 
of disease can ultimately impede the progress of drug development and discovery as it 
does not lead to the identification of new targets.40  
 
On the other hand, forward chemical genetic screening, also known as phenotype-
based screening, screens small molecules against whole cells, allowing for the 
identification of potential new and unexpected targets and multiple signalling 
pathways, unlike reverse chemical genetics, which screen against a single isolated 
protein. This process has become possible due to the recent advances made in assay 
technology and involves the direct screening of small molecules to evaluate their 
effects on biological processes.41 The budding yeast Saccharomyces cerevisiae is a 
commonly used organism in phenotype-based screening due to its extensively studied 
genetics, rapid doubling time and easy maintenance, making it an ideal organism for 
HTS. Yeasts are screened against a library of small molecules in an attempt to induce 
a phenotypic change of interest. If the targeted phenotypic change occurs, the 
bioactive molecule will be selected for further investigation. This process allows for 
the rapid identification of bioactive compounds.  
 
The development and use of forward chemical genetic screening has proved of great 
importance, with 28 of 75 first-in-class drugs being approved between 1999 – 2008 
resulting directly from phenotype-based screening compared to only 17 having been 
developed from target-based screens.39 Although forward chemical genetics allows 
for the potential discovery of new therapeutic targets, the elucidation of the molecular 
target remains one of the greatest limitations and challenges of forward chemical 
genetics. To this end, chemical proteomics methods such as affinity chromatography 
and chemical genetic analysis can be undertaken to identify the molecular target.43 
 
1.5.1 Affinity-based identification 
 
Affinity purification to identify bioactive small molecules and their targets has proved 
to be the most direct method for target identification in which whole cell extracts are 
passed through the affinity matrices and a protein target are isolated.44 For example, 
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the identification of calcineurin as a common target for both immunosuppressant’s 
FK506 and cyclosporin A39,38,45 was achieved by subjecting a whole cell lysate  to a 
FK506 and cyclospoirn A affi-gel 10 affinity matrix. Affinity purification is 
considered to be the oldest, yet most commonly used method for target 
identification.46  
 
Affinity purification is commonly achieved through one of two methods. The first 
method involves the incorporation of an affinity tag such as a fluorescent 
chromophore to the bioactive molecule, whereas the second method typically requires 
a chemical modification of the compound so it can be immobilised onto a resin. 
Resins such as agarose are commonly employed, and the bioactive compounds are 
attached via a spacing linker group. Ideally, the linker group should be long enough to 
prevent steric interactions between the resin and the target protein and be mildly 
hydrophobic therefore preventing auto-aggregation.38,46 A reactive terminal on the 
linker allows it to undergo the appropriate coupling reaction to an appropriate 
functional group of the bioactive compound (figure 1.2). Alternatively, the bioactive 
compound can be conjugated onto moieties such as biotin, which interact strongly 
with avidin, resulting in a high affinity loading of the bioactive compound onto avidin 
agarose resin.38, 39  
 
However, the modification of bioactive small molecules must be carried out carefully 
in order to avoid a reduction in the bioactivity. To this end, it is essential that, after 
derivatisation of the bioactive molecule, it retains its target-recognising properties. 
This requires some prior knowledge of the interaction with the target, which can be 
established through SAR assays. The resulting analogue must then be re-evaluated to 
ensure that biological activity or target affinity is retained.47  
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Following the installment of the bioactive compound to an affinity resin, it is then 
exposed to its target protein. This is done by passing either whole cell lysates or 
protein extracts through a column containing the immobilised compound, a process 
known as affinity pull-down (figure 1.2).41,39 This must be done under suitable 
conditions, as salts and detergents used in the cell lysate process can affect the target-
compound interaction. This is normally followed by a series of washes to remove any 
non-specifically bound proteins. Finally, the tightly bound specific target proteins are 
removed using a wash or tryptic digest which hydrolyses proteins into peptides that 
can then be identified by process such as mass spectrometry.48,47,49, 42  
 
Figure 1.2: Linker groups attached to agarose or sepharose allow for the attachment of chemically 
modified bioactive compound. Cell lysate interact with the bioactive compounds allowing for 
interaction with the target protein. Non-specific proteins are eluded and treatment of the 
agarose/sepharose matrix with tryptic digest allows isolation of the specific binding proteins.     
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1.5.2 Chemical genetics 
 
The process of target identification via genetics or genomic methods relies on the 
principle of genetic interacting pathways.41 This is most commonly done by the 
mutation of yeast genomes through deletion or over-expression of desired genes. The 
yeast genome was the first eukaryotic genome to be fully sequenced. It consists of 16 
chromosomes, with approximately 6400 open reading frames (ORFs), of which 
approximately 4800 genes are non-essential such that deletion of the gene does not 
affect the viability of the yeast under standard laboratory conditions. Antibiotic-
resistant markers and a synthetic barcode sequence have been integrated individually 
into the 4800 non-essential genes, allowing for the formation of yeast genome 
deletion sets (YGDS).50,37,51 Small bioactive molecules used in combination with 
YGDS can be used to help better understand gene activity. This is done through a 
process much like synthetic lethality. Synthetic lethality occurs when mutations of 
two non-essential genes lead to cell death, indicating the two pathways have the same 
essential end point.52 Chemical genetic analysis, however, requires the use of small 
inhibitory molecules to act as the ‘second mutation’ as shown in figure 1.3. HTS of a 
YGDS allows for the investigation of these interactions, as the small bioactive 
molecules act as modulators of gene activity. This high-throughput process is known 
as a deletion mutant array (DMA).51 Yeast that become non-viable or show a reduced 
viability will give insight to pathways and targets that are potentially involved in the 
bioactivity of the compounds.  
 
 
 
Figure 1.3: Chemical genetic approach to identifying drug pathways and interactions. Demonstrating 
the concept of chemical genetics, showing that cells are not viable with inhibition of the drug target 
and deletion of the identifiable gene. 
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1.6  Basis of this research project 
 
Initial interest began in mechanistic studies during the development of an effective 
synthetic route for the formation of oxepines. The inclusion of oxepines in numerous 
natural products and heptanoses presented these molecules as challenging synthetic 
targets. To this end, 1,2-cyclopropyl carbohydrates were chosen as substrates for the 
formation of oxepines through a cyclopropyl ring opening reaction and subsequent 
elimination of the C-3 substituent (scheme 1.5).33 However, later research by Harvey 
and colleagues utilising 1,2-dibromocyclopropyl carbohydrate for the investigation of 
synthetic routes to oxepines dervatives, noticed an unexpected ring opening reaction 
and elimination of the C-7 substituent which took place, leading to the unexpected 
synthesis of 2-C-branched pyranosides (scheme 1.4).34 These unusual and unexpected 
ring opening and expansion reactions were further examined in a mechanistic study.53 
Once these mechanisms were better understood, the question was posed whether ring 
opening and ring expansion reactions of 1,2-cyclopropyl carbohydrates could be 
enzymatically catalysed and, if so, might lead to a mechanism-based inhibition 
reaction.  
 
An initial project exploring the use of cyclopropanated glucals as covalent inhibitors 
was conducted by Dylan Davies at Victoria University of Wellington.2 He 
hypothesised that cyclopropanated sugars could undergo enzymatic ring opening or 
ring expansion reactions resulting in formation of a covalent bond between the 
cyclopropanated sugars and its target. Should the synthesised cyclopropanated glucals 
bind covalently to a target it was suggested that this would occur through one of the 
three mechanisms discussed in section 1.4.1 and shown in schemes 1.4, 1.5 and 1.6.  
 
He synthesised a compound library of 27 glucals with varying substituents at the 
carbon positions 1-7 (numbering shown in figure 1.4). Of the 27 compounds 
synthesised, 20 contained a cyclopropane, 12 contained chlorine at the R4 and/or R5 
position while six contained bromine at the same positions. Substituents in the R1, R2 
and R3 position included benzyl, acetyl, trityl, formyl as well as hydroxyl groups. The 
27 compounds were subjected to a high-throughput SAR assay to identify the most 
bioactive compounds in S. cerevisiae. The SAR assay was run against the yeast strain 
pdr1Δpdr3Δ (drug efflux pump knockout strain). Of the 27 compounds subjected to 
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this yeast strain, five were active, with only one also showing activity against the 
BY4741 wild-type strain. Structural similarities between the five bioactive 
compounds allowed for the postulation of the essential pharmacophore elements for 
this series of compounds.  
 
 
 
The SAR study indicated that the presence of a benzyl group on the R2 and R3 
positions was essential to the bioactivity of the compound. Lack of this benzyl group 
resulted in inactivity of the compounds. This indicated that nucleophilic attack of the 
C-1 carbon, resulting in ring expansion and loss of the C-3 substituent as shown in 
scheme 1.4 (section 1.4.1), was and unlikely mechanism for the bioactive compound 
synthesised by Davies as the benzyl group is a poor leaving group.  
 
It was also noted from the SAR results that the compounds containing chloride at the 
R4 and R5 positions resulted a higher bioactivity. As bromine is a substantially better 
leaving group than chlorine, this greater activity of the chlorine-containing products 
was proposed to be due to the increased ability of chlorine to stabilise an adjacent 
negative charge due to its increased electronegativity. Bickelhaupt and colleagues54 
computationally showed that α-stabilisation of a carbanion by CH2X is favoured by 
fluorine and progressively decreases for halogens of lower electronegativity. 
Therefore this would suggest that the formation of a covalent bond between the 
cyclopropanated glucals and the target was most likely to proceed by ring opening 
due to nucleophilic attack at the C-1 position resulting in the formation of a carbanion 
at the C-7 position as shown in scheme 1.5 (section 1.4.1). This negative charge will 
then be better stabilised due to the electron-withdrawing effects of the chlorine atoms. 
 
 
Figure 1.4: IUPAC numbering of carbons on both glucals and cyclopropanated carbohydrates. 
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This hypothesis will be further explored in this thesis by synthesising compounds 
with the ability to better stabilise a carbanion. Of the compounds synthesised by 
Dylan Davies, 23 was found to be the most active, shown in figure 1.5. 
 
 
Davies synthesised a derivative of 23 to act as a molecular probe in order to ascertain 
whether the target protein could be identified using chemical proteomic affinity 
purification. This was attempted via the addition of two p-azidobenzyl protecting 
groups at the R2 and R3 position with the intention of the azide moiety undergoing a 
copper-assisted azide-alkyne cycloaddition with an alkyne-substituted sepharose 
matrix. However, although he was successful in adhering this derivative to the 
column matrix, no target was obtained and later analysis indicated bioactivity of this 
product was lost. This result reconfirms the necessity for benzyl groups at the C-3 and 
C-4 position.  
 
Due to lack of target identification in the affinity purification, deletion set chemical 
genomic analysis was conducted2 in an attempt to identify a mode of action. However 
although a number of sensitive mutants were identified to 23, no enrichment through 
gene ontology (GO) analysis was found. Unusually, there were more deletion mutants 
that were resistant to the active compound than were sensitive. These resistant strains 
contained a higher percentage of genes involved in ribosomal translation. Therefore 
Davies hypothesised that 23 may affect a process that is involved in translation, 
processing of ribosomal subunits, or protein folding although the exact biological 
process remains unknown.  
 
Figure 1.5: Chemical structure of 1,5-anhydro-3,4-di-O-benzyl-1,2-C-(dichloromethylene)-D-glycero-
D-gulo-hexitol  and carbon numbering according to IUPAC. 
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1.7  Research hypothesis and objectives  
 
This thesis will further explore principles discussed in the thesis of Dylan Davies and 
extend his work done on 1,2-cyclopropyl carbohydrates.2 It will be divided into two 
sections, an organic synthesis-based section and a biology-based section. Initial aims 
of this research will explore the hypothesis that ring opening occurs through 
nucleophilic attack at the C-1 carbon, leading to the formation of a carbanion. This 
will be achieved by the synthesis of 23 and variants that contains a carboxyalkyl 
group at the C-7 position of the cyclopropanated carbohydrate (24) instead of the 
chlorines (figure 1.6). We have hypothesised that the carbonyl will allow for 
resonance stabilization through the formation of an enolate, providing carbanion 
stabilisation.55 The synthesised compounds will then be subjected to a bioactivity 
assay to see if bioactivity against S. cerevisiae is retained.  
 
 
 
 
The second aspect of this thesis will attempt to identify a mechanism of action and 
molecular target of 24a and derivatives if they prove to be bioactive. Chemical 
genetic analysis using a pdr1∆pdr3∆xxx∆ yeast deletion set library on all bioactive 
derivatives will be conducted in an attempt to identify a mechanism of action through 
enrichment via gene ontology. This deletion library contains systematic gene deletion 
mutants (denoted xxx∆) in a genetic background, which includes deletion of PDR1 
and PDR3 genes, both of which encode transcription factors for the pleiotropic drug 
resistance-related drug efflux pumps. Resistant and sensitive strains will be validated 
to ensure no false positives.   
 
Figure 1.6: The proposed structure for a new lead compound, 1,5-anhydro-3,4-di-O-benzyl-2-deoxy-
1,2-C-(exo-carbmethoxymethylene)-D-glycero-D-gulo-hexitol 
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As previous attempts to isolate a molecular target were unsuccessful through the 
addition of a molecular probe at the C-3 and C-4 position, our aim is to modify the 
carboxyl group via the addition of a propargyl group. If bioactivity is retained, cell 
lysate will be subjected to the compound and a subsequent affinity pull down by a 
copper-assisted Huisgen azide-alkyne cycloaddition.56,57 Any isolated protein will be 
identified via mass spectrometry.  
 
However, if 24 and its derivatives do not prove to be bioactive, further chemical 
genetic screening with 23 will be done in order to better identify the mode of action of 
the dichlorocyclopropane. This will include the use of yeast-based deletion and gene 
over-expression sets as well as fluorescent protein strains not used in the earlier study 
by Dylan Davies. 
 
The main objectives of this research will begin with the initial aim to reproduce work 
done by Davies2 in attempts to optimise his synthesis of 23 and produce a true 
biological replicate. This will be followed by the synthesis of carboxyalkyl 
derivatives 24. Synthesised compounds will then need to undergo a bioactivity assay 
to assess whether they have retained bioactivity. Bioactivity assays will be conducted 
on pdr1∆pdr3∆his3∆ yeast in liquid media. If bioactivity is retained within the new 
set of synthesised compounds, modification of the ester to incorporate a linker group 
(24b), allowing for, a chemical proteomic affinity pull-down therefore isolation of the 
molecular target will be undertaken. If a molecular target is isolated, analysis of the 
target will be conducted through mass spectrometry. Chemical genetic analysis using 
the pdr1∆pdr3∆xxx∆ yeast deletion set library will then be conducted on the lead 
compound and results compares to the chemical genetic screen of 23, in attempt to 
identify a mechanism of action and enrichment through GO. Analysis will look at 
both resistant and sensitive strains.  
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Chapter 2 
Chemical synthesis 
2.1 Aims and objective 
 
Aims follow those presented in chapter 1. The aims of the work presented in this 
chapter are to synthesise target compound 23, as well as the potential exploration of 
new C-6 protecting groups on this scaffold. This will be followed by the synthesis of 
1,2-cyclopropyl carboxyalkyl derivatives 54 (ethyl) and 61 (propargyl). 
Introduction 
2.2 Cyclopropane synthesis 
 
Since Simmons and Smith first reported their synthetic procedure for the preparation 
of cyclopropanes in 1959,58 many new approaches have since been developed. The 
basis of the reactions, however, which is the addition of a carbene or carbene-like 
reagent across an alkene, remains the same.59 Although reaction conditions have been 
expanded to use a range of different reagents, such as sulfur ylides, ethyl 
trichloroacetate, sodium trichloroacetates and methyl azides,60 the focus of this 
chapter will be on the more common Simmons-Smith, Mąkosza and diazo-
cyclopropanation methodologies.60, 61, 62 
 
2.2.1 Simmons-Smith cyclopropanation 
 
Although the methodology for cyclopropane synthesis had already been established, 
Simmons and Smith reported the first cyclopropanation reaction that was 
stereoselective, high yielding and free of any unusual side reactions leading to 
unwanted by-products.63, 3 The synthesis consists of the addition of an alkene to  
diiodomethane and a zinc-copper couple. Although the exact mechanism of the 
reaction remains unknown, experimental evidence showed the formation of an 
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organozinc transition state (26), namely iodomethylzinc iodide, which can promote a 
methylene transfer through π-donation from the alkene, leading to subsequent ejection 
of zinc iodide and formation of the cyclopropane (scheme 2.1A).58, 64,63,62 Despite the 
known formation of transition state 26, however, controversy around the exact 
mechanism still remains. The high stereoselectivity of the Simmons-Smith 
cyclopropanation system bearing an allylic oxygen atom is said to be due to the 
coordination of the zinc to the oxygen-containing substituents, such as a hydroxyl or 
ether group, proximal to the alkene resulting in the syn-product (scheme 2.1B).62,61 
This has been shown to give diastereoselectivities in excess of 250:1.61 
 
 
 
 
 
 
 
Scheme 2.1: (A) Proposed mechanism for the Simmons-Smith reaction, indicating the proposed 
transition state through the complexation of the zinc iodide.64 (B) Stereoselective addition of the 
cyclopropane directed through oxygen complexation with organozinc.65 
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2.2.2 Mąkosza gem-dihalocyclopropanation 
 
Doering and Hoffmann were the first to report the synthesis of gem-
dihalocyclopropane, with the synthesis of both dichloro- and dibromocyclopropanes 
in 1954.66 This was achieved through the addition of chloroform to a solution of 
cyclohexane, potassium tert-butoxide and tert-butyl alcohol, which proceeds through 
an α-elimination of hydrochloric acid and formation of the dichlorocarbene.66 
However, emphasis was put on this reaction needing to occur under anhydrous 
conditions due to the rapid reaction of dichlorocarbene with water. Mąkosza and 
Wawrzyniewicz reported an improvement of this synthesis in 1969,67 in which 
dichloro- and dibromocyclopropanes were synthesised from the corresponding 
haloforms in the presence of concentrated sodium hydroxide and catalytic amounts of 
triethylbenzylammonium chloride (TEBAC). Although the reaction was carried out 
under aqueous conditions, it was reported that only a small percentage (approximately 
7%) of the dihalocarbene reacted with water. This is due to the use of TEBAC as a 
quaternary ammonium phase-transfer catalyst.67 In this two-phase catalytic system, 
the haloform is initally deprotonated by the aqueous sodium hydroxide at the 
interfacial region of the reaction, forming the sodium haloform salt (scheme 2.2A). 
The haloform anion then complexes with the quaternary ammonium salt at the 
interfacial region, allowing it to enter the organic phase, where it begins to decompose 
into the highly reactive carbene (scheme 2.2B). The carbene can then react with the 
alkene to form the desired cyclopropane (scheme 2.2C).67, 60  
 
Unlike the Simmons-Smith cyclopropanation, addition of the carbene is not directed 
through the oxygen substituent, instead the addition of the carbene across the alkene 
is directed through steric interactions, where the carbene is stereoselectively added 
across the sterically less hindered face.68,3 The Mąkosza cyclopropanation provides an 
effective and high yielding synthesis of gem-dihalocyclopropanes due to the biphasic 
nature of the reaction, preventing the harsh aqueous condition from promoting any 
undesirable side reactions, such as ring opening reactions, without the need to keep 
the reaction in absolutely anhydrous conditions as seen in the methodology proposed 
by Doering and Hoffmann.66  
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2.2.3 Diazoester cyclopropanation 
 
The decomposition of diazo compounds into carbenes has been employed for more 
than a hundred years,69 however, the suggestion that the bond formation between the 
transition-metal catalyst and the diazo compounds promotes the ejection of the 
dinitrogen species was only proposed some 50 years ago by Peter Yates.70 Here, 
Yates hypothesised that after the ejection of the dinitrogen species the carbene 
remained bound to the metal catalyst (scheme 2.3).70 A milestone in the catalytic use 
of copper in this manner came many years later when Salomon and Kochi reported 
the use of copper triflate as an effective metal catalyst in the addition of diazo-
compounds to an alkene. The addition caused a reduction of copper (II) to copper (I), 
 
 
Scheme 2.2:  Mąkosza cyclopropanation mechanism, indicating phase shifts (Org: organic phase; Int: 
interphase; Aq: Aqueous); (A) Deprotonation of chloroform; (B) Complexation of the quaternary 
ammonium cation with the chloroform anion; (C) Decomposition of quaternary ammonium and 
chloroform, formation of the carbene and synthesis of the cyclopropane.  
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confirming that copper (I) is the active catalyst in the transformation of the 
carbenoid.71  
 
Although very effective copper catalysts were still being discovered,71 the coinciding 
use of palladium (II) acetate and rhodium (II) acetate by Teyssie and colleagues72,73 
was proving far more successful. In the case of rhodium acetate, this is due to the 
thermal and air stability of the catalyst, its inability to undergo π-π interaction with 
the alkene as well as its coordination unsaturation. As rhodium acetate is a binuclear 
compound with D4h symmetry and four bridging acetates it possesses only one empty 
axial coordination site per metal atom.69 At the stable oxidation state of +2 with five 
surrounding ligands (four metal-oxygen bonds and one metal-metal bond), rhodium 
acetate is a coordinatively unsaturated catalyst as it is lacking two electrons to satisfy 
the 18 electron rule. This means rhodium acetate does not need to undergo ligand 
displacement before it becomes a reactive catalyst, making it an effective electrophile, 
readily undergoing nucleophilic attack by the diazo compounds (scheme 2.3).  
 
The proposed mechanism for the rhodium carboxylate begins with the generation of a 
metal-carbene species, which adds across the alkene at a later stage to form the 
cyclopropane, completing the catalytic cycle (scheme 2.4). The suggested formation 
of the carbenoid occurs through the complexation of the electrophilic α-centre onto 
the metal catalyst. This in turn leads to the ejection of nitrogen gas to form the 
carbon-metal double bond (scheme 2.3). Position of the alkene and overall 
stereochemistry depends on the steric effects of the substituents on both the diazo-
compound and the alkene. In the absence of any dominating steric effects syn-
stereoselectivity is typically observed, with the ratio of syn/anti decreasing as the 
steric bulk of both the alkene and diazo-compound increases.74,69 As expected, the 
addition of the carbene favourably occurs across the sterically less hindered face. 
Diazoester cyclopropanation provides an effective way to introduce a cyclopropane 
moiety into a compound, particularly due to the high controllability of the resulting 
stereochemistry established by metal catalysts such as rhodium acetate. 
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Scheme 2.3: Mechanism for the formation of a carbenoid species. 35 shows the ejection of the 
dinitrogen and the formation of the carbenoid species 36.75 
 
Scheme 2.4: Catalytic cycle of carbenoid cyclopropanation.  
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Results and discussion 
 
2.3 Synthesis of 1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-6-O-trityl-D-
arabino-hex-1-enitol (40) 
 
The use of glycals as precursors for the synthesis of 1,2-cyclopropyl carbohydrates is 
well precedented in literature as reported by Hoberg,76,77 Nagarajan68 and Harvey.3,34 
Synthesis of 1,2-cyclopropyl carbohydrates is commonly achieved by the addition of 
a carbene to the glycal alkene through one of the three methods discussed in section 
2.2. Throughout this project the protected glucal 1,5-anhydro-3,4-di-O-benzyl-2-
deoxy-6-O-trityl-D-arabino-hex-1-enitol (40) was used as a substrate for the synthesis 
of 1,2-cyclopropyl carbohydrates, as its derivatives have been shown to facilitate 
bioactivity.2 It can also be readily synthesised from D-glucose (63) in five steps 
(scheme 2.5). Methodology for the synthesis of glucals was initially developed by 
Karl Zach and Emil Fischer in 191378 and subsequently optimised by others.79,80 
Synthesis of 39 proceeded with the per-acetylation of D-glucose (63) via the addition  
of acetic anhydride and catalytic amounts of perchloric acid. The resulting 
peracetylated glucose was subjected to a selective substitution reaction at the C-1 
position through the addition of HBr leading to isolation of the α-bromoglycoside 
(64) intermediate as a white solid. Following its isolation, the crude glucosyl halide 
64 was then taken up in a solution of H2O, acetic acid and zinc dust to undergo a 
reductive elimination reaction,81 where the anomeric bromide and the C-2 acetyl 
group are eliminated, resulting in the formation of the 1,2-alkene 37 in a 65% yield 
over 3 steps. Addition of a reduced amount of HBr compared to literature led to the 
formation and isolation of the by-product glucose penta-acetate, resulting in the 
overall moderate yield of 37.  
 
Scheme 2.5: Synthesis of tri-O-acetyl-D-glucal (37). 
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The de-acetylation of 37 is a well-documented reaction with many established 
procedures. Reaction conditions developed by Czernecki and colleagues82 involving 
methanol and an anion exchange resin resulted in high yields, however, reaction times 
of approximately 15 hours made the reaction undesirable. Therefore, a modification 
by Moore and colleagues35 involving Zemplén type conditions, was preferred, with 
the much shorter reaction time of approximately 15 minutes. Accordingly, the tri-
acetate 37 was dissolved in methanol and treated with catalytic amounts of solid 
sodium, resulting in the in situ formation of sodium methoxide to yield the crude 
deprotected glucal 38 within 15 minutes.  The isolated crude material was then 
subjected to purification via the successive additions of methanol, acetone and diethyl 
ether, allowing for precipitation and therefore removal of any impurities, resulting in 
an overall yield of 99% of the pure triol 38 (scheme 2.6).  
 
 
 
In order to retain the integrity of the cyclopropane that will eventually be installed, an 
orthogonal protecting group in relation to the highly strained cyclopropane group was 
required. To this end, trityl chloride was chosen to selectively protect the C-6 OH 
group due to its mild acid-mediated deprotecting conditions, which would avoid the 
possibility of base-mediated cyclopropane ring opening reactions or benzyl 
 
Scheme 2.6: Synthesis of 1,5-anhydro-3,4-di-O-benzyl-6-O-trityl-D-arabino-hex-1-enitol (40). 
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deprotection.34,68 In a modification of the procedure published by Schmidt and 
colleagues,83 protection of the primary hydroxyl on the triol 38 was achieved through 
the addition of trityl chloride to a solution of 38 in a 1:1 mixture of 
pyridine:dichloromethane (v:v),  resulting in high yields of the mono-protected glucal 
39. This then allowed for the protection of both secondary alcohols at the C-3 and C-4 
positions. Benzylation was achieved through a modification of the methodology 
reported by Schmidt and colleagues,84 wherein diol 39 was dissolved in DMF 
followed by the slow addition of NaH and BnBr. Initial benzylation attempts were 
low yielding due to the inability to keep the reaction under anhydrous conditions. 
Optimisation of the reaction through the prior co-evaporation of the starting material 
39 with DMF to remove traces of water, along with the addition of the TBAI to 
provide a source of iodide anions for a nucleophilic displacement reaction, proved to 
be very successful, yielding 40 in high yields (86%). No C-4 mono-benzylated 
product was isolated as often seen in literature.36 
 
2.4 Synthesis of gem-dichlorocyclopropane 
 
Brimacombe and colleagues85 reported the first addition of a carbene to an 
unsaturated sugar in 1967 through a modification of the initial cyclopropanation 
procedure proposed by Doering and Hoffmann.66 However, the essentiallity of highly 
anhydrous conditions made this reaction particularly challenging. To this end, Gross 
and colleagues86 utilised a modification of the methodology proposed by Mąkosza67 
in the synthesis of cyclopropane-containing compounds from unsaturated sugars, in 
which a phase transfer catalyst was used, allowing for the use of a 50% (w/w) 
solution of aqueous sodium hydroxide. Reactions times ranged from 1-6 hours 
resulting in yields of ≥96%. This provided the first reported synthesis of a small 
library of unsaturated cyclopropyl carbohydrates under aqueous conditions. 
Nonetheless, due to the safety hazards associated with the high concentration of 
sodium hydroxide utilised in the synthesis proposed by Gross and colleagues, 
optimisation of the reaction was necessary.  
 
Using a modification of the procedures employed by Gross and colleagues,86 the 
protected glucal 40 was dissolved in chloroform and treated with the phase transfer 
	 33	
catalyst TEBAC. In attempts to reduce the high concentration of sodium hydroxide 
used by Gross,86 the reaction was treated with the dropwise addition of a 33% (w/w) 
solution of aqueous sodium hydroxide. As expected, the reduction in sodium 
hydroxide concentration led to a longer reaction time of two days compared to the 
reported 6 hours. This, however, still successfully yielded both the major (41) and the 
minor (42) product in yields of 83% and 13%, respectively (scheme 2.7) which is 
comparable to those achieved by Gross. Conceivably, the isolated major stereoisomer 
resulted from the addition of the carbene to the α-face of the glucal due to the steric 
hindrance exerted by the C-3 benzyl group as well as the bulky C-6 trityl protecting 
group.  
 
 
 
 
Separation of the two stereoisomers was achieved through silica column 
chromatography utilising a 14:1 (v:v) hexanes:ethyl acetate solvent system. Only the 
major α-stereoisomer 41 was utilised throughout the rest of this thesis as this 
stereochemistry was shown to be favourable for the compound’s bioactivity.2 
 
1H NMR data for the major product 41 matched those previously reported by 
Nagarajan and colleagues.68 Successful cyclopropanation was marked by the 
noticeable upfield shift in H-1 from 6.49 ppm in the glucal 40 to 4.05 ppm (doublet, 
JH1-H2 = 8 Hz) and H-2 from 4.88 ppm to 1.89 ppm (doublet of doublets, JH-H = 8.1, 
4.9 Hz). The assignment of the spectral data of the minor product 42 was consistent 
with that proposed by Moore,36 with again a notable shift in H-1 when compared to 
the glucal starting material 40 from 6.49 ppm to 4.05 ppm (doublet, J H1-H2 = 8.1 Hz) 
 
Scheme 2.7: Synthesis of cyclopropane derivatives 41 and 42. 
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and H-2 from 4.88 ppm to 2.12 ppm (triplet, J H-H = 7.8 Hz)  as shown in figure 2.0 
Small amounts of inseparable impurities were present in 42, however, this 
stereochemistry has been shown to yield little bioactivity as an IC50 of 300µm in 
pdr1∆pdr3∆xxx∆ yeast deletion sets was reported by Davies2, therefore no further 
synthetic efforts were taken with this compound. Successful cyclopropanation was 
also confirmed by HMBC through the coupling of C-7 (61 ppm) to H-2 (4.88 ppm) 
and H-3 (4.17 ppm).  
 
 
 
Figure 2.0: 1H NMR of compound 40 (red), 41 (green) and 42 (blue) showing noticeable upfield shifts 
in both H-1 and H-2.   
 
Acid-mediated deprotection of the C-6 trityl group was demonstrated by Nagarajan 
and colleagues68 via the dropwise addition of formic acid. However, it was later 
noticed that the unexpected formation of the by-product 43 resulted from the 
esterification of the primary alcohol on 23 with formic acid under the acidic 
conditions.36 Reaction conditions were optimised by Davies2 in order to reduce the 
production of the formate ester by-product. Although some of the formate ester by-
product was still formed, optimised conditions recommended a reaction time for 2 
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hours in diethyl ether resulting in a 7:3 ratio in favor of the desired product at a 45% 
yield, along with the recovery of 20% starting material.2 Despite the recovered 
starting material, this was a substantial improvement from the previous synthesis 
where an isolated yield of 22% was reported in a 1:2.5 ratio in favor of the formate 
ester by-product. In the current study, synthetic attempts using the reaction conditions 
proposed by Davies, led to low yields and a 1:1 ratio of the desired product (23) to 
by-product (43). Therefore optimisation of the reaction proposed by Nagarajan and 
colleagues68 was undertaken by slightly increasing the concentration of formic acid 
and decreasing the amount of solvent, in turn concentrating the reaction. The reaction 
was then very closely followed by TLC analysis and quenched after 50 min resulting 
in high yields and a 9:1 ratio of the desired product (23) to the formic ester by-product 
(43) (scheme 2.8). Optimisation of the workup proposed by Nagarajan and 
colleagues68 was also undertaken as it was noted by Moore59 that the concentration of 
the reaction, before the dilution with dichloromethane as initially proposed by 
Nagarajan, resulted in conditions favourable for ester formation. The reaction was 
therefore quenched with diethyl ether and washed with saturated sodium bicarbonate 
before the concentration of the crude material. These changes led to production of the 
desired deprotected alcohol 23 in 81% yield, a substantial improvement from the 
previously reported 45%.2  
 
Scheme 2.8: Synthesis of 23 and 43. 
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2.5 Synthesis of (((2R,3S,4R)-3,4-bis(benzyloxy)-3,4-dihydro-2H-
pyran-2-yl)methoxy)(tert-butyl)diphenylsilane (45) 
 
Before the optimisation of the trityl deprotection reaction (scheme 2.8) was 
undertaken, alternative primary alcohol protecting groups were explored due to the 
loss of yield caused by the formation of the formate ester by-product during 
detritylation.36 A literature search revealed several alternative C-6 protecting groups, 
however, the decision to use tert-butyldiphenylsilyl chloride (TBDPSCl) was made 
due to two factors. Firstly, selective deprotection of TBDPSCl occurs through the use 
of tetrabutylammonium fluoride hydrate (TBAF) at very moderately basic conditions, 
reducing the likelihood of base-mediated cyclopropane ring opening,34,68,36 along with 
orthogonality with benzyl protecting groups.87 Secondly, the use of a bulky protecting 
group would increase the facial steric effects, leading to a higher stereoselectivity for 
cyclopropane formation on the α-face of the carbohydrate.61 The literature also 
indicated no significant reduction in yield during both protection and deprotection 
using TBDPSCl.88,89,90 
 
The use of TBDPSCl as a primary protecting group on unsaturated carbohydrates has 
become prevalent in the literature since it was first reported in 1976 by Guthrie and 
colleagues.91 In a modification of the procedure written by Lellouche and 
colleagues,92 a solution of the triol 38 and imidazole in DMF was treated with a slight 
excess of the TBDPSCl at low temperatures (scheme 2.9). It was important to keep 
the temperature low and the amount of TBDPSCl close to stoichiometric to prevent 
the undesirable protection of either the C-3 or C-4 hydroxyl groups. Due to the 
sensitivity of TBDPSCl to water, it was also important to keep the reaction 
anhydrous. To this end, imidazole was co-evaporated with toluene three times, 
followed by the co-evaporation of the starting material 38 and imidazole with DMF to 
remove any traces of water. However, the reaction resulted in disappointing yields, 
which was accounted for by the poor quality of the TBDPSCl as two spots were seen 
on the TLC of the reagent and 1H NMR spectroscopy of the TBDPSCl showed the 
presence of TBDPSOH, indicating the presence of water in the reagent.  
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It was also suspected that 44 could undergo silyl migration during the benzylation 
reaction of the secondary C-3 and C-4 hydroxyl groups as reported in the literature,92 
therefore assessment of this was first undertaken before attempting to improve the 
yields of the previous reaction. In an optimisation of the method proposed by 
Lellouche,92 BnBr was added to a solution of the diol 44 in DMF prior to the slow 
addition of NaH in an attempt to reduce the chances of any silyl migration. No silyl 
migration was observed, however, the mono-benzylated by-product (63) was 
observed after the reaction in addition to the desired product 45 (scheme 2.9). 
Benzylation had been expected to occur at the less sterically hindered C-3 hydroxyl 
group first, but this was contrary to the isolation of 63 in a 30% yield. Whilst waiting 
for delivery of new, dry TBDPSCl the decision to optimise the detritylation reaction 
was undertaken resulting in very favourable results (section 2.4, scheme 2.8). It was 
therefore decided to continue along that synthetic route and further optimisation of 
TBDPSCl was not undertaken.  
 
 
 
Scheme 2.9: TBDPSCl protection and syntheses of compounds 44, 45 and 63. 
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2.6 Synthesis of the ethoxycarbonyl substituted 1,2-cyclopropyl 
carbohydrates 54 and 55. 
 
Due to the hypothesis that mechanism-based inhibition of the dichloropropyl 
derivative 23 occurred through a ring opening reaction and formation of a carbanion 
(scheme 1.6), the carboxy ether cyclopropane 24 became the new synthetic target. 
Enolate stabilisation of the carbanion was hypothesised to encourage ring opening 
reactions. Therefore the synthesis of diazoacetates, in particular ethyl diazoacetate 
(49) was undertaken. In a modification of a procedure reported by Patnaik and 
colleagues,93 glycine was added to a pre-mixed solution of acetyl chloride and ethanol 
to undergo a Fischer esterification reaction, yielding 47 quantitatively (scheme 2.11). 
As shown in scheme 2.10A, the pre-mixing of acetyl chloride and ethanol provides an 
anhydrous source of HCl. The resulting acidic conditions allow for the protonation of 
the glycine carbonyl and initiates the Fischer esterification reaction (scheme 2.10B).94 
This reaction was repeated to synthesise the methyl and butyl derivatives, 46 and 48, 
respectively, from the corresponding alcohols in quantitative yields (scheme 2.11). 
The syntheses of 46, 47 and 48 as hydrochloride salts provided greater stability of the 
compounds.95  
 
 
 	
 
Scheme 2.10: A) In situ synthesis of HCl through esterification of acetyl chloride (63). B) Fischer 
esterification of glycine (66) for the synthesis of ethyl glycine hydrochloride (47). 
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Since the synthesis of the first diazo compound over 100 years ago,96 new versatile 
and effective methodologies have been developed.97 Much effort is focused around 
creating safer synthetic routes for these explosive compounds98,99 or making them 
more environmentally friendly by removing the necessity for heavy metals.97b To this 
end, a modification of the well-documented procedure initially published by Searle100 
in 1955 was utilised101, 97 where ethyl glycinate hydrochloride 47 was reacted with 
sodium nitrite at -9 °C. Care was taken to maintain the reaction at -9 °C  during the 
addition of concentrated sulfuric acid as increases in temperature have been reported 
to result in reduced yields. Due to the explosive nature of the diazo compound 49, the 
final product was not concentrated and a yield of 70% was assumed as per the 
literature (scheme 2.11).100 Furthermore, due to the specific warning about the 
especially explosive nature of methyl diazoacetates (69),100 it was decided to 
discontinue its synthesis. 
 
For the syntheses of cyclopropyl carbohydrates 54, 55, 56, several different catalysts 
and procedures were considered. Although palladium and copper catalysts are known 
to form metal-alkene pre-complexes which allows for a more directed stereoselective 
addition of the carbenoid across the alkene,102 rhodium acetate was selected for the 
following synthesis due to the higher yields reported in literature and reasons 
 
Scheme 2.11: Syntheses of compounds 46, 47, 48 and 49. Proposed syntheses of 69 and 70 was not undertaken 
due to safety concerns around the explosive nature of the compounds.   
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discussed in section 2.2.3.102,72,76 It was also believed that, due to the steric effects of 
the C-3 and C-4 benzyl groups along with the C-6 trityl protecting group on the diol 
40, steric hindrance would favour selective addition of the carbenoid from the desired 
α-face of the alkene. Due to the likeness of starting materials, methodology proposed 
by Timmers and colleagues103 was first employed. Although methodology for the 
cyclopropanation of the substrate triacetyl glucal was well-precedent in the literature, 
it was believed that the added steric stress of the benzylated glucal utilised in the 
procedure proposed by Timmer and colleagues103 would give a more accurate 
representation of the substrate 40. Thus, protected glucal 40 was treated with ethyl 
diazoacetate (EDA) over 1 hour, however this resulted in a 95% recovery in starting 
material (table 2.0, entry 1). Accordingly, optimisation of the reaction was undertaken 
as shown in table 1. Hoberg and colleagues76 reported that rapid addition of EDA to 
unsaturated glucals causes a decomposition of the EDA species, the formation of 
ethyl fumarates and the recovery of the starting material. The addition of the EDA 
was thus extended to a dropwise addition over 4 hours according to the procedure 
proposed by Risseeuw and colleagues,104,105 however this still led to a disappointing  
yield and large amount of recovered starting material (entry 2). 
Entry Glucal (equiv.) 
Time  
(hours) 
Temperature 
(°C) 
Rhodium 
Acetate 
Rhodium 
acetate equiv. Yield 
1 40 (1.5) 1 r.t Sigma (1) 0.5 
0%  
(95% SM) 
2 40 (1.5) 4 r.t Sigma (1) 0.5 
7%  
(90% SM) 
3 40 (1.5) 14 r.t Sigma (1) 0.05 
25%  
(61% SM) 
4 38 (3) 14 r.t Sigma (1) 0.05 
0%  
(60% SM) 
5 38 (3) 12 40 Sigma (1) 0.05 
3%  
(81% SM) 
6 38 (3) 12 r.t 
Compound 
50 0.05 
21%  
(37% SM) 
7 40 (3) 12 r.t Sigma (2) 0.05 
28%  
(70% SM) 
8 40 (3) 1 r.t Sigma (2) 0.05 
0%  
(90% SM) 
9 40 (3) 14 r.t Sigma (2) 0.05 
58%  
(21% SM) 
 
Table 2.0: Optimisation of diazoester cyclopropanation reaction. Sigma (1) and Sigma (2) represents 
the 1st and 2nd batch of rhodium acetate purchased from Sigma respectively. All yields reported are 
combined yield of both stereoisomers. 
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A slower addition of EDA of 14 hours improved the yield to 25%, nonetheless an 
appreciable amount of starting materials were still recovered (entry 3). This was 
thought to be due to the high steric bulk of the alkene 40 impeding the addition of the 
carbenoid to the alkene, as increases in the size of the glucal substituents have been 
shown to cause a reduction in yield.76 Therefore the fully unprotected model glucal 38 
was used to evaluate the influence of steric hindrance of the starting materials. 
However, comparable yields to literature76 were not obtained even at higher 
temperatures as shown in entries 4 and 5. The results put doubt on the purity of the 
rhodium acetate, which prompted the synthesis of fresh rhodium acetate.   
 
The synthesis of rhodium acetate was undertaken by the treatment of hydrated 
rhodium trichloride with sodium acetate in methanol. Crystallisation of the reaction 
mixture allowed for the formation of the methanol adduct (Rh(OAc2)MeOH), where 
methanol is bound as a ligand, which upon drying yielded the active rhodium acetate 
(50) in a 28% yield. Not only did the use of the newly synthesised rhodium acetate on 
the triol 38 give higher yields, but more importantly, this gave the lowest amount of 
recovered starting materials yet (entry 6), indicating a much more reactive catalyst. 
Thus, a newly purchased batch of rhodium acetate was used with the benzylated 
glucal 40 under the same conditions to give modest yields similar to those obtained 
before (entry 7). To confirm the effect given by the speed of EDA addition, the 
reaction was repeated where EDA was added over an hour, which proved 
unsuccessful (entry 8). Finally, increasing the time of addition to 14 hours resulted in 
a favourable yield of 58% (entry 9) for the desired stereoisomers 52 and 53 (scheme 
2.12). Separation of the two stereoisomers was attempted, unsuccessfully, therefore 
the assignment of the stereochemistry was not facile via NMR. However, NMR data 
indicated the major isomer, which was assumed to be 52 on the basis of steric 
arguments, was in approximately a 9:1 ratio to the minor isomer 53. These results 
were consistent with those reported by Risseeuw and colleagues104 in which 
separation of the two stereoisomers was not achieved until after the selective 
deprotection of the C-6 protecting group.  
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Utilising the aforementioned optimised C-6 trityl deprotection conditions (scheme 
2.7),2 detritylation of compounds 52 and 53 was achieved with minimal formation of 
the formate ester by-product (scheme 2.13). Due to the low yields of the formate ester 
by-product, no formate of the minor isomer was detected. Deprotection of the trityl 
group allowed for the separation of the stereoisomers through silica gel column 
chromatography utilising a slow gradient elution of hexane:ethyl acetate of 14:1 to 
1:1 (v:v), and allowing for the isolation of the major product in a pleasing 61% yield 
(scheme 2.13). 
 
 
 
 
Scheme 2.12: Optimised synthesis of 52 and 53, leading to an inseparable mixture of both 
stereoisomers as reported by Risseeuw and colleagues.104 
 
Scheme 2.13: Deprotection of the trityl group of the inseparable mixture of stereoisomers 52 and 53, 
affording 54, 55, and 56. 
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HMBC spectroscopy along with correlated 1D and 2D NMR spectroscopy data were 
used to confirm the formation of the cyclopropane moiety through the interaction 
between the carbene and the alkene (figure 2.1). As shown in figure 2.1, coupling of 
both H-2 and H-3 to C-7 indicates the successful addition of the carbene to the glucal 
alkene.  
 
Although the α-product 52 being the major product was consistent with the hypothesis 
that carbine addition to the α-face would be more favourable due to the steric 
hindrance of the pseudo-axial protecting groups on C-6 and C-3, and the opposite 
being true for the minor product 53, it was deemed prudent to confirm this via 
computational modelling of both compounds. To this end, lowest energy conformers 
of the diastereomeric C-7 ethoxycarbonyl 1,2-cyclopropane carbohydrates 54 and 55, 
differing in the configuration at the ring fusion between C-1 and C-2, as well at C-7, 
were determined by molecular mechanics.  Each structure was subjected to exhaustive 
conformational searching using the mixed torsional/low mode sampling routine as 
implemented in MacroModel version 9.7 and visualised in Maestro 9.0. A minimum 
 
Figure 2.1: HMBC coupling of 54 (CDCl3) showing the interactions of H-2 and H-3 with C-7, 
indicating a successful cyclopropanation. 
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of 20,000 steps were applied.  Structures obtained were minimised using the 
OPLS_2005 force field using the GB/SA chloroform continuum solvent model and 
the Polak–Ribiere conjugate gradient (PRCG) conjugate gradients method and 
terminated on a gradient threshold of 0.05 kJ mol-1A˚-1. The simulation was continued 
until the lowest energy structure reported had been replicated at least 50 times. The 
global minimum structure of major diastereomer 54 from this calculation was 
subjected to equilibrium geometry optimisation using the B3LYP hybrid density 
functional method 23, 24 and the 6-31G** basis set in Spartan ’08, resulting in no 
differences in the key dihedral angles around the pyranose and cyclopropane rings. 
The lowest energy conformers for both 54 and 55 reported from the molecular 
modelling are presented in figure 2.2. From the molecular model, the dihedral angles 
around both the glucose derived ring and the cyclopropane ring were obtained, 
allowing for the calculation of the expected coupling constants. The dihedral angles 
obtained from the molecular modeling are shown in table 2.1 
 
 
Figure 2.2: Lowest energy conformations of 54 and 55. 
  Dihedral angles   
 H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 54 2.7 104.5 143.8 146.6 
Compound 55 4.5 34.3 143.3 146.5 
Table 2.1: Calculated dihedral angle of compound 54 and 55 utilising MacroModel version 9.7. 
	 45	
From the calculated dihedral angles, predicted coupling constants were then obtained 
for the lowest energy conformers through the utilisation of a modified Karplus 
equation proposed by Haasnoot106 and implemented by Sweet J computer 
program.107,107b As shown in table 2.2, the comparison of the calculated coupling 
constants and the measured coupling constants show a reasonable correlation. 
Deviation away from the measured coupling constants is most likely to be due to the 
strain of the cyclopropane ring. 
 
 
Due to the deviation of the measured coupling constant away from the calculated 
coupling constant of the H-1, H-7 coupling on 54 and H-1, H-2 coupling on 55, NOE 
analyses of both compounds 54 and 55 were undertaken to provide further weight to 
the stereochemical assignment. NOE analysis of compound 54 through the irradiation 
of H-7 showed the interactions between H-7 with H-5 and H-3, which confirmed that 
the addition of the carbene had occurred from the α-face of the alkene with the 
carboxyethyl group in the exo-position to the C-3 and C-2 hydrogen (figure 2.3A). 
Irradiation of proton H-2 of compound 55 also showed its interactions with H-5, 
which confirmed the addition of the carbene from the β-face of the alkene as 
predicted by molecular modeling (figure 2.3B). 
 
 
 
  
Calculated coupling constants 
 
 
H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 54 7.42 Hz 0.90 Hz 6.95 Hz 9.44 Hz 
Compound 55 7.39 Hz 7.34 Hz 6.75 Hz 9.44 Hz 
     
  
Measured coupling constants 
 
 
H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 54 7.25 Hz 0 Hz 2.25 Hz 6.25 Hz 
Compound 55 2.5 Hz 5 Hz 6.5 Hz 9.5 Hz 
 
 
Table 2.2: Calculated coupling constants generated by Sweet J from the dihedral angle obtain from 
MacroModel version 9.7 compared to the measured coupling constants of compound 54 and 55. 
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Figure 2.3: B) NOE of 55, irradiation at H-2, NOE correlations shown on compound 55. 
 
 
Full characterisations of compounds 54 and 55 were thus achieved using a 
combination of both 1D and 2D NMR data, along with molecular modelling and NOE 
correlations. This allowed for parallel identification of the stereochemistry of both the 
cyclopropane and the carboxyethyl groups.  
 
 
Figure 2.3: A) NOE of 54, irradiation at H-7, NOE correlations shown on compound 54.  
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2.7 Synthesis of the propargyloxycarbonyl substituted 1,2-
cyclopropyl carbohydrates 61 and 62. 
 
Due to the successfully optimised methodology used in the synthesis of the 
ethoxycarbonyl substituted 1,2-cyclopropyl carbohydrates 54 and 55, a similar 
synthetic route was proposed for the synthesis of propargyloxycarbonyl 1,2-
cyclopropyl carbohydrates 61 and 62. As with the synthesis of the ethyl diazoacetate, 
initial synthesis of propargyl glycinate hydrochloride was first targeted. This was 
undertaken through a Fischer esterification of propargyl alcohol with glycine utilising 
acetyl chloride as a precursor for the in situ formation of HCl as proposed by Patnaik 
and colleagues (scheme 2.14).93 However this resulted in a black viscous solution, 
which after several attempts at purification yielded no product. The formation of a 
black by-product was thought to be due to a side reaction with acetyl chloride 
resulting in polymerisation of the propargyl alcohol. Accordingly, an alternative 
method reported by Ramapanicker and colleagues108 was then employed in which 
they state that no black by-product formed. Their methodology involves first bubbling 
HCl gas through cold propargyl alcohol to provide a saturated HCl solution before the 
addition of glycine. HCl gas was readily synthesised via the dropwise addition of 
concentrated sulfuric acid onto NaCl and, once formed, was then bubbled through 
concentrated sulfuric acid in order to remove any water before bubbling though the 
propargyl alcohol. However this methodology, also disappointingly, led to the 
formation of the black by-product. Purification of the resulting black solution was 
again unsuccessful and no product was isolated (scheme 2.14).  
 
 
 
 
 
Scheme 2.14: Unsuccessful syntheses of propargyl glycinate hydrochloride utilising methodology proposed  
by both Patnaik and colleagues93 and Ramapanicker and colleagues.108 
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Due to the unsuccessful synthesis of propargyl glycinate hydrochloride, a new 
synthetic strategy for propargyl diazoacetate that by-passed the propargyl glycinate 
hydrochloride altogether was required. A method first reported by Fukuyama and 
colleagues109 was selected due to its high yielding synthesis of propargyl diazoacetate 
and its reduced explosive characteristics. This method involved a two-step process: 
formation of propargyl bromoacetate, followed by a diazo-transfer reaction with 
N,N-ditosylhydrazine (57).109 The synthesis of N,N-ditosylhydrazine (57) was 
undertaken through a nucleophilic attack by the primary amine of p-toluenesulfonyl 
hydrazide on p-toluenesulfonyl chloride (TsCl). After recrystallisation, this led to 
very favourable 81% yield of 57 (scheme 2.15).  
 
 
 
 
 
 
As stated by Fukuyama and colleagues N,N-ditosylhydrazine proved to be a useful 
reagent due to its ease of handling, thermal stability and shelf stability.109,97a With 
hydrazine 57 in hand, the two-step synthesis of the desired diazoacetate 58 was 
undertaken. Initial treatment of propargyl alcohol (73) with bromoacetyl bromide (74) 
led to the formation of propargyl bromoacetate (75) via an esterification reaction 
(scheme 2.16). Without further purification, the resulting ester 75 was subjected to a 
substitution reaction through nucleophilic attack by the hydrazine 57 in the presence 
of the bulky base 1,8-diazobicycloundec-7-ene (DBU). This led to the double 
elimination of toluenesulfinic acid (78) resulting in the final propargyl diazoacetate 
 
Scheme 2.15: Synthesis of 57 and 58. 
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(58) as a orange oil in a 57% yield after purification. A proposed mechanism for the 
formation of 58 is presented in scheme 2.16 in which double elimination of the 
toluenesulfinic acid proceeds through the formation of the nitrene species 80. 
Moderate yields are typical due to the volatile nature of 58 as noted by Fukuyama and 
colleagues.109 
 
Cyclopropanation of the glucal 40 with the diazoacetate 58 followed the same 
optimised procedure as with previous diazoacetates (see scheme 2.12), in which a 
solution of rhodium acetate and glucal 40 in dichloromethane were treated with a 
solution of 58 in dichloromethane over 14 hours under an argon atmosphere. As 
mentioned, addition over 14 hours reduced both the undesired formation of fumarates 
and amount of starting material recovered. Silica gel flash column chromatography 
was used in an attempt to purify the crude material, utilising both hexanes:ethyl 
acetate and toluene:ethyl acetate solvent systems, however, although purification was 
successful, separation of the stereoisomers was not achieved and an inseparable 
mixture of both stereoisomers 59 and 60 were isolated in a 38% yield (scheme 2.17). 
Therefore the stereochemistry of the two isomers could not yet be established, 
 
Scheme 2.16: Proposed mechanism of the synthesis of 58 noting two-fold elimination of 
toluenesulfinic acid. 
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however, it was predicted that the major isomer would result from the sterically-
directed addition of the carbenoid to the α-face of the alkene, as seen in the synthesis 
of the ethyl derivatives 54 and 55. Despite the inability to separate the 
stereoisomers, 1 H NMR data indicated the presence of the stereoisomers in a 5:1 
ratio. The slightly reduced yield compared to the ethoxycarbonyl derivatives 54 and 
55 was thought to be due to partial quenching of the carbenoid by the alkyne. Carbene 
addition to terminal alkynes undergoing a C-H insertion or cyclopropene formation is 
precedented in the literature110,111 when catalysed by organometallic complexes such 
as rhodium acetate.112  
 
 
 
Scheme 2.17: Cyclopropanation of 40 with 58 forming an inseparable mixture of stereoisomers 59 and 
60. 
 
 
As with the separation of the stereoisomers 52 and 53 (scheme 2.13) it was expected 
that separation of both 59 and 60 would be possible upon removal of the C-6 trityl 
protecting group. The optimised conditions developed in the selective deprotection of 
the dichlorocyclopropyl derivative 41 were again utilised in order to reduce the 
formation of the formate ester by-product. To this end, the mixture of stereoisomers 
59 and 60 was treated with formic acid and the reaction quenched after 50 minutes 
based on closely following the reaction progress by TLC. As stated previously, 
optimisation of the proposed workup by Nagarajan and colleagues68 was undertaken 
through the addition of NaHCO3, as concentration of the reaction mixture before 
quenching led to the perfect conditions for undesired ester formation.59 Separation of 
the resulting deprotected stereoisomers 61 and 62 proved to be difficult as separation 
by silica column chromatography utilising both hexanes:ethyl acetate and 
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toluene:ethyl acetate solvent systems were unsuccessful. The exploration of many 
different solvent systems to separate the two isomers on TLC seemed futile, however 
using dichloromethane:ethyl acetate solvent system showed a small amount of 
promise. A long silica gel column utilising a slow gradient elution of 100:1 → 3:1 
dichloromethane:ethyl acetate (v:v) was successful, yielding 61 and 62 in a 43% and 
10% yield, respectively (scheme 2.18).  
 
 
 
 
 
Scheme 2.18:  Detritylation of the C-6 trityl and separation of stereoisomers 61 and 62. 
 
 
 
 
With the successful separation of 61 and 62, HMBC data were then obtained and the 
outcomes of the cyclopropanation reactions were confirmed. As shown in figure 2.4, 
analysis of the HMBC spectrum revealed interactions between H-2 and C-7, H-3 and 
C-7, as well as H-7 and C-2 for compound 61. Figure 2.5 shows the interactions 
between H-2 and H-3 to C-7 as well as H-7 to C-2 exhibited in the HMBC spectrum 
of 62.  
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Figure 2.4: HMBC spectrum of 61 showing coupling between H-2 and H-3 to C-7 along with H-7 to 
C-2. 
 
Figure 2.5: HMBC spectrum of 62 confirming showing between H-2 and H-3 to C-7 as well as H-7 
to C-2.  
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The challenge of determining the stereochemistry was again undertaken in a similar 
manner to that used for compounds 54 and 55. As per compounds 54 and 55, the same 
methodology utilising the molecular modelling systems with MacroModel version 9.7 
was applied in order to identify the lowest energy conformations of both 61 and 62. 
The calculated dihedral angles are shown in table 2.3. The dihedral angles determined 
for compounds 61 and 62 were the same as those reported for compounds 54 and 55, 
as shown in table 2.3. 
 
 
The measured and calculated coupling constants are shown in table 2.4. Reasonable 
correlations were observed as shown in table 2.4, though not without discrepancies, 
which may be due to the steric strain applied by the cyclopropane ring affecting the 
position of the Karplus curve.    
 
 
  
 Calculated coupling constants 
 
 
H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 61 7.42 Hz 0.90 Hz 6.95 Hz 9.44 Hz 
Compound 62 7.39 Hz 7.34 Hz 6.75 Hz 9.44 Hz 
     
  
Measured coupling constants 
 
 
H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 61 7.25 Hz 0 Hz 2.5 Hz 6.5 Hz 
Compound 62 4 Hz 4 Hz 9.25 Hz 6.75 Hz 
 
Table 2.4: Comparison of the calculated and measured coupling constants of 61 and 62. 
 
 
Again NOE analyses of both compounds 61 and 62 were undertaken to further 
confirm the stereochemistry of the two diastereoisomers (figures 2.6 and 2.7). For 
 Dihedral angles (degrees)  
 H-1, H-2 H2, H-3 H-1, H-7 H-2, H-7 
Compound 61 2.7 104.5 143.8 146.6 
Compound 62 4.5 34.3 143.3 146.5 
 
Table 2.3: Calculated dihedral angle of the lowest energy conformers of 61 and 62 as modelled by 
MacroModel. 
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compound 61, irradiation of H-7 indicated clear coupling interactions of H-7 with 
both H-3 and H-5, indicating that the cyclopropane ring is α to the pyranose ring and 
carboxyalkyl substituent is in the exo position (figure 2.6). Irradiation of H-7 in 62 
resulted in the coupling of H-7 solely with H-4 indicating the β-exo configuration of 
the cyclopropane and carboxyalkyl group (figure 2.7). The results are consistent with 
the lowest energy configuration calculated by the molecular modelling.  
 
 
Figure 2.6: NOE analysis of the stereoisomer 61 with irradiation at H-7. 
 
 
Figure 2.7: NOE analysis of the stereoisomer 62 with irradiation at H-7. 
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Due to the similarities in both molecular modelling and the NOE results, the lowest 
energy structures of compounds 61 and 62 were visually overlaid in the Spartan 
software with compounds 54 and 55 to allow for comparison of their conformation. 
As shown in figure 2.8, the structures overlay very closely in both cases. The 
deviation of the C-3 benzyl group, seen in figure 2.8A, has a low barrier of activation 
to the requisite bond rotation. The corresponding propargyl conformation in which the 
C-3 benzyl group overlays the ethyl conformer is within 1 kJ/mol. This reflects the 
flexibility of the benzyl substituents under ambient temperatures.  
 
 
 
  
Figure 2.8: Lowest energy conformers of A) 54 and 61, B) 55 and 62. Compounds 54 and 55 are 
indicated in green and red, and compounds 61 and 62 are shown in white and blue. 
 
Summary  
 
Synthesis of the final products 61 and 62 concluded the chemical aspect of this thesis, 
which included the successful syntheses of the target 1,2-cyclopropyl carbohydrates 
derivatives 23, 54, 55 and 56. Development of new methodologies and optimisation 
of reported literature procedures have led to a high yielding synthetic route to 1,2-
cyclopropyl carbohydrates. Synthesis of compound 23 was achieved over 7 steps at a 
modest overall yield of 32%. Similar results were obtained for the carboxyalkyl 
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derivatives with the isomeric mixtures of 54 and 55, and 61 and 62 being achieved in 
overall yields of 22% and 9% respectively over 7 steps. The exploration of a new C-6 
TBDPSCl protecting groups was undertaken, however due to low yields and lack of 
reagent, optimisation of the current trityl protection procedure was the preferred route. 
This led to very pleasing results during deprotection, leading to a 15% reduction of 
the formate by-product compared to previously reported syntheses.2 All 
stereochemistry was determined through the use of molecular modeling, analysis of 
coupling constants and NOE spectroscopy. The target compounds 23, 54, 55, 56, 61 
and 62 will now be subjected to biological analysis to assess their bioactivity. The 
compounds will be screen against a yeast deletion library in order to identify chemical 
genetic interactions and elucidate a potential mechanism of action.  
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Experimental 
 
2.8 General experimental  
 
Unless otherwise stated, all reactions were conducted under nitrogen atmosphere in 
oven-dried glassware using HPLC grade solvents. CH2Cl2, Et2O and THF were 
obtained from the PureSolv (Innotive Technologies). Hexanes, ethanol, methanol, 
ethyl acetate, toluene (Ficher Scientific) and chloroform (Vickers Laboratory) were of 
HPLC grade and used for reactions and column chromatography as received. DMF 
(Acros Organics) was stored over molecular sieves. Perchloric acid (Sigma-Aldrich), 
formic acid (BDH biochemical), D-Glucose (Sigma-Aldrich), NaH (Sigma-Aldrich), 
TBAI (Honeywell Riedal-de Haën), BnBr (Sigma-Aldrich), TEBAC (Sigma-Aldrich), 
glycine (BDH bioscience), RhCl2•3H2O (Merck & Co.), NaAc•3H2O (Univar), p-
toluenesulfonyl hydrazine (Sigma-Aldrich), p-toluenesulfonyl chloride (Sigma-
Aldrich), propargyl alcohol (Sigma-Aldrich), bromoacetyl bromide (Sigma-Aldrich), 
and DBU (Merck & Co.) were all used as received. Concentration of solvents in 
vacuo was achieved through the use of a rotary evaporator fitted to a vacuum pump in 
a water bath of 40 °C.   
 
Reaction progress was monitored using TLC (thin layer chromatography) plates pre-
coated in silica DC-Fertigfolien Polygram® SIL G/UV254 and visualised by dipping 
in potassium permanganate in water, anisaldehyde, and phospomolybdic acid, as well 
as detection by UV absorption (254 nm). Purification of products was achieved using 
flash column chromatography. Columns were packed using silica 60 (Pure Science 
Silica Gel, 40-60 microns) as the stationary phase, using the solvent system indicated. 
1H NMR and 13C NMR spectra were recorded on a Varian Unity Inova 500 (operating 
at 500 MHz for 1H and 125 MHz for 13C) spectrometer, NOSEY spectra were 
recorded on Varian Directed Drive instrument equipped with an inverse-detected 
triple resonance HCN probe operating at 25 °C (600 MHz for 1H). All chemical shifts 
(δ) were referenced to the solvent peaks (CDCl3: 1H - 7.26 ppm; 13C - 77.16 ppm, 
(CD3)2SO: 1H - 2.50 ppm; 13C - 39.52 ppm, D2O: 1H - 4.79 ppm;).113 NMR peaks 
were assigned based on COSY, HSQC and HMBC 2D experiments. Melting points 
were obtained using Gallenkamp melting point apparatus and are uncorrected. 
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Infrared spectra was recorded using thin films on a Bruker Tensor 27 FTIR 
spectrometer outfitted with an Attenuated Total Reflactance (ATR) sampling 
accessory. Optical rotation measurements were recorded on a Rudolph research 
analytical Autopol II automatic polarimeter. 
 
2.9 Chemistry synthesis 
 
 
Tri-O-acetyl-D-glucal (37) 
 
Using a modification of the Kozikowski’s procedure79, perchloric 
acid (0.48 mL, 4.5 mmol) was added dropwise to a mechanically 
stirred solution of D-glucose (72 mg, 0.4 mmol) in acetic anhydride 
(38.2 mL).  Additional D-glucose (9.93 g, 55.1 mmol) was added 
over a period of 40 minutes at 45 °C, after which the reaction was 
allowed to cool to room temperature. The solution was then treated 
with a 33% (w/w) solution of HBr in acetic acid (39 mL, 
149 mmol) and left to stir for 1.5 h. After TLC-analysis showed the disappearance of 
starting materials, the solution was diluted with CH2Cl2 (106 mL). The organic layer 
was then extracted and washed with ice-cold H2O (3 × 50 mL), followed by sat. aq. 
NaHCO3 (6× 50 mL) before it was dried over anhydrous MgSO4, which was removed 
by filtration. The filtrate was then concentrated in vacuo to give the crude tetra-O-
acetyl-D-glucopyranosyl bromide as an off-white solid, which was used without 
further purification.  
 
A mechanically stirred solution of zinc dust (24 g, 366.3 mmol) in H2O (76 mL) was 
cooled to 0 °C before it was diluted with acetic acid (76 mL). The solution was then 
treated to a dropwise addition of the crude tetra-O-acetyl-D-glucopyranosyl bromide 
(25.06 g, 61.1 mmol) in Et2O (76 mL) over a period of 1 h. The reaction was allowed 
to warm to room temperature and left to stir overnight. After TLC-analysis showed 
the disappearance of starting materials, the solution was filtered removing the zinc 
dust, then diluted with CH2Cl2 (110 mL). The organic layer was collected and washed 
with H2O (3 × 50 mL), sat. aq. NaHCO3 (4 × 50 mL) and brine (60 mL) before it was 
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dried over anhydrous MgSO4. Filtration and concentration in vacuo yielded the crude 
material as a white powder. Recrystallisation from hexanes : Et2O yielded tri-O-
acetyl-D-glucal 37 as a white solid (14.9 g, 65%). The spectral data matched those 
previously reported.36,79  
 
Rf = 0.26 (3:1 hexanes : EtOAc, v:v); M.p. 48.5-50.5 ºC (lit. 50.0-52.0 ºC)114; 
[α]D26.6= -2.0 (c=1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3): δ 6.47 (d, J = 6.4 Hz, 1H, 
H-1), 5.34 (m, 1H, H-3), 5.22 (dd, J = 7.6, 5.9 Hz, 1H, H-4), 4.84 (dd, J = 6.3, 3.4 Hz, 
1H, H-2), 4.4 (dd, J = 12.2, 5.8 Hz, 1H, H-6a), 4.26 (m, 1H, H-5), 4.20 (dd, J = 12.2, 
3.2 Hz, 1H, H-6b), 2.09 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 2.04 (s, 3H, 
CH3CO); 13C NMR (125 MHz, CDCl3): δ  170.7 (C, CH3CO), 170.5 (C, CH3CO), 
169.6 (C, CH3CO), 145.6 (CH, C-1), 99.0 (CH, C-2), 74.0 (CH, C-5), 67.5 (CH, C-3), 
67.2 (CH, C-4), 61.4 (CH, C-6), 21.0 (CH3, CH3CO), 20.83 (CH3, CH3CO), 20.77 
(CH3, CH3CO); IR (film from CH2Cl2): νmax  = 2982, 1742, 1650, 1433, 1370, 1221, 
1141, 1030, 601 cm-1. 
 
 
 D-Glucal (38) 
 
To a solution of sodium (0.23 g, 9.84 mmol) in MeOH (300 mL), a 
solution of 37 (8.87 g, 32.8 mmol) in MeOH (113 mL) was added. 
The reaction was then left to stir at r.t. for 15 min, after which TLC-
analysis deemed the reaction complete. The solution was then 
concentrated in vacuo to provide the crude product. Purification was 
done through the successive additions of MeOH (7 mL), acetone 
(50 mL) and Et2O (100 mL). The solution was then filtered and concentrated in vacuo 
to afford the pure glucal 38 as viscous yellow oil (4.77 g, 99.4%). Spectral data 
matched those previously reported.36  
 
Rf = 0.30 (EtOAc); [α]D26.7 = +8.0 (c=1.0, H2O); 1H NMR: (500 MHz, D2O) δ 6.29 
(dd, J = 5.8, 1.3 Hz, 1H, H-1), 4.68–4.65 (m, 3H, 3 x OH), 4.80 (dd, J = 6.1, 2.4 Hz, 
1H, H-2), 4.23 (ddd, J = 7.0, 2.3, 1.7 Hz, 1H, H-3), 3.92– 3.85 (m, 3H, H-5, H-6a, H-
6b), 3.67 (dd, J = 9.0, 7.1 Hz, 1H, H-4); 13C NMR (125 MHz, D2O) δ 143.6 (CH, C-
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1), 102.7 (CH, C-2), 78.0 (CH, C-5), 68.7 (CH,C-4), 68.2 (CH, C-3), 60.0 (CH, C-6);  
I IR (neat, cm-1) νmax = 3293, 28812, 1648, 1410, 1228, 1070, 1011,  
 
 
1,5-anhydro-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol (39) 
 
In a modification of the Esswein procedure,84 38 (4.44 g, 32.64 
mmol) was dissolved in a solution of CH2Cl2 and pyridine 
(69 mL, 1:1, v:v) before trityl chloride (14.6 g, 52.22 mmol) 
was added over a period of 3 minutes at r.t. The solution was 
stirred for 19 hours at r.t. after which, TLC analysis showed 
completion of the reaction. The reaction was then concentrated 
in vacuo and extracted with CHCl3 (3 × 60 mL). The organic 
layers were then collected and washed with sat. aq. NaHCO3 (3 × 60 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo to provide a yellow oil. The 
crude yellow oil was then purified via silica gel column chromatography (1:1 hexanes 
: EtOAc, v:v) to afford 39 as a white solid (9.87 g, 87%).  
 
Rf = 0.48 (2:1 hexanes : EtOAc, v:v); M.p. 59.0-61.8 °C (lit. 62-64 °C); [α]D25.4= 
+40.0 (c=1.0, CH2Cl2); 1H  NMR (500 MHz, CDCl3): δ 7.48 - 7.25 (m, 15H, Ph), 6.39 
(dd, J = 6.1, 1.7 Hz, 1H, H-1), 4.76 (dd, J = 6.1, 2.2 Hz, 1H, H-2), 4.24 (d, J =  6.6 Hz 
1H, H-3), 3.9 (dd, J = 9.5, 7.1 Hz, 1H, H-4), 3.84 (dt, J = 13.2, 3.6 Hz, 1H, H-5), 3.57 
(dd, J = 10.5, 3.6 Hz, 1H, H-6a), 3.36 (dd, J = 10.5, 3.9 Hz, 1H, H-6b), 2.33 (m, 1H, 
OH-4); 13C NMR (125 MHz, CDCl3): δ  144.6 (CH, C-1), 143.4 (C, Ph), 128.5 (CH, 
Ph), 128.0 (CH, Ph), 127.3 (CH, Ph), 102.5 (CH, C-2), 87.0 (C, C-7), 76.5 (CH, C-5), 
71.6 (CH, C-4), 69.4 (CH, C-3), 62.8 (CH, C-6); IR: νmax = 3342, 3058, 2880, 1644, 
1489, 1447, 1226, 1000, 745, 697.   
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1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol (40) 
In a slight modification of Schmidt’s procedure,84 39 (1.05 g, 
2.71 mmol) was co-evaporated in vacuo with DMF (18 mL) 
two times, with an additional evaporation whereupon the 
volume of DMF (30 mL) was reduced to half to ensure 
dryness. The solution was then cooled to -5 °C before NaH 
(0.3 g, 7.3 mmol) was added portion-wise over a period of 3 
minutes followed by the addition of TBAI (0.1 g, 0.27 mmol). 
The solution was left to stir for 15 min before the dropwise 
addition of BnBr (0.9 mL, 7.3 mmol), after which it was allowed to warm to room 
temperature and left to stir overnight. After TLC analysis showed the disappearance 
of starting materials, the reaction was then quenched with H2O (8 mL) and extracted 
with CHCl3 (3 × 10 mL). The organic fractions were combined, dried over anhydrous 
MgSO4, and concentrated under reduced pressure to give the crude product. The 
crude material was then purified via silica gel column chromatography (14:1 → 1:1 
hexanes : EtOAc, v:v) to produce 40 as a white solid (1.32 g, 86%). 
Rf = 0.40 (9:1 hexanes : EtOAc); M.p. 114.0-116.0 °C (lit. 116 °C84); [α]D24.2= +0.6 
(c=1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3): δ 7.48 - 7.01 (m, 25H, Ph), 6.49 (d, J = 
6 Hz, 1H, H-1), 4.88 (dd, J = 6.0, 4.0 Hz, 1H, H-2), 4.73 (d, J = 11 Hz 1H, PhCH2), 
4.62 (d, J = 11.5 Hz, 1H, PhCH2), 4.55 (d, J = 11.5 Hz, 1H, PhCH2), 4.5 (d, J = 11 
Hz, 1H, PhCH2), 4.17 (m, 1H, H-3), 4.0 (m, 2H, H-4, H-5), 3.54 (d, J = 10 Hz, 1H, H-
6a), 3.39 (dd, J = 10, 4 Hz, 1H, H-6b); 13C NMR (125 MHz, CDCl3): δ 144.9 (CH, C-
1), 143.9 (C, Ph), 138.3 (C, Ph), 138.1 (C, Ph), 128.8 (CH, Ph), 128.4 (CH, Ph), 128.2 
(CH, Ph), 127.9 (CH, Ph), 127.8 (CH, Ph), 127.64 (CH, Ph), 127.6 (CH, Ph), 126.9 
(CH, Ph), 99.8 (CH, C-2), 86.5 (C, C-7), 77.2 (CH, C-5), 76.1 (CH, C-3), 74.6 (CH, 
C-4), 73.8 (CH2, PhCH2), 70.8 (CH2, PhCH2), 62.1 (CH2, C-6); IR (film from 
CH2Cl2): νmax 3060, 3030, 2923, 2874, 1744, 1647, 1492, 1449, 1238, 1099, 1068, 
1028, 900, 745, 698 cm-1. 
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1,5-anhydro-3,4-di-O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C- 
(dichloromethylene)-D-glycero-D-gulo-hexitol (41) and 1,5-anhydro-3,4-di-O-
benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C- (dichloromethylene)-D-glycero-D-
talo-hexitol (42) 
 
In a modification of the procedure conducted by Gross 
and colleagues,86 a solution of the protected glucal 40 
(1.29 g, 2.27 mmol) in CHCl3 (8.2 mL) was treated with 
TEBAC (16 mg, 0.078 mmol), followed by the dropwise 
addition of 33% NaOH in H2O (12 mL). The biphasic 
solution was stirred rapidly for 48 hours at r.t., after 
which TLC analysis showed completion of the reaction. 
The reaction mixture was then quenched with H2O 
(60 mL) and extracted with CH2Cl2 (3 × 60 mL). The 
organic layer was collected, dried over anhydrous MgSO4 
and concentrated in vacuo to afford a crude mixture of 
both stereoisomers 41 and 42. The crude products were 
purified using column chromatography (14:1 hexanes : 
EtOAc, v:v) to afford the major isomer 41 (1.23 g, 83%) 
as a white solid and the minor product 42 (0.26 g, 13%) 
as a yellow oil.  
 
Data for 41: Rf = 0.52 (9:1 hexanes : EtOAc); M.p. 51.5-53.5 °C; [α]D25.7= +8.0 
(c=1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3): δ 7.47– 7.22 (m, 25H, Ph), 4.81 (d, J = 
3.9 Hz, 1H, PhCH2), 4.79 (d, J = 3.2 Hz, 1H, PhCH2), 4.70 (d, J = 11.5 Hz, 1H, 
PhCH2), 4.26 (d, J = 10.8 Hz, 1H, PhCH2), 4.05 (d, J = 8 Hz, 1H, H-1), 3.88–3.84 (m, 
2H, H-4, H-5), 3.78 (dd, J = 9.5, 4.9 Hz, 1H, H-3), 3.48 (dd, J = 10.5, 2.4 Hz, 1H, H-
6a), 3.17 (dd, J = 10.3, 3.0 Hz, 1H, H-6b), 1.89 (dd, J = 8.1, 4.9 Hz, 1H, H-2); 13C 
NMR (125 MHz, CDCl3): δ 147.7 (C, Ph), 138.0 (C, Ph), 137.6 (C, Ph), 128.9 (C, 
Ph), 128.8 (C, Ph), 128.4 (C, Ph),128.1 (C, Ph), 128.0 (C, Ph), 127.9 (C, Ph), 127.8 
(C, Ph), 127.1 (C, Ph), 86.7 (C, C-8), 80.3 (C, C-5), 77.4 (CH, C-4), 75.7 (CH, C-4), 
74.8 (CH2, PhCH2), 72.0 (CH2, PhCH2), 63.6 (CH2, C-6), 61.6 (C, C-7), 59.2 (CH, C-
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1), 34.6 (CH, C-2); IR (film from CH2Cl2): νmax 3086, 3060, 3030, 2924, 2868, 1491, 
1449, 1130, 1093, 1014, 744, 697, 632 cm-1.  
 
Data for 42: Rf = 0.29 (9:1 hexanes: EtOAc, v:v); [α]D25.9= -6.0 (c=1.0, CH2Cl2); M.p. 
49-51 °C; 1H NMR (500 MHz, CDCl3): δ 7.50–7.17 (m, 23H, Ph), 6.90 (dd, J = 7.3, 
1.4 Hz, 2H, Ph), 4.87 (d, J = 11.7 Hz, 1H, PhCH2), 4.74 (d, J = 12.0 Hz, 1H, PhCH2), 
4.69 (d, J = 10.5 Hz, 1H, PhCH2), 4.34 (d, J = 10.7 Hz, 1H, PhCH2), 4.14–4.09 (m, 
2H, H-3, H- 4), 4.05 (d, J = 8.1 Hz, 1H, H-1), 3.56 (dd, J = 10.3, 2.0 Hz, 1H, H-6a), 
3.41 (m, 1H, H-5), 3.19 (dd, J = 9.3, 2.9 Hz, 1H, H-6b), 2.12 (t, J = 7.8 Hz, 1H, H-2); 
13C NMR (125 MHz, CDCl3): δ 143.9 (C, Ph), 138.1 (C, Ph), 137.9 (C, Ph), 128.8 
(CH, Ph), 128.6 (CH, Ph), 128.1 (CH, Ph), 128.06 (CH, Ph), 127.93 (CH, Ph), 127.91 
(CH, Ph), 127.84 (CH, Ph), 127.79 (CH, Ph), 127.5 (CH, Ph), 86.4 (C, C-8), 78.3 
(CH, C-5), 78.1 (CH, C-4), 76.4 (CH, C-3), 74.8 (CH2, PhCH2), 71.5 (CH2, PhCH2), 
62.2 (CH2, C-6), 62.12 (CH, C-1), 61.9 (CH, C-7), 33.0 (CH, C-2); IR (film from 
CH2Cl2): νmax 3380, 3061, 3030, 2932, 2875, 1647, 1491, 1449, 1275, 1091, 1022, 
747, 699 cm -1. 
 
 
1,5-anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-glycero-D-
gulo-hexitol (23) and 1,5-anhydro-3,4-di-O-benzyl-6-O-(formyl)-2-deoxy-1,2-C- 
(dichloromethylene)-D-glycero-D-gulo-hexitol (42) 
 
 To a solution of 41 (1.23 g, 1.9 mmol) in Et2O (11 mL), 
formic acid (9.05 mL) was added dropwise. The solution was 
left to stir at r.t. for a period of 50 min before it was diluted 
with Et2O (90 mL). The organic layer was collected, washed 
with sat. aq. NaHCO3 (4 × 100 mL), dried over anhydrous 
MgSO4, and concentrated in vacuo to afford the crude 
products 23 and 43. The crude products were purified via 
column chromatography (14:1 → 5:1 hexanes : EtOAc, v:v) 
to give 23 (0.64 g, 81%) as a white solid and 43 (0.067g, 
8%) as clear oil.  
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Data for 23: Rf = 0.53 (3:1 hexanes : ethyl acetate, v:v); M.p. 84.5-86.0 °C;  
[α]D25.5= +29.0 (c=1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3): δ 7.42–7.26 (m, 10H, 
Ph), 4.95 (d, J = 11.2 Hz, 1H, PhCH2), 4.81 (d, J = 12.0 Hz, 1H, PhCH2), 4.71 (d, J = 
11.8 Hz, 1H, PhCH2), 4.67 (d, J = 11.2 Hz, 1H, PhCH2), 3.87 (d, J = 8.5 Hz, 1H, H-
1), 3.81 (dd, J = 9.2, 3.9 Hz, 1H, H-3), 3.73 (dt, J = 8.3, 3.7 Hz, 1H, H-5), 3.68 (s, 2H, 
H-6a,b), 3.59 (t, J = 8.7 Hz, 1H, H-4), 1.83 (dd, J = 8.3, 3.9 Hz, 1H, H- 2), 1.75 (s, 
1H, OH); 13C NMR (125 MHz, CDCl3) δ 137.9 (C, Ph), 137.4 (C, Ph), 128.6 (CH, Ph 
), 128.5 (CH, Ph ), 128.2 (CH, Ph ), 128.0 (CH, Ph), 127.98 (CH, Ph ), 79.4 (CH, C-
5), 77.3 (CH, C-3), 74.8 (CH2, PhCH2), 74.7 (CH, C-4), 72.0 (CH2, PhCH2), 62.7 
(CH2, C-6), 60.9 (C, C-7), 58.8 (CH, C-1), 33.7 (CH, C-2). IR (neat, cm-1)  νmax = 
3362, 3935, 2954, 2912, 2863, 1496, 1453, 1327, 1108, 989, 885, 820, 731, 694.   
 
Data for 43: Rf = 0.30 (9:1 hexanes : EtOAc, v:v); [α]D26.6= +18.0 (c=1.0, CH2Cl2); 1H 
NMR (500MHz, CDCl3): δ 8.03 (m, 1H, CHO), 7.47–7.26 (m, 10H, Ph), 4.95 (d, J = 
11.5 Hz, 1H, PhCH2), 4.81 (d, J = 11.8 Hz, 1H, PhCH2), 4.70 (d, J = 12 Hz, 1H, 
PhCH2), 4.63 (d, J = 11.2 Hz, 1H, PhCH2), 4.30 (dd, J = 11.7, 4.8, 1H, H- 6a), 4.15 
(dd, J = 12.2, 2.7, 1H, H-6b), 3.87 (dddd, J = 8.3, 5.1, 2.7, 0.7 Hz, 1H, H-5), 3.86 (d, 
J = 7.8 Hz, 1H, H-1), 3.80 (dd, J = 9.3, 4.1 Hz, 1H, H-3), 3.57 (t, J = 8.6 Hz, 1H, H-
4), 1.82 (dd, J = 8.0, 4.6 Hz, 1H, H-2); 13C NMR (125 MHz, CDCl3) δ 160.5 (C, C-8), 
137.6 (C, Ph), 137.3 (C, Ph), 128.6 (CH, Ph ), 128.5 (CH, Ph ), 128.3 (CH, Ph ), 
128.1 (CH, Ph), 128.0 (CH, Ph ), 127.99 (CH, Ph ),  77.7 (CH, C-5), 77.3 (CH, C-3), 
74.7 (CH2, PhCH2), 74.4 (CH, C-4), 71.9 (CH2, PhCH2), 63.2 (CH2, C-6), 60.9 (C, C-
7), 58.4 (CH, C-1), 34.0 (CH, C-2); IR (neat, cm-1)  νmax = 3031, 2869, 1724, 1497, 
1454, 1151, 1087, 733, 696. 
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6-O-(tert-butyldiphenylsilyl)-1,5-anhydro-2-deoxy-arabino-hex-1-enopyranose 
(44) 
 
Using a modification of Lellouche and co-workers’ 
procedure,92 imidazole (0.45 g, 6.6 mmol) was added to a 
solution of D-glucal 38 (0.46 g, 3.2 mmol) in DMF (7.5 mL) 
and then cooled to -18°C using dry ice in a 9:1 ethylene glycol 
: ethanol (v:v) slurry. TBDPSCl (0.83 mL, 3.2 mmol) was then 
added dropwise and the reaction was left overnight at -18 °C. 
After TLC analysis showed the disappearance of starting 
materials, the solution was quenched by the addition of H2O (20 mL) and extracted 
with Et2O (3 × 8 mL). The organic fractions were combined and washed with H2O 
(5 mL), dried over anhydrous MgSO4, and concentrated in vacuo to give the crude 
product as a viscous yellow oil. Purification by silica gel column chromatography (1:1 
hexanes: ethyl acetate, v:v) yielded 44 as a colourless viscous oil (226 mg, 19%). 
Spectral data matched those previously reported.92  
 
Rf = 0.38 (1:1 hexanes : EtOAc, v:v); [α]D27.7= +38.0 (c=1.0, CH2Cl2); 1H NMR: (500 
MHz, CDCl3) δ 7.69-7.67 (m, 4H,), 7.47-7.39 (m, 6H), 6.32 (dd, J = 6.5, 2 Hz, 1H, H-
1), 4.73 (dd, J = 6.0, 2.0 Hz, 1H, H-2), 4.27 (d, J = 7.1, 1H, H-3), 3.99-3.97 (m, 2H, 
H-6a, H-6b), 3.95-3.79 (m, 2H, H-4, H-5), 2.78 (s, 2.18, 1H, OH), 2.15 (s, 1H, OH), 
1.07 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 144.3 (C, C-1), 135.7 (C, Ph), 135.5 
(CH, Ph), 132.8 (CH, Ph), 130.0 (CH, Ph), 127.9 (CH, Ph), 102.3 (CH, C-2), 76.7 
(CH, C-5), 71.9 (CH, C-4), 69.6 (CH, C-3), 63.8 (CH, C-6), 26.8 (CH3, SiCH3), 19.25 
(CH3, SiCH3); IR (neat, cm-1)  νmax = 3367, 3071, 3013, 2930, 2857, 1646, 1472, 
1428, 1233, 1107, 1051, 753, 701.  
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(((2R,3S,4R)-3,4-bis(benzyloxy)-3,4-dihydro-2H-pyran-2-yl)methoxy)(tert-
butyl)diphenylsilane (45) 
 
In a slight modification of Schmidt’s procedure,84 the protected 
diol 44 (0.217g, 0.6 mmol) was dissolved in DMF (7 mL) and 
cooled to -5°C. BnBr (0.17 mL, 1.4 mmol) was then added 
dropwise, followed by the portionwise addition of NaH (0.034 
g, 1.4 mmol) over a period of 1 minute. The reaction was then 
left to warm to r.t. and react overnight. TLC analysis showed 
that the reaction was not complete therefore addition of 
catalytic amounts of TBAI (0.02 g, 0.06 mmol) was added to aid in the completion of 
the reaction. Following completion of the reaction, deemed by TLC analysis, it was 
quenched by the addition of H2O (20 mL) and extracted with CHCl3 (3 × 20 mL). The 
organic fractions were combined, dried over anhydrous MgSO4, and concentrated in 
vacuo to give the crude product. The crude material was then purified via silica gel 
column chromatography (9:1 → 1:1 hexanes : EtOAc, v:v) to give 45 (80 mg, 25%),  
 
Rf = 0.40 (12:1 hexanes : EtOAc, v:v); [α]D27.7= +24.0 (c=1.0, CH2Cl2); 1H NMR (500 
MHz, CDCl3): δ 7.7-7.66 (m, 5H, Ph), 7.38-7.28 (m, 15H, Ph), 6.40 (dd, J = 6, 1 Hz, 
1H, H-1), 4.91 (d,  J = 11 Hz, 1H, PhCH2), 4.85 (dd,  J = 6, 2.5 Hz, 1H. H-2), 4.75 (d, 
J = 11.5 Hz, 1H, PhCH2), 4.65 (d,  J = 11.5 Hz, 1H, PhCH2), 4.59 (d,  J = 11.5 Hz, 
1H, PhCH2), 4.23 (m, 1H, H-3), 4.05-4.01 (m, 2H, H-4, H-5), 3.97-3.93 (m, 2H, H6a, 
H6b), 1.05 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 154.0 (C, C-1), 135.1 (C, Ph), 
135.0 (CH, Ph), 130.2 (CH, Ph), 127.9 (CH, Ph), 127.7 (CH, Ph), 99.9 (CH, C-2), 
76.7 (CH, C-5), 75.7 (CH, C-3), 74.4 (CH, C-4), 73.5 (CH2, PhCH2), 70.5 (CH2, 
PhCH2), 68.5 (CH, C-6), 26.5 (CH3, SiCH3), 19.0 (CH3, SiCH3); IR (neat, cm-1)  
νmax = 3399, 3070, 2930, 2858, 1496, 1427, 1361, 1107, 820, 739, 696, 607, 502.  
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Methyl glycinate hydrochloride (46).  
 
 In a modification of Patnaik and colleagues’ procedure,93 
acetyl chloride (2.5 mL, 34.6 mmol) was added dropwise 
to MeOH (16 mL) at 0 °C and stirred for a period of 40 
minutes before the portion-wise addition of glycine (1.0 g, 13.3 mmol). The solution 
was then heated to reflux and left to stir for a period of 3 hours. Completion of the 
reaction was indicated by TLC-analysis, after which the solution was concentrated 
under reduced pressure to produce 46 as an off-white solid (1.68 g, quant.). 
 
Rf = 0.68 (2:10 Methanol : EtOAc, v:v); M.p. 174.0-175.0 °C; 1H NMR (500MHz, 
D2O): δ 3.92 (s, 2H, H-1a, H-1b), 3.84 (s, 3H, H-3); 13C NMR (125 MHz, D2O): δ 
168.60 (C, C-2), 53.23 (C, C-1), 39.92 (CH3, C-3) ; IR (neat, cm-1)  νmax = 3011, 
2881, 2686, 2632, 1743, 1583, 1495, 1437, 1400, 1256, 1139, 1057, 955, 900, 879. 
 
 
Ethyl glycinate hydrochloride (47) 
 
 In a modification of Patnaik and colleagues’ 
procedure,93 acetyl chloride (2.5 mL, 34.6 mmol) was 
added dropwise to EtOH (16 mL) at 0 °C and stirred 
for a period of 40 minutes before the portion-wise 
addition of glycine (1.0 g, 13.3 mmol). The reaction was then heated to reflux and left 
to stir for a period of 3 hours. After TLC-analysis deemed the reaction complete, the 
solution was concentrated under reduced pressure to afford 47 as an off white solid 
(1.82 g, quant.).  
 
Rf = 0.60 (2:10 Methanol : EtOAc, v:v); M.p. 142.6-143.0 °C; 1H NMR (500MHz, 
D2O): δ 4.29 (dd, J= 14.5, 7.5 Hz, 2H, H-1a, H-1b), 3.9 (s, 2H, H-3a, H-3b), 1.28 (t, 
J= 7.5 Hz, 3H, CH3); 13C NMR (125 MHz, D2O): δ 168.09 (C, C-2), 63.21 (C, C-1), 
40.07 (C, C-3), 13.07 (CH3, C-4); IR (neat, cm-1)  νmax = 2975, 2909, 2635, 1742, 
1503, 1411, 1244, 1135, 1051, 904, 854.  
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Butyl glycinate hydrochloride (48) 
 
 
 In a modification of Patnaik, S., and 
colleagues procedure 93 n-butanol (16 mL) was 
cooled to 0 °C followed by the dropwise 
addition of acetyl chloride (2.5 mL, 
34.6 mmol). The solution was stirred at 0 °C for 40 min. Glycine (1 g, 13.3 mmol) 
was then added portionwise over 1 min. The reaction was then heated to reflux and 
left to stir for 3 hours. TLC (2:10 Methanol : EtOAc, v:v) analysis showed completion 
of the reaction. The solution was then concentrated under reduced pressure to afford 
48 (2.18 g, Quan. yield) as an off white solid.  
 
Rf = 0.48 (2:10 Methanol : EtOAc, v:v); M.p. 71.0-71.5 °C; 1H NMR (500MHz, 
D2O): δ 4.25 (t, J= 7.2 Hz, 2H, H-1a, H-1b), 3.9 (s, 2H, H-3a, H-3b), 1.65 (t, J= 7.5 
Hz, 2H, H-4a, H-4b), 1.36 (dd, J= 15, 7.5 Hz, 2H, H-5a, H-5b), 0.89 (t, J= 7.5 Hz, 
3H, H-6a, H-6b, H-6c); 13C NMR (125 MHz, D2O): δ 168.20 (C, C-2), 66.88 (C, C-
1), 40.03 (C, C-3), 29.61 (C, C-4), 18.28 (C, C-5), 12.77 (CH3, C-6); IR (neat, cm-1)  
νmax =  2955, 2873, 2697, 2603, 1740, 1477, 1379, 1238, 1220, 1133, 1062, 917. 
 
 
Ethyl diazoacetate (49) 
 
In a slight variation for the well-established method by 
Searle,100 a solution of ethyl glycinate 47 (0.523 g, 
3.7 mmol) in H2O (1 mL) and CH2Cl2 (2.2 mL) was 
cooled to -5 °C. An ice cold solution of sodium nitrite 
(0.38 g, 4.4 mmol) and H2O (1 mL) was then added and the reaction was further 
cooled to -9 °C. Paying careful attention to retaining the cold temperature, 5% H2SO4 
(0.01 mL, 0.18 mmol, w/w) in H2O (0.34 mL) was then added dropwise over a period 
of 10 minutes. The solution was left to stir for a period of 15 minutes at -9 °C before 
TLC analysis showed the completion of reaction. The solution was then transferred to 
an ice-cold separating funnel containing a solution of cold 5% NaHCO3 in H2O 
(1 mL, w/w), followed by extraction with CH2Cl2 (3 x 10 mL). The organic layers 
were then collected, combined, and transferred back into an ice-cold separating 
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funnel, followed by repetitive washings with NaHCO3 until the solution is basic as 
according to indicator paper. The organic layer was again collected, dried over 
anhydrous NaSO4, and filtered. The final product was not concentrated due to its 
explosive nature and a 70% yield of 49 was assumed as stated in the literature.100  
 
Rf = 0.50 (3:1 Hexanes : EtOAc, v:v); M.p. 124.8-126.0 °C; 1H NMR (500MHz, 
D2O): δ 4.19 (dd, J= 14.0, 7.0 Hz, 2H, H-1a, H-1b), 3.89 (s, 2H, H-3a, H-3b), 1.27 (t, 
J= 7.0 Hz, 3H, CH3); 13C NMR (125 MHz, D2O): δ 168.1 (C, C-2), 63.20 (C, C-1), 
40.06 (C, C-3), 13.57 (CH3, C-4); IR (film from CH2Cl2): νmax 2987, 2113, 1745, 
1625, 1244, 1196, 1066, 1025, 767 cm-1.  
 
 
Rhodium (II) acetate dimer (50).  
 
Following methodology of Legzdins and colleagues,115 
rhodium chloride trihydrate (100 mg, 0.38 mmol) and 
sodium acetate trihydrate (200 mg, 1.48 mmol) were 
dissolved in absolute EtOH (2 mL) and acetic acid (2 mL) 
and heated to reflux for a period of 1 hour. Upon reflux, the 
solution rapidly turned green and a green precipitate was 
deposited. Once the solution had cooled to r.t., the solution 
was filtered and the solid collected and recrystallised from 
boiling MeOH. The crystals were dried at 45 °C in vacuo 
for a period of 40 hours to yield the dimer 50 as emerald green crystals (0.048 g, 
28.2 %). 
 
M.p. 202 °C; 1H NMR (500MHz, D2O): δ 1.90 (s, 12H, CH3); 13C NMR (125 MHz, 
D2O): δ 169.12 (C, CO2), 20.91 (C, CH3); IR (film from CH2Cl2): νmax 2970, 2929, 
2857, 1738, 1682, 1584, 1415, 1365, 1217, 695 cm-1. 
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1,5-Anhydro-2-deoxy-1,2-C-(exo-carbmethoxymethylene)-3,4,6-O-acetyl-α-D-
arabino-hexitol (51) 
 
In a modification of the procedure proposed by 
Hoberg and colleagues,33 the dimer 50 (0.01 g, 
0.02 mmol) was added to a solution of glucal 37 
(0.09 g, 0.34 mmol) in dry CH2Cl2 (1.5 mL) and 
stirred vigorously under argon atmosphere. A 
solution of ethyl diazoacetate (49) (0.165 g, 1.36 
mmol) in dry CH2Cl2 (4.4 mL) was then added 
dropwise over a period of 14 hours via a syringe pump. After addition of the ethyl 
diazoacetate solution TLC analysis showed the presence of both starting material and 
product. The reaction solution was then concentrated in vacuo and purified via silica 
gel column chromatography (5:1 → 1:1 hexanes : EtOAc, v:v) to yield 51 as a pale 
yellow viscous oil (0.032 g, 27%).  
 
Rf = 0.40 (2:1 hexanes : EtOAc, v:v); [α]D26.9= +31.0º (c=1.0, CH2Cl2); 1H NMR 
(500MHz, CDCl3): δ 5.1 (d, J = 4.5 Hz, 1H, H-4), 4.86 (t, J = 4.5 Hz, 1H, H-3), 4.48 
(dd, J = 12, 7 Hz, 1H, H-6a), 4.15-4.11 (m, 3H, H-6b, H-9a, H-9b), 3.95 (dd, J = 7.5, 
2.0 Hz, 1H, H-1), 3.85 (m, 1H, H-5), 2.1-2.07 (m, 9H, CH3CO), 2.04 (t, J = 9.5 Hz, 
1H, H-7), 1.77 (t, J = ?? Hz, 1H, H-2), 1.3-1.25 (m, 3H, CH3-Et); 13C NMR (125 
MHz, CDCl3): δ 170.7 (C, C-8), 169.5 (C, CH3CO), 168.5 (C, CH3CO), 168.1 (C, 
CH3CO), 71.9 (CH, C-5), 68.4 (CH, C-4), 66.9 (CH, C-3), 61.8 (CH, C-6), 61.1 (CH2, 
C-9), 55.9 (CH, C-1), 24.6 (CH, C-2), 23.1 (CH, C-7), 20.92 (CH3, CH3CO), 20.86 
(CH3, CH3CO), 20.79 (CH3, CH3CO), 14.2 (C, C-10); IR (neat, cm-1)  νmax = 2983, 
1739, 1368, 1214, 1182, 1130, 1030, 914. 
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1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(exo-carbmethoxymethylene)-D-
glycero-D-gulo-hexitol (54), 1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(exo-
carbmethoxymethylene)-D-glycero-D-talo-hexitol (55) and 1,5-Anhydro-3,4-di-O-
benzyl-6-O-(formyl)-2-deoxy-1,2-C-(exo-carbmethoxymethylene)-D-glycero-D-
gulo-hexitol (56) 
 
In a modification of the procedure reported by 
Hoberg and Claffey,76 the dimer 50 (0.042 g, 0.095 
mmol) was added to a solution of the protected 
glucal 40 (1.09 g, 1.9 mmol) in dry CH2Cl2 (8 mL) 
and the resulting mixture stirred vigorously. A 
solution of ethyl diazoacetate 49 (4.2 mL, 
5.7 mmol) in dry CH2Cl2 (27 mL) was then added 
dropwise over a period of 14 hours (2.3 mL/h) via a 
syringe pump. According to literature the reaction 
was quenched after 14 hours. The reaction mixture 
was then concentrated in vacuo and purified via 
silica gel column chromatography (20:1 → 5:1 
hexanes : EtOAc, v:v). However, consistant with the 
report of Risseeuw and colleagues,104 this led to an 
inseparable mixture of both stereoisomers 52 and 53 
as a clear viscous oil (0.723 g, 58%). The 
inseparable stereoisomers 52 and 53 (0.545 g, 
0.84 mmol) were then dissolved in Et2O (4.5 mL) 
and treated with the dropwise addition of formic 
acid (3.9 mL, 104 mmol). The reaction was left to stir for 50 minutes, after which 
TLC analysis showed the presence of both starting material and product. It is 
important to note that the reaction should not be left for longer in order to avoid the 
formation of a C6-formyl by-product. The solution was diluted in Et2O (40 mL), 
washed with sat. aq. NaHCO3 (4 x 50 mL), and dried over anhydrous MgSO4. The 
solution was filtered and concentrated in vacuo to produce the crude product as a 
viscous yellow oil. Purification via silica gel column chromatography (14:1 → 1:1 
hexanes : EtOAc) yielded 54 (208 mg, 61%), 55 (68 mg, 20%), and 56 (7.7 mg, 2%) 
as pale yellow oils.  
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Data for 54: Rf = 0.40 (2:1 hexanes : EtOAc, v:v); [α]D26.7= +3.0 (c=1.0, CH2Cl2); 
1H NMR (500MHz, CDCl3): δ 7.35-7.28 (m, 10H, Ph), 4.76 (d, J = 11.5 Hz, 2H, 
PhCH2), 4.62 (d, J = 11.5 Hz, 1H, PhCH2), 4.59 (d, J = 12 Hz, 1H, PhCH2), 4.16 (m, 
2H, CH2-Et), 3.95 (dd, J = 7.5, 2.0 Hz, 1H, H-1), 3.85 (d, J = 5.0 Hz, 1H, H-3), 3.79 
(m, 1H, H-6a), 3.70 (m, 1H, H-6b), 3.50 (m, 2H, H-4, H-5), 2.02 (dd, J = 5.5, 2.5 Hz, 
1H, H-7), 1.82 (t, J = 7.0 Hz, 1H, H-2), 1.27 (t, J = 7.0 Hz, 3H, CH3-Et); 13C NMR 
(125 MHz, CDCl3): δ 171.7 (C, C-8), 137.8 (C, Ph), 137.5 (C, Ph), 128.6 (CH, Ph), 
128.5 (CH, Ph), 128.1 (CH, Ph), 128.0 (CH, Ph), 127.95 (CH, Ph), 127.93 (CH, Ph), 
127.8 (CH, Ph), 76.4 (CH, C-3), 75.2 (CH, C-5), 73.9 (CH, C-4), 73.6 (CH2, PhCH2), 
71.6 (CH2, PhCH2), 62.1 (CH, C-6), 60. 8 (CH2, C-9), 58.1 (CH, C-1), 23.9 (CH, C-2), 
23.3 (CH, C-7), 14.2 (CH3, C-10); IR (neat, cm-1) νmax = 3483, 3031, 2980, 2872, 
1715, 1428, 1298, 1089, 853, 735, 696. 
 
Data for 55: Rf = 0.30 (2:1 hexanes : EtOAc, v:v); [α]D26.5= -24.0 (c=1.0, CH2Cl2); 
1H NMR (500MHz, CDCl3): δ 7.38-7.28 (m, 10H, Ph), 4.98 (d, J= 11.5 Hz, 1H, 
PhCH2), 4.77 (d, J = 11.5 Hz, 1H, PhCh2), 4.70 (t, J = 12.5 Hz, 2H, PhCH2), 4.49 
(dd, J = 9.5, 4.5 Hz, 1H, H-3), 4.13 (q, J = 7.0 Hz, 2H, H-9a, H9b), 3.89 (m, 2H, H-1, 
H-4), 3.66 (m, 2H, H-6a, H-6b), 3.60 (t, J = 9.0 Hz, 1H, H-5), 1.75 (t, J = 6.0 Hz, 1H, 
OH), 1.61 (dd, J = 9.5, 6.5 Hz, 1H, H-7), 1.48 (m, 1H, H-2), 1.26 (t, J = 7.5 Hz, 3H, 
EtCH3); 13C NMR (125 MHz, CDCl3): δ  168.8 (C, C-8), 138.4 (C, Ph), 138.3 (C, Ph), 
128.4 (CH, Ph), 128.37 (CH, Ph), 128.0 (CH, Ph), 127.8 (CH, Ph), 127.7 (CH, Ph), 
127.8 (CH, Ph), 79.8 (CH, C-3), 76.4 (CH, C-4), 74.4 (CH2, PhCH2), 71.9 (CH2, 
PhCH2), 63.0 (CH, C-1), 60.5 (CH2, C-9), 53.6 (CH, C-1), 24.2 (CH, C-2), 22.0 (CH, 
C-7), 14.3 (CH3, C-10); IR (neat, cm-1)  νmax = 3054, 1724, 1422, 1264, 1072, 896, 
732, 704. 
 
 Data for 56: Rf = 0.50 (3:1 hexanes : EtOAc, v:v); [α]D27.7= +42.0 (c=1.0, CH2Cl2); 
1H NMR (500MHz, CDCl3): δ 8.05 (s, 1H, H-11), 7.39-7.28 (m, 10H, Ph), 4.73 (d, J 
= 12 Hz, 1H, PhCH2), 4.72 (d, J = 11.5 Hz, 1H, PhCH2), 4.58 (d, J = 11.5 Hz, 1H, 
PhCH2), 4.579 (d, J = 11.5 Hz, 1H, PhCH2), 4.46 (dd, J = 12.5, 7.5 Hz, 1H, H-6a), 
4.20 (dd, J = 11.5, 2.0 Hz, 1H, H-6b), 4.12 (m, 2H, CH2-Et), 3.93 (dd, J = 7.0, 2.0 
Hz, 1H, H-1), 3.82 (d, J = 6.0 Hz, 1H, H-3), 3.75 (m, 1H, H-5), 3.49 (t, J = 6.0 Hz, 
1H, H-4), 2.02 (dd, J = 5.5, 2.0 Hz, 1H, H-7), 1.83 (t, J = 7.0 Hz, 1H, H-2), 1.26 (t, J 
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= 7.0 Hz, 3H, CH3-Et); 13C NMR (125 MHz, CDCl3): δ  193.7 (C, C-11), 171.4 (C, C-
8), 137.6 (C, Ph), 137.5 (C, Ph), 128.54 (CH, Ph), 128.52 (CH, Ph), 128.0 (CH, Ph), 
127.9 (CH, Ph), 127.8 (CH, Ph), 75.4 (CH, C-3), 74.7 (CH2, PhCH2), 72.6 (CH, C-5), 
71.5 (CH2, PhCH2), 62.5 (CH, C-6), 60.8 (CH2, C-9), 57.1 (CH, C-1), 24.2 (CH, C-2), 
24.1 (CH, C-7), 14.2 (CH2, C-10); IR (neat, cm-1)  νmax = 3013, 2872, 1714, 1454, 
1367, 1297, 1216, 1180, 1090, 748.  
 
 
N,N’-Ditosylhydrazine (57) 
 
p-Toluenesulfonyl hydrazine (5.5 g, 29.6 mmol) 
and p-toluenesulfonyl chloride (8.5 g, 44.3 mmol) 
were dissolved in CH2Cl2 (50 mL) and stirred 
vigorously at r.t., before it was treated to a 
dropwise addition of  pyridine (3.6 mL). The 
addition of pyridine caused the solution to become homogenous and after 5 minutes a 
white precipitate was formed. The reaction mixture was left to stir at r.t. for 1.5 hours 
before it was cooled to 0 °C, diluted with Et2O (120 mL) and H2O (60 mL), and left to 
stir for a further 15 minutes. The white precipitate was collected via Büchner filtration 
and washed with Et2O (100 mL). Purification was achieved through recrystallisation 
from boiling MeOH (60 mL). The recrystallised product was then collected and 
washed with cold MeOH (40 mL) and Et2O (60 mL) to give the final product 57 as 
white crystals (8.13 g, 81%). Spectral data matches that of Toma and colleagues.109 
 
 Rf = 0.50 (3:1 hexanes : EtOAc, v:v); M.p. 209 °C;1H NMR (500MHz, DMSO-d6): 
δ 8.73 (s, 1H, SO2NH), 6.79 (d,  J = 8 Hz, 2H, Ph), 6.54 (d, J = 8 Hz, 2H, Ph), 1.54 
(s, 3H, CH3); 13C NMR (125MHz, DMSO-d6) δ  143.9 (C, Ph), 135.9 (C, Ph), 129.9 
(CH, Ph), 128.2 (CH, Ph), 21.5 (C, CH3); IR (neat, cm-1) νmax = 3232, 3206, 1598, 
1200, 1189, 1171, 810. 
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2-Propynyl 2-diazoaceate (58) 
 
In a modification of Fukuyama and colleagues,109 
propargyl alcohol (1.03 mL, 17.8 mmol) and NaHCO3 
(4.5 g, 53.51 mmol) were dissolved in acetonitrile 
(36 mL) and cooled to 0 °C before bromoacetyl 
bromide (2.3 mL, 26.7 mmol) was added dropwise 
over a period of 3 minutes. Addition of bromoacetyl bromide caused the solution to 
become homogenous and the reaction was left to stir at 0 °C for 15 minutes before it 
was quenched with H2O (100 mL). The solution was extracted with CH2Cl2 (3 x 
40 mL) and the organic layers were collected and washed with brine (3 x 50 mL) 
before being dried over anhydrous MgSO4, filtered, and concentrated in vacuo to 
leave a viscous orange oil. The formed bromoacetate product was used without 
further purification and along with 57 (12g, 35.6 mmol) was dissolved in THF before 
being cooled to 0 °C. DBU (13.3 mL, 13.3 mmol) was then added dropwise over a 
period of 5 minutes, causing the solution to turn into a homogenous mixture. The 
reaction was left to stir for 15 minutes at 0 °C before the reaction was quenched with 
sat. aq. NaHCO3 (60 mL). The solution was extracted with Et2O (3 x 40 mL) and the 
organic layers were collected, washed with brine (3 x 40 mL), dried over anhydrous 
MgSO4 and concentrated in vacuo to provide the crude product. Purification by 
neutralised silica gel column chromatography (3:1 hexanes : EtOAc, v:v) to give 58 
as a viscous orange oil (1.3 g, 57%). Spectral data matches that of Toma and 
colleagues.109 
 
 Rf = 0.50 (3:1 hexanes : EtOAc, v:v); 1H NMR (500MHz, CDCl3): δ 4.84-4.76 (m, 
3H), 2.50-2.42 (m, 1H); 13C NMR (125MHz, CDCl3): δ 165.8 (C, C-2), 77.6 (C, C-4), 
75.0 (CH, C-5), 52.2 (C, C-1), 46.2 (C, C-3); IR (neat, cm-1) νmax = 3286, 3117, 2951, 
2114, 1731, 1987, 1387, 1344, 1219, 1165, 1028, 993, 644. 
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(1S,3R,4S,5R,6S)-prop-2-yn-1-yl-4,5-bis(benzyloxy)-3-(hydroxymethyl)-2-
oxabicyclo[4.1.0]heptane-7-carboxylate (61) and (1R,3R,4S,5R,6R)-prop-2-yn-1-
yl-4,5-bis(benzyloxy)-3-(hydroxymethyl)-2-oxabicyclo[4.1.0]heptane-7-
carboxylate (62) 
 
Using a modification of the method employed 
by Hoberg and colleagues,76 protected glucal 
40 (1.0 g, 1.9 mmol) was dissolved in dry 
CH2Cl2 (8 mL) and stirred under argon. 
Rhodium acetate (0.047 g, 0.095 mmol) was 
then added to the reaction mixture, followed by 
vigorous stirring, before the dropwise addition 
of diazoacetate 58 (0.7 g, 5.7 mmol) in CH2Cl2 
(27 mL) via syringe pump over a period of 14 
hours (2.2 mL/h). The reaction was then left to 
stir for a further 3 hours before the solution was 
concentrated in vacuo to yield the crude 
product. The crude material was then purified 
via silica gel column chromatography (20:1 → 1:1 hexanes : EtOAc, v:v) to give an 
inseparable mixture of both stereoisomers 59 and 60 in a combined yield of 38% 
(447 mg). The isomeric mixture was then dissolved in Et2O (4.1 mL) and treated with 
a dropwise addition of formic acid (3.2 mL, 84 mmol). The solution was allowed to 
stir for 50 minutes at r.t., after which TLC-analysis deemed the reaction complete. 
The reaction mixture was then diluted with Et2O (30 mL) and washed with sat. aq. 
NaHCO3 (4 x 30 mL). The organic layer was collected, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to afford the crude material. Purification by silica 
gel column chromatography (1:100 → 3:10 EtOAc : CH2Cl2, v:v) to provide 61 
(123 mg, 43%) and 62 (27 mg, 10%) as clear viscous oils.  
 
Data for 61: Rf = 0.40 (2:1 hexanes : EtOAc, v:v); [α]D27.7= +38.0 (c=1.0, CH2Cl2); 
1H NMR (500MHz, CDCl3): δ 7.36-7.28 (m, 10H, Ph), 4.75 (d, J = 12.0 Hz, 2H, 
PhCH2), 4.69 (dd, J = 5.0, 2.5 Hz, 2H, H-9a, H-9b), 4.70 (t, J = 12.0 Hz, 2H,  
PhCH2), 4.00 (dd, J = 7.5, 2.5 Hz, 1H, H-1), 3.85 (d, J = 4.5 Hz, 1H, H-3), 3.79 (m, 
1H, H-6a), 3.70 (m, 1H, H-6b), 3.52 (m, 2H, H-4, H-5), 2.50 (t, J = 2.5 Hz, 1H, H-
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11), 2.10 (dd, J = 6.0, 2.5 Hz, 1H, H-7), 1.99 (t, J = 6.0 Hz, 1H, OH), 1.87 (t, J = 7.0 
Hz, 1H, H-2); 13C NMR (CDCl3) δc  170.9 (C, C-8), 137.8 (C, Ph), 137.4 (C,  Ph), 
128.6 (CH, Ph), 128.5 (CH,  Ph), 128.0 (CH,  Ph), 127.9 (CH,  Ph), 127.8 (CH,  Ph), 
76.0 (CH, C-3), 75.1 (CH, C-4), 75.0 (CH, C-5), 73.9 (CH, C-11), 73.6 (CH2, 
PhCH2), 71.7 (CH2, PhCH2), 62.0 (CH2, C-6), 58.4 (CH, C-1), 52.3 (CH2, C-9), 24.5 
(CH, C-2), 23.0 (CH, C-7); IR (neat, cm-1) νmax = 3467, 3286, 3062, 2871, 1723, 
1427, 1292, 1209, 1117, 1088, 825, 736, 696.  
 
Data for 62: Rf = 0.40 (2:1 hexanes : EtOAc, v:v); [α]D27.7= +59.0 (c=1.0, CH2Cl2); 
1H NMR (500MHz, CDCl3): δ 7.38-7.29 (m, 10H, Ph), 4.99 (d, J = 11.5 Hz, 1H, 
PhCH2), 4.75-4.61 (m, 5H, CH2Ph, H-9a, H-9b), 4.44 (dd, J = 9.5, 4.0 Hz, 1H, H-3), 
3.92 (t, J = 6.5 Hz, 1H, H-4), 3.90 (dd, J = 9.0, 4.0 Hz, 1H, H-1), 3.66 (m, 2H, H-6a, 
H-6b), 3.61 (t, J = 9.0 Hz, 1H, H-5), 2.49 (t, J = 2.0 Hz, 1H, H-11), 1.75 (bs, 1H, 
OH), 1.65 (dd, J = 9.5, 6.5 Hz, 1H, H-7), 1.55 (dd, J = 7.0, 4.0 Hz, 1H, H-2); 13C 
NMR (CDCl3) δc  167.9 (C, C-8), 138.4 (C, Ph), 138.2 (C,  Ph), 128.44 (CH, Ph), 
128.4 (CH,  Ph), 128.0 (CH,  Ph), 127.9 (CH,  Ph), 127.8 (CH,  Ph), 79.8 (CH, C-3), 
79.2 (CH, C-4), 74.9 (CH, C-11), 74.5 (CH2, PhCH2), 73.9 (CH, C-5), 72.1 (CH2, 
PhCH2), 63.0 (CH2, C-6), 54.1 (CH, C-1), 51.9 (CH2, C-9), 24.9 (CH, C-2), 21.7 (CH, 
C-7); IR (neat, cm-1)  νmax = 3018, 1733, 1411, 1215, 1126, 1099, 747. 
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Chapter 3 
Biological analysis  
 
3.1 Aims and objectives 
 
This aspect of the thesis focused on the elucidation of the mechanism of action of 
bioactive 1,2-cyclopropyl carbohydrates. Initial work was done testing the bioactivity 
of compounds 23, 54, 55, 56, 61 and 62 through a liquid phase dose-response assays 
using pdr1∆pdr3∆his3∆ as a proxy wild-type yeast from the pdr1∆pdr3∆xxx∆ yeast 
genome deletion set. If the synthesised compounds show bioactivity, they will 
undergo a chemical genetic screen using the pdr1∆pdr3∆xxx∆ library, genetic 
interactions will be validated and subjected to a gene ontology search in order to 
identify chemical pathways involved in the mechanism of action of the drug. Finally, 
target isolation and identification will be attempted with either compound 61 or 62 
through affinity purification by way of a copper-assisted azide-alkyne cycloaddition 
reaction with a modified agarose matrix. 
Introduction  
  
3.2 Yeast as a model organism 
 
The budding yeast, Saccharomyces cerevisiae, has a long and well-documented 
history as the first eukaryotic organism to have undergone complete genomic 
sequencing, which was completed in 1996.116 In 1970, over 600 scientists from North 
America, Europe and Japan discussed the unique advantages S. cerevisiae offers as a 
model organism for eukaryotic cells as the natural progression from the extensive 
studies done on prokaryotic cells and phages.116 Accordingly, this led to the 
completion of the yeast S. cerevisiae genome project, which revealed the yeast’s 
genome to be much more compact than initially expected. The genome sequence of 
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12 million nucleotides encodes approximately 6000 protein-encoding genes, which is 
about 70% of the total genome. In contrast, the human genome contains 
approximately 2.85 billion nucleotides that only codes for 20,00-25,000 protein-
encoding genes.117 Even compared to other yeast species the S. cerevisiaes genome is 
remarkably unique with a much higher ratio of protein-coding genes to genome 
nucleotides.118,116 Coinciding with the completion of the yeast genome project was the 
first complete proteome of a eukaryotic cell. This led to the classification of yeast 
proteins into their functions, allowing researchers to see an approximate percentage of 
proteins involved in each cellular process. For example, a total of 7% of the proteome 
is involved in the process of intracellular trafficking, whereas 11% of its proteome is 
responsible in metabolism.116  
 
Since the yeast genome project started four decades ago, the biochemical, genetic and 
genomic tools available to study this organism have greatly helped in solving many 
biological problems and questions, more so than any other eukaryotic cells. 
Accordingly, this has made yeast the most commonly used organism for 
understanding both vital cellular processes and human diseases.119 A great example of 
this has been the work on understanding telomeres and telomerase. Work done by 
Lingner and colleagues120 identified two essential genes in S. cerevisiae involved in 
the process of telomere formation, Est2 (reverse transcriptase) and Est1 (accessory 
proteins).  Involvement of the two genes was tested and proven through site-directed 
mutagenesis in three key conserved amino acids, which led to a complete prevention 
of telomerase activity.120 This allowed for extensive research to be done on the 
mechanism of telomerase activity in yeast, however, the mechanism of telomerase 
activity in other eukaryotes remained unknown until an iterative profile search found 
human homologs of both the Est1 and Est2 genes, with the region of highest 
homology being the TPR sequence within the Est (figure 3.0).121 This extensive cross-
species homology allowed for the conduction of structure-function analysis of the 
human homolog of both Est1 (hEST1A, hEST1B, hEST1C) and Est2 (hTERT). 
Findings in human cell lines confirmed the results seen in S. cerevisiae with the 
human hEST1 and hTERT genes forming both protein-protein interactions in the 
formation of the telomerase complex, comparable to the Est2 and Est1 genes.122 
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This cross-species homology combined with the yeast genome project and yeast 
deletion libraries make the budding yeast one of the most valuable tools in studying 
eukaryotic life. As with the previous example, studying cellular processes in yeast can 
identify genes previously unknown in other eukaryotes and help identify their 
functions. This is also useful in studying human diseases with approximately 285 
yeast proteins being homologous to 155 proteins associated in human disease,123 
allowing drugs and other inhibitory molecules to be tested through methods such as 
chemical genetic screens to elucidate a potential mechanism of action.  
 
 
 
Figure 3.0: Representation of homology between human and S. cerevisiae Est1 gene. The area of highest 
homology is shown by the shaded area, which all contain TRP (tetratricopeptide). ScEst1 is the yeast 
genes and the three human homologs associated with it: hEST1A/SMG6, hEST1B/ SMG5 and 
hEST1C/SMG7. Figure adopted from Sealey and colleagues.122 PIN (PilT N-terminal), TRID (hTR-
interaction domain), DBD (DNA binding domain). 
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3.3 The yeast pdr1∆pdr3∆xxx∆ deletion mutant array 
 
Yeast ABC transporters are utilised in many biological processes including the 
regulation of mitochondrial function and peptide pheromone secretion, however, they 
are primarily used as xenobiotic efflux pumps conferring pleiotropic drug resistance 
(PDR).124,125 The presence of such effective efflux pumps allows the yeast to quickly 
adapt to toxic environmental changes as well as aiding in the protection against 
unwanted endogenous toxic metabolites.124 Although this aids in the viability of the 
yeast, many xenobiotic activities are masked by the pleiotropic drug resistant (PDR) 
efflux transporters resulting in reduced sensitivity when compared to mammalian cell 
lines.125 This limits the application of yeast in biological screens.  
 
Therefore, the preparation of the pdr1∆pdr3∆ deletion library was undertaken by 
Coorey and colleagues,125 which involved the deletion of the genes for the two major 
transcription factors, pdr1p and pdr3p resulting in a pleiotropic drug resistant (PDR) 
network attenuated deletion mutant array. As shown in figure 3.1 many efflux pumps 
are tightly regulated through the pdr1p, pdr3p transcription factors. Much research has 
been conducted using the single deletion of the ABC transporter PDR5,126,127 
however, the deletion of the pdr1p and pdr3p transcription was found to give a greater 
hypersensitivity to a larger array of compounds as a reduction in all ABC efflux 
pumps was observed.125  
 
 
Figure 3.1: The PDR network in yeast are tightly regulated by the pdr1p and pdr3p transcription 
factors. Only the PDR ABC transporters are represented in this figure, however, it is worth noting more 
non-ABC transporters are involved in the PDR network however their functions are not well 
understood. Arrows indicate positive regulation. 
	 81	
 
Preparation of the MATa pdr1∆pdr3∆xxx∆ library was completed through the mating 
of the MATα pdr1∆pdr3∆ double mutant with the MATa single gene deletion mutant 
array (DMA) gifted to Coorey and colleagues by Dr Charles Boone (University of 
Toronto).125 The pdr1∆pdr3∆xxx∆ deletion library was then subjected to a range of 
compounds including known pdr5p substrates. Previous compounds that displayed 
bioactivity in wild-type yeast were now found to cause hypersensitivity in the 
pdr1∆pdr3∆ deletion library whereas with the known pdr5p substrates bioactivity was 
now detectable. This indicated that the constructed pdr1∆pdr3∆xxx∆ deletion library 
was more sensitive to a broad range of xenobiotics, which in turn allowed for the 
elucidation of the mechanism of action of a wider range of xenobotic substances than 
could be achieved with the parental deletion library.125 
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Materials and methods 
 
3.4 Compounds  
 
All 1,2-cyclopropyl carbohydrates used in the biological screens were synthesised in 
this study (chapter 2), and were purified to >95% as indicated through spectroscopic 
methods (1D and 2D NMR spectroscopy, IR spectroscopy). Samples were stored at -
20 °C under nitrogen atmosphere, and stock solutions were freshly made at a 
concentration of 100 mM in DMSO. All studies were completed using a single batch 
unless otherwise stated. Unless otherwise stated, all reagents were purchased from 
Sigma-Aldrich. 
 
3.5 Yeast strain  
 
Previous bioassays of 23 indicated appreciable potency only against yeast strains 
containing a pdr1∆pdr3∆ background.2 Chemical genetic profiling was undertaken 
using the pdr1∆pdr3∆xxx∆ library, which was obtained from a -80 °C glycerol freezer 
stock originally prepared by Namal Coorey from the Chemical Genetics Laboratory, 
within the School of Biological Sciences at Victoria University of Wellington.125 
 
Strain Genotype 
pdr1∆pdr3∆xxx∆ 
pdr1∆::NAT; pdr3∆::URA3; xxx∆::kanR; can1∆::STE2pr-
Sp_His5; Lyp1∆; his3∆1; leu2∆0;ura3∆0; met15∆0 LYS2 
 
 
3.6 Yeast culture and growth conditions 
 
The pdr1∆pdr3∆xxx∆ yeast strains were cultured in one of the following three media 
conditions: synthetic complete media, synthetic drop-out miuns URA media and yeast 
peptone dextrose media, and supplemented with either of two antibiotics: ClonNat at 
a final concentration of 100 mg/L or geneticin (G418) a final concentration of 200 
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mg/L. All media was sterilised via autoclave for 21 min at 124 °C and 210 kPa. All 
yeast were grown under standard protocols as specified by Sherman.128 
 
3.6.1 Synthetic complete (SC) media 
 
For 800 mL of SC media, 1.36 g of yeast nitrogen base, without amino acids and 
ammonium sulfate (Formedium™ ltd), 0.8 g of L-Glutamic acid monosodium salt 
hydrate (sigma Aldrich) and 1.6 g of the corresponding amino acid mix (see section 
3.6.4) was added to 360 mL of distilled water (dH2O). The mixture was autoclaved at 
124 °C for 21 min then allowed to cool before the addition of 40 mL of a 40% 
glucose solution in dH2O along with the appropriate antibiotic. dH2O is then added to 
make the solution up to 800 mL. For solid SC agar, the same process is followed, with 
the slight variation where 16 g of agar (Formedium™ Ltd.) in 400 mL dH2O was 
autoclaved and added to the SC mixture, making the total volume to 800 mL. The 
agar must be kept at approximately 65 °C otherwise it will begin to solidify.  
 
3.6.2 Synthetic drop-out (SD) minus URA media 
 
SD media is prepared in the same way as SC, though the amino acid mix used for this 
media does not contain uracil (URA).  
 
3.6.3 Yeast peptone dextrose (YPD) media  
 
For 800 mL of YPD media, 8 g of BactoTM yeast extract (BD bioscience), 16 g of 
peptone (Formedium™ ltd) and 0.096 g of adenine (Sigma-Aldrich) was added to 360 
mL of water and autoclaved at 124 °C for 21 min. The solution was then allowed to 
cool before the addition of 40 mL of a 40% glucose solution in dH2O, followed by the 
desired antibiotic. dH2O was then added to make the resulting solution up to 800 mL.  
For the solid YPD agar, the same procedure is followed, with the addition of 16 g of 
agar (Formedium™ ltd) in 400 mL water to the YPD media after autoclaving to bring 
the total volume to 800 mL. The solid agar was kept at 65 °C to prevent it from 
solidifying at lower temperatures before pouring plates. 
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3.6.4 Amino acid mix for SC media 
 
The amino acid mixture for SC media consists of; 3 g adenine, 2 g alanine, 0.2 g p-
aminobenzoic acid, 2 g asparagine, 2 g aspartic acid, 2 g cysteine, 2 g glutamic acid, 2 
g glutamine, 2 g glycine, 2 g histidine, 2 g inositol, 2 g isoleucine, 10 g leucine, 2 g 
lysine, 2 g methionine, 2 g phenylalanine, 2 g proline, 2 g serine, 2 g threonine, 2 g 
tryptophan, 2 g tyrosine, 2 g uracil and 2 g valine. As stated above SD amino acid mix 
does not contain uracil, however everything else remains the same.  
 
3.7 Dose-response assay in Saccharomyces cerevisiae  
 
3.7.1 Liquid phase dose-response assay 
 
All dose-response assays were conducted using a single colony of pdr1∆pdr3∆his3∆ 
yeast cells. Cells were inoculated into 2 mL of YPD and SC media. The inoculated 
cells were then placed in a rotating drum (Digisystem Laboratory Instruments) at 
30 °C at a speed of 45 rpm and left to grow overnight. Cell concentration was 
calculated using a UV/VIS spectrometer (Unicam 8625) reading at OD660. Cells were 
diluted with the respective media to make a 10 mL solution with a final cell 
concentration of 5 x 105 cells/mL. Using a multichannel pipette, 99 µL of the cell 
solution was plated out into flat bottom 96 well plates (Corning Incorporated).  
 
In a separate deep-well 96 well plate (Gene era biotech), a 1.5-fold serial dilution was 
prepared of compounds 23, 54, 55, 56, 61 and 62 from the corresponding 100 mM 
stock solution. Dilutions of the 1,2-cyclopropyl carbohydrates were achieved using 
DMSO (Sigma-Aldrich).   
 
Subsequently 2 µL of the 1.5-fold drug dilution was added to each well of a 96 well 
microtiter plate containing the cell solution, making a final DMSO concentration of 
2%. A row was treated with 2 µL of DMSO alone to act as a negative control to allow 
for the calculation of residual growth as well as the inclusion of an individual row 
containing only media in order to calculate optical density of the growth media. The 
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plates were then mixed via vortex for 30 seconds at 1000 rpm using an Eppendorf 
Mix Mate (Krackeler Scientific Inc.) and incubated at 31 °C for 24 hours. After 
24 hours, the cells were re-suspended via vortex for 30 seconds at 1000 rpm and the 
optical density read at 590 nm using a multi-well plate reader (PerkinElmer, Envision 
Multiplate Reader). Residual growth was calculated as:  
 𝑂𝐷!"# exp− 𝑚𝑒𝑎𝑛 𝑂𝐷!"# 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑𝑚𝑒𝑎𝑛 𝑂𝐷!"# 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −𝑚𝑒𝑎𝑛 𝑂𝐷!"# 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑  ×100 
 
Where mean OD590 control is the mean optical density of the DMSO control wells, 
OD590 background is the mean optical density of wells containing only media and 
OD590 is the optical density for each experimental well.  
 
3.7.2 Solid phase dose-response assay 
 
A solid phase dose response was conducted using YPD agar. Based on the results of 
the liquid IC50 results (see section 3.17.1), seven falcon tubes were prepared for both 
23 and 54 with a range of increasing drug concentrations of 0, 20, 50, 100, 200 and 
400 µM for 23 and 0, 50, 100, 150, 200 and 300 µM for 54, at a final DMSO 
concentration of 2%. Hot agar (55 °C) was added to each falcon tube to a final 
volume of 30 mL and the solution was gently mixed through rotation. Each falcon 
tube was poured into separate Singer plates (Singer instruments, Somerset UK) and 
allowed to cool and set. Plates were not stacked to allow fast cooling and to avoid any 
potential breakdown of compound 23 and 54, as reported by Davies.2 Once cooled, a 
single plate from the pdr1∆pdr3∆xxx∆ library was pinned using the singer RoToR 
HAD (Alphatech systems Ltd) robot onto all the plates in a 1536 format resulting in 
quadruplicate colonies. The plates were incubated for 24 hours and then 
photographed. Colony size and circularity was calculated using the colony-based 
screening program Gitter.129 Results were compared to control, from which the 
residual growth could be calculated. 
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3.8 Chemical genetic screening 
 
All chemical genetic screens were conducted using the pdr1∆pdr3∆xxx∆ library.125 
Excluded from the pdr1∆pdr3∆xxx∆ DMA are essential genes and 441 known slow 
growing deletion strains. The non-essential pdr1∆pdr3∆xxx∆ yeast DMA is composed 
of 14 plates, arranged in a 386 format, which include a pdr1∆pdr3∆his3∆ border to 
account for the effects of nutrition access on colony size. All plates were expanded to 
a 1536 format, allowing for quadruplicates of each colony.  
 
Based on the results of the solid phase dose response assay (see section 3.17.2), 14 
plates containing 40 mL of SC agar with no antibiotics were prepared with compound 
23 at a concentration of 50 µM (15 µL from a 100 mM stock solution in 285 µL 
DMSO) to a final DMSO concentration of 1%. This was repeated with 54 at a 
concentration of 160 µM (48 µL from a 100 mM stock solution in 252 µL DMSO). 
The solution containing the corresponding drug and DMSO was not added to the agar 
until the agar had cooled to approximately 55 ºC. For each drug treatment, 
corresponding control plates were also poured using SC agar, which contained 
300 µL of DMSO. Plates were then allowed to set over 1 hour before drying in the 
laminar flow (Holten Lamin Air). Using the singer RoToR HDA the pdr1∆pdr3∆xxx∆ 
library was pinned from a previously prepared working copy onto the treated and 
controlled plates. A separate working copy was used for both 23 and 54 and their 
corresponding control plates. Plates were incubated at 33 ºC and photographed at 18, 
22 and 36 hours. Images were processed by the colony-based screening program 
Gitter,129 where average circularity and size of each quadruplicate strain was 
calculated and compared against control. Results of the Gitter processing were run 
through a Screen Mill130 search resulting in a p-value and z-score for all quadruplicate 
colonies compared to control.  
 
Resistant strains were defined as having a p-value less the 0.05 and a z-value (for the 
ratio of growth control/growth treatment) of -1.95 or less. Sensitive strains are defined 
as a p-value of 0.05 or less and a z-score (for the ratio of growth control/growth 
treatment) of greater than 1.95.  
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3.9 Validation of chemical genetic screens 
 
Validations of both resistant and sensitive pdr1∆pdr3∆xxx∆ strains were conducted in 
liquid media. Results from the chemical genetic assay (section 3.18) indicated a large 
number of the resistant and sensitive deletion strains were the same for both 
compounds 23 and 54 suggesting both compounds have the same target. Therefore, 
resistant and sensitive strains were combined for the validation. A total of 169 
resistant strains and 155 sensitive strains were inoculated into individual wells of four 
flat bottom 96 well plates (Corning Inc), containing 100 µL of SD-URA liquid media. 
A single row containing only pdr1∆pdr3∆his3∆ was added on each plate as a control. 
Plates were placed on vortex for 30 sec at 1000 rpm and incubated at 33 ºC for 48 
hours until all strains were at saturation. Plates were then briefly vortexed for 30 
seconds at 1000 rpm and pinned using the singer RoToR HDA to four working copy 
of flat bottom 96 well plates containing 100 µL of SD-URA. The new working copies 
were again placed upon the vortex for 30 seconds at 1000 rpm and incubated for 
48 hours at 33 ºC.  
 
For compound 23, four flat bottom 96 well plates were prepared consisting of 99 µL 
of SD-URA liquid media and 2 µL of 23 in DMSO in each well, at a final 
concentration of 40 µM. Resistant and sensitive strains were then pinned from the 
previously prepared working copy using the singer RoToR HDA. Plates were placed 
upon the vortex for 30 seconds at 1000 rpm and incubated at 33 ºC. Optical density 
measurements were then acquired at 24, 30, 36 and 48 hour time periods. The above 
process was repeated with compound 54 at a final concentration of 160 µM. For both 
compounds each resistant and sensitive plate was run with an untreated control plate 
with final DMSO concentration of 2%.  Resistant strains were defined as having 
residual growth 4 standard deviations above the residual growth pdr1∆pdr3∆his3∆ 
strain. Sensitive strains were defined in a similar manner, in which residual growth 
was 2 standard deviations below the pdr1∆pdr3∆his3∆ strains. Slow growing control 
strains were identified as having 40% reduction in growth compared to the mean 
control colony size and were subsequently excluded from the data.  
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Gene ontology analysis was conducted on all validated strains utilising both 
yeastmine131,132 and g:Profiler.133,134   
 
3.10 Mammalian cell experiments 
 
PhD candidate Richard Little, in the School of Biological Sciences, Victoria 
University of Wellington, conducted the following mammalian MTT cell proliferation 
experiments.  
 
Under normal cell culture conditions, human HL-60 promyelocytic leukemia cells at a 
concentration of 1x104 cells/well were seeded into a 96 well plate and incubated with 
23 for 48 hours. Cell were then treated with 20 µL of MTT and left to incubate for a 
further 2 hours at 37 °C. Addition of 100 µL of a solubilising agent containing 45% 
DMF and 10% SDS (pH 4.5, adjusted with acetic acid addition) allowed for the 
solubilisation of the blue crystals overnight at 37 °C. Absorbance readings at 570 nm 
indicated MTT reduction. IC50 values were calculated from a concentration-response 
curve using prism (Prism Graphpad Software Inc).  
 
3.11 Affinity matrix synthesis  
 
Epoxy-activated agarose (600 mg, 12 µM) was added to 2 mL of dH2O in a 15 mL 
falcon tube and allowed to swell for 2 hours. Sodium azide (6 mg, 90 µM) was then 
added to the solution and stirred lightly via vortex, followed by the addition of cerium 
(III) chloride heptahydrate (1.4 mg, 5.4 µM). The solution was rotated for 16 hours at 
33 °C. The solution was then centrifuged at 2000 rpm for 1 min followed by the 
removal of the solvent. Purification was achieved by the successive addition of 
ethanol and diethyl ether, where ethanol (6 mL) was added and the solution and 
lightly shaken via vortex for 1 min before being centrifuged at 1000 rpm for 1 min. 
The solvent was removed and replaced with diethyl ether (6 mL). This was again 
shaken lightly via vortex and centrifuged at 1000 rpm for 1 min before being decanted 
off. The whole process was then repeated to ensure full conversions of epoxide to 
azide. The final white precipitate was then dried under vacuum.  
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3.12 Cell lysate preparation 
 
Glass beads (0.5 mm diameter, dnature Ltd) were soaked in a solution of 1 M HCl 
overnight followed by extensive rinsing with water to ensure the pH was neutral. The 
glass beads were dried under vacuum at 80 °C overnight and chilled in ice before use. 
A pdr1∆pdr3∆his3∆ yeast colony was inoculated into a 15 mL solution of SD-URA 
and allowed to shake overnight at 33 °C. The 15 mL yeast culture was centrifuged for 
2 min at 20,000 rpm and the supernatant was decanted off. The pdr1∆pdr3∆his∆ 
culture was resuspended in 2 mL or lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% DMSO and 10 µL of protease inhibitor cocktail). Chilled glass beads were 
added to the solution at a ratio of 3 g per gram of yeast cell (wet weight). The solution 
was then shaken at full speed via vortex 5 times for 3 min, keeping the cells on ice for 
2 min between vortex sessions. The glass beads were removed via pipette and the 
cellular debris was removed through centrifugation at 4 °C for 30 min at 16,000 rpm. 
 
3.13 Copper-assisted azide-alkyne cycloaddition  
 
From a prepared stock solution of 61 (100 mM) in DMSO, 40 µL was added to a 
1 mL solution of prepared yeast lysate (section 3.12). The solution was allowed to 
shake for 6 hours at 33 °C before the addition of 25 mg of azide-activated agarose 
matrix (section 3.11), 0.1 mL of saturated copper sulfate and 5 mg of ascorbic acid 
neutralised in aqueous sodium hydroxide. The reaction mixture was left to shake at 
33 °C for 12 hours before undergoing centrifugation at 7,000 rpm for 5 min. The 
supernatant was decanted providing the derivatised matrix, which was washed three 
times with a buffer solution (1 M Tris-HCl buffer pH  8), centrifuging at 7,000 rpm 
for 5 min and decanting the supernatant between each wash. The above method was 
repeated with the exclusion of the saturated copper sulfate and ascorbic acid solution 
as a control.  
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3.14 Isolation of binding proteins 
 
A 500 µL low salt wash solution (0.1% triton X-100 in 0.5 M Tris-HCl pH 7.6) was 
added to the lysate-matrix complex for both the treatments and negative control 
(section 3.12) and resuspended. The solution was then centrifuged for 5 min at 
7,000 rpm and the supernatant decanted, followed by the addition of a 500 µL high 
salt wash solution (1M NaCl, 0.1% triton X-100 in 0.5 M Tris-HCl pH 7.7). The 
solution was shaken via vortex, centrifuged at 7,000 rmp for 5 min and the 
supernatant was removed. An LDS wash was performed with the addition of 100 µL 
of NuPAGE LDS sample buffer (4X) loading buffer. The solution was again shaken 
via vortex and centrifuged at 7,000 rpm for 2 min and the supernatant was collected. 
The lysate-matrix complex was then washed twice with dH2O and twice with a buffer 
solution (100 mM aqueous ammonium bicarbonate) with the last buffer wash lasting 
10 min. The washes were centrifuged at 7,000 pm for 5 min and supernatant decanted. 
The lysate-matrix complex was then reduced with a 100 µL solution of 10 mM DTT 
in 100 mM ammonium bicarbonate at 30 °C for 30 min then allowed to cool to room 
temperature before the addition of 1 µL of a 1 M solution iodoacetamide to make a 
final concentration of 10 mM. The solution was incubated for 30 min at 35 °C with no 
exposure to light, followed by centrifugation (7,000 rpm, 5 min) and removal of 
supernatant before the lysate-matrix complex was washed with 50% acetonitrile in 
100 mM ammonium bicarbonate buffer. The resulting solution was centrifuged 
(7,000 rpm, 5 min) and the supernatant decanted. The matrix was then rehydrated in 
20 µL of 50 mM ammonium bicarbonate, followed by the addition of 1 µg of trypsin 
and incubated overnight at 33 °C. The solution was centrifuged (7,000 rpm, 5 min) 
and the supernatant was collected and concentrated via speed vac to afford the 
peptides.  
 
3.15 ZipTip purification 
 
The concentrated peptides were resuspended in 10 µL of a 0.2% formic acid solution. 
For the preparation of the ZipTip (Millipore Corp.), 10 µL of a 0.2% formic acid 
solution was aspirated twice. Care was taken to not pass any air through the ZipTip. 
The sample was then aspirated 10X followed by 2X aspiration with 10 µL of a 0.2% 
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formic acid solution then 10X aspiration with a 1:1 formic acid:acetonitrile solution. 
Utilising the same ZipTip, this procedure was repeated ensuring binding of all the 
peptides onto the ZipTip followed by the final aspiration in 70% acetonitrile solution. 
The 1:1 formic acid:acetonitrile solution was then added to the 70% acetonitrile 
solution and concentrated via speed vac to yield the purified isolated peptides. The 
procedure was then repeated with the control sample.  
 
3.16 Protein identification 
 
Following protein puficication and isolation, identification was undertaken utilising 
either liner ion trap (LTQ) spectroscopy (LTQ XL™ Linear Ion Trap Mass 
Spectrometer, Thermofischer), or MALDI (AB SCIEX TOF/TOF™ 5800). 
 
3.16.1 LTQ tandem mass spectroscopy 
 
Samples were prepared by resuspending the purified peptides in 50 µL of formic acid 
buffer (0.1% conc. formic acid in HPLC water). Ionisation of the peptide solution was 
conducted by electrospray with a silica tip emitter (360 µm OD X 20 µm ID X 10 µm 
tip opening, New objectives, USA), with a set voltage potential of 1.8 kV, a heat 
capillary set to 275 ºC, and a tube lens at 120 V allowed the positive ions to enter. 
Ions with a mass to range of 200-1850 m/z were analysed in a 6 hour acquisition time 
utilising Fourier transform mass spectroscopy (FTMS) in the orbitrap. At a resolution 
of 30,000, a full scan in the FTMS identified the 6 top intensity ions were selected for 
collision-induced dissociation (CID) and detection in the LTQ. The following 
dynamic exclusion criteria were as stated: repeat duration 30 s, repeat counts 2, 
exclusion duration 90 s, exclusion list size 500.  
 
3.16.2 MALDI spectroscopy 
 
Preparation of the MALDI matrix was undertaken via the addition of 500 µL of 
acetonitrile, 500 µL of MilliQ water and 1 µL of concentrated trifluoroacetic acid 
(TFA). The solution was mixed via vortex before the addition of 10 mg of alpha-
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cyano-4-hydroxycinnamic acid (CHCA). The solution was shaken at full speed via 
vortex followed by a centrifugation at 16,000 rpm for 5 min. The supernatant was 
decanted and used as matrix. A calibration mixture was also prepared consisting of 
1 µL of CalMix2 (Applied biosystems) in 100 µL of the matrix solution.  
 
The purified isolated peptides from treatment and control samples (see section 3.13) 
were resuspended in 10 µL of MilliQ water. A series of dilutions were made to a total 
volume of 6 µL consisting of a 1:1, 5:1 and 10:1 matrix:sample solution. The 
dilutions and their corresponding controls were each added as individual spots on the 
MALDI detection plate at a volume of 1 µL. The corresponding calibration spot was 
also added. The prepared plate was allowed to dry.  
 
Calibration was internally conducted utilising CalMix2 monoisotopic peaks of 
adrenocorticotropic hormone (ACTH) clip 7-38 (m/z 3657.9294), ACTH clip 18-39 
(m/z 2465.1990), ACTH clip 1-17 (m/z 2093.0870), angiotension 1 (m/z 1296.6770) 
and des-Arg1-brodykinin (m/z 904.4680). Criteria of calibration included a minimum 
of three matched peaks, mass tolerance of ± 0.1 m/z, signal to noise ratio ≥ 5 and a 
outlier error of 1 m/z. The spectrum was acquired through a positive reflector mode. 
Laser intensity was fixed at 4600 and a pulse range of 400 Hz. A total of 500 laser 
shots were taken and peptide fragments were collected in a mass rage of 700 to 
4000 Da. MS/MS sequence was imported into the ProteinPilot™ (Sciex) software. 
The generated peak list was sequence was analysed with the MASCOT algorithm 
(Matrix science) generating a peak list, which was run against the NCBI database for 
S. cerevisiae generating a list of isolated proteins.  
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Results 
 
3.17 Dose-response assay in Saccharomyces cerevisiae  
 
3.17.1 Liquid phase dose-response assay 
 
Previously established results by Davies2 indicated no bioactivity of compound 23 
and other 1,2-cyclopropyl carbohydrates in the haploid wild-type yeast strain 
BY4741. However bioactivity of the 1,2-cyclopropyl carbohydrates synthesis by 
Davies was reported in the pdr1∆pdr3∆xxx∆ strain due to the deletion in the pdr1p 
and pdr3p efflux pumps. Therefore all dose-response assays conducted during this 
study were undertaken using the pdr1∆pdr3∆his3∆ strain as a surrogate for a wild 
type in the pdr1∆pdr3∆xxx∆ library. A liquid growth assay (section 3.7) was used in 
order to establish an inhibitory concentration of compounds 23, 54, 55, 61 and 62. As 
shown in figure 3.2, inhibition of growth over a 24 hour period for compound 23 was 
recorded with an IC50 value of 20.4 µM. The recorded IC50 value varies slightly from 
that reported by Davies (44 µM).2 IC50 values were calculated from triplicate data and 
determined through fitting a sigmoidal curve from the dose response data. A maximal 
cell death was reported at 60.14 µM as shown in figure 3.2.  
 
Figure 3.2: Compound 23 dose-response assay. IC50 values of sensitised pdr1∆pdr3∆his∆ strain yeast 
to compound 23 were measured over a 24 hour period. The triplicate data was fitted by a sigmoidal 
curve and presented through a dose- response curve. Error bars represent standard error of the mean.  
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Of the 1,2-cyclopropyl carbohydrate library tested by Davies,2 inhibitory effects were 
only noted in compounds containing the α-cyclopropyl ring. However, this was not 
the case in this study as inhibitory effects were observed in both the α- and β-
stereoisomers of the 1,2-cyclopropyl carbohydrates (54 and 55) as well as (61 and 
62), although, greater inhibition was observed in the α stereoisomers (54 and 61) 
compared to the β isomer. As shown in figure 3.3, both compounds 54 and 61 still 
inhibit in the low µM range, though a noticeable increase in IC50 is observed 
compared to compound 23, with the calculated IC50 for 54 and 61 being 148 µM and 
110 µM, respectively. IC50 were again recorded from triplicate data and calculated 
through the fitting of a sigmoidal curve (figure 3.3). All results were recorded at a 
24 hour time point. Comparison of inhibition of compounds 54 and 55, and 61 and 62 
are demonstrated in figure 3.4A and 3.4B, respectively. It is worth noting that the 
increase in the residual growth demonstrated in figure 3.4 at higher concentrations is 
due to the precipitation of the compounds 54, 55, 61 and 62 in the liquid agar. 
Formation of the cloudy precipitate is noticeable immediately upon addition of the 
inhibitor. 
 
 
 
 
 
 
 
Figure 3.3: Dose-response assay for both compound 54 (A) and 61 (B). IC50 values of sensitised  
pdr1∆pdr3∆his3∆ strain yeast to compound 54 and 61 were measured over a 24 hour period. The 
triplicate data was fitted by a sigmoidal curve and presented through a dose- response curve. Error bars 
represent standard error of the mean. 
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3.17.2 Solid phase dose-response 
 
A solid phase dose-response was conducted in order to establish the necessary dose 
required in the chemical genetic screen. A solid phase dose-response was only 
conducted on compounds 23 and 54 as these compounds displayed a low IC50 in the 
liquid dose-response. Due to limitations in the amount of compound, 61 did not 
undergo a solid dose-response and a chemical genetic analysis. Results shown in 
figure 3.5 are consistent with that of the liquid dose-response showing inhibition by 
both compounds. The treated plates were photographed at 24 hours and the images 
were processed to determine average circularity and colony size. Average circularity 
and colony sizes were then compared to the negative control and residual growth was 
calculated to determine the respective IC50 values. Solid phase inhibition at 24 hours 
of compounds 23 and 54 resulted in an IC50 values of 52.2 µM and 158.5 µM, 
respectively (figure 3.5). This data was not repeated in triplicates due to low 
compound amounts. Again, a small increase in the residual growth of compound 23 is 
noticeable at 200 µM and 300 µM, which is due to the precipitation of the compound 
within the agar when the plates are poured. 
 
 
 
 
 
Figure 3.4: A) Comparison of compounds 54 and 55, indicating a prominent increase in the IC50 of the  
β product (55) compared to the α  (54). B) Comparison of compounds 61 and 62, indicating a 
prominent increase in the IC50 of the β product (62) compared to the α  (61). Results are consistent with 
similar trends observed by Davies. Error bars show standard error of the mean.  
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3.18 Chemical genetic screens 
 
Using the pdr1∆pdr3∆xxx∆ deletion mutant library of S. cerevisiae, a high-throughput 
synthetic genetic array was conducted with compounds 23 and 54. This would allow 
for the identification of any chemical genetic interactions and ideally identification of 
a mechanism of action of both compounds. From the solid phase dose response 
(section 3.17.2), an inhibitory concentration of both compounds 23 and 54 was 
selected that would give approximately a 50% reduction in growth. This would allow 
for the identification of both sensitive and resistant strains. The pdr1∆pdr3∆xxx∆ 
library was expanded from 384 colonies to the 1536 colony format to produce 
quadruplicates of each strain, with each plate containing a pdr1∆pdr3∆his3∆ border, 
which acts as a proxy wild-type strain. The his3 deletion is neutral in the growth 
media and the pdr1∆pdr3∆his3∆ strain has a common genetic background with the 
rest of the library bearing a full set of deletion markers. The deletion library was 
photographed at 24, 36 and 48 hours and the images were processed allowing for the 
determination of both colony size and circularity.129 As shown in figure 3.6, resistant 
 
 
Figure 3.5: Solid phase dose-response of compound 23 and 54 indication IC50 values of 52.2  µM and 
158.5 µM respectively. Data was not repeated in triplicates therefore standard error of the mean was 
not calculated. IC50 was calculated by fitting a sigmoidal curve.  
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strains were defined by an increase in growth with a p-value of >0.05 and a z-score of 
<-1.95 (for the ratio of growth control/growth treatment) against the negative control. 
Of the 4800 homozygous deletion strains tested, 132 were resistant against compound 
23 and 83 strains were found to be resistant against compound 54. In addition, 
sensitive strains were defined as having a decreased growth with a p-value of >0.05 
and a z-score of >1.95 (for the ratio of growth control/growth treatment) against the 
control. This identified 67 strains sensitive to compound 23 and 106 strains sensitive 
to compound 54 (Figure 3.6). Identification of both resistant and sensitive strains 
allowed for early speculation of potential mechanisms of actions of both compounds. 
An early gene ontology analysis indicated enrichment among the resistant strain for 
cytoplasmic translation with a p-value of 2.17x10-6 and 0.018 for both compounds 23 
and 54, respectively. Ontology was found among the sensitive strains with 
corresponding p-values of 0.001 and 0.01 respectively for compounds 23 and 54, 
which indicated a degree of involvement in protein folding in the endoplasmic 
reticulum (ER). Due to both compounds identifying similar resistant and sensitive 
strains as well as having matching ontology results, they were assumed to have the 
same target. However identified strains were validated before definitive conclusions 
can be made, as high-throughput techniques are susceptible to false positive and 
negative results.  
 
 
 
Figure 3.6: Example of a single plate (plate 8) from the homozygous pdr1∆pdr3∆xxx∆ deletion mutant 
library, screened against 23, indicating both a resistant and sensitive strain compared to control (right 
plate). Each plate contains 306 deletion strains in quadruplicate colonies with a pdr1∆pdr3∆his3∆ 
boarder around the edge of the plate acting as proxy wild-type strain.  
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3.19 Validation of chemical genetic hits 
 
A number of factors in the high-throughput screens can lead to false positive or 
negative results. Variation in the amount of yeast collected during pinning, 
competition for nutrients with neighboring colonies and inherently fast or slow 
growing strains are all factors that can lead to errors in chemical genetic arrays. It was 
therefore decided to conduct the validations in liquid SD-URA media in order to 
eliminate some of these potential error-producing factors and to ensure sensitivity and 
resistance was robust across different growth media. Due to the similarities in the 
identified sensitive and resistant strains of both compounds 23 and 54 in the genomic 
screens, and the hypothesis that both compounds are hitting the same target, all 
identified hits were combined for validation. Therefore, a total of 168 resistant and 
151 sensitive strains were chosen for validation against both compounds.  
 
For these validations, resistant strains were defined as having a residual growth 4 
standard deviations greater than the average ∆his control.  Slow growing strains were 
identified as having a 40% in the control stain compared to the mean control OD. This 
identified 61 resistant strains for compound 23 and 12 resistant strains for compound 
54 (Appendix, table 4.0). Gene ontology analysis showed significant interactions of 
both 23 and 54. Utilising a Holm-Bonferroni test correction, enrichment of the 
cytosolic ribosome to a significant p-value of 0.019 for compound 23 was noted (table 
3.0). However, with compound 54, ontology enrichment was shown both in the 
SNARE complex and SNAP receptor activity. Both enrichments were statistically 
significant, indicated by a p-value less than 0.05 utilising the Holm-Bonferroni test 
correction (table 3.1). 
 
  Compound 23 Resistant   
Ontology Enrichment P-value # of genes 
Biological process - - - 
Cellular component Cytosolic ribosome 1.37x10-7 11 
Molecular function - - - 
 
Table 3.0: Gene ontology enrichments of resistant validated hits for compound 23. 
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Additionally, sensitive strains were defined as having a residual growth 2 standard 
deviations below than the average ∆his control and again slow growing strains were 
identified as having a 40% in the control stain compared to the mean control OD. This 
allowed for the successful identification of 112 sensitive strains to compound 23 and 
53 strains sensitive to compound 54 (appendix, table 4.1). Gene ontology analysis was 
again undertaken on the identified sensitive strains for both compounds 23 and 54. 
Analysis using a Holm-Bonferroni test correction of the sensitive strains identified by 
compound 23 showed enrichment in protein folding in the endoplasmic reticulum, 
along with a large assortment of enrichments in the cellular process of the ER (table 
3.2). Despite slightly varied results in compound 54 when compared to 23, there were 
also noticeable similarities. Enrichment was found in intra-golgi vesicle-mediated 
transport utilising a Holm-Bonferroni test correction for both compounds. 
Interestingly, the same assortment of enrichments relating to the ER was found for 54 
as they were for 23 (table 3.3). It is worth noting that gene ontology terms are 
“nested”, containing parental and daughter terms. Thus the list of enrichments shown 
in table 3.0, 3.1, 3.2, 3.3 and 3.4 include such nested terms and are found because of 
overlapping sets of sensitive deletion strains.  
 
 
  Compound 54 Resistant   
Ontology Enrichment P-value # of genes 
Biological process - - - 
Cellular component SNARE complex 3.14x10-3 3 
Molecular function SNAP receptor activity 1.44x10
-2 3 
 
Table 3.1: Gene ontology enrichments of resistant validated hits for compound 54. 
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Ontology Enrichment P-value # of genes 
Biological process Intra-Golgi vesicle-mediated transport 2.45x10-2 5 
Cellular component Endoplasmic reticulum part 7.19x10-6 17 
  Endomembrane system 9.40x10-7 26 
  Endoplasmic reticulum 3.55x10-5 18 
  Endoplasmic reticulum membrane protein complex  9.89x10
-3 3 
  Endoplasmic reticulum membrane 1.21x10-4 15 
  Nuclear outer membrane-endoplasmic reticulum membrane network 1.92x10
-4 7 
  Integral component of endoplasmic reticulum membrane  6.21x10
-4 7 
  Intrinsic component of endoplasmic reticulum membrane  6.21x10
-4 7 
  Bounding membrane of organelle 8.89x10-6 24 
  Organelle membrane 1.51x10-3 25 
 
Table 3.3: Gene ontology interaction of sensitive validated hits for compound 54. 
 
Ontology Enrichment P-value # of genes 
Biological process Protein folding in endoplasmic reticulum 1.15x10-2 5 
Cellular component Endoplasmic reticulum part 3.60x10-7 26 
  Endomembrane system 3.96x10-7 40 
  Endoplasmic reticulum 5.02x10-7 29 
  Endoplasmic reticulum  membrane protein complex  5.65x10
-6 5 
  Endoplasmic reticulum membrane 4.93x10-5 5 
  Nuclear outer membrane-endoplasmic reticulum membrane network 9.20x10
-5 22 
  Integral component of endoplasmic reticulum membrane  6.15x10
-3 8 
  Intrinsic component of endoplasmic reticulum membrane  6.15x10
-3 8 
  Bounding membrane of organelle 1.71x10-2 30 
 
Table 3.2: Gene ontology interaction of sensitive validated hits for compound 23. 
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Following the hypothesis that compounds 23 and 54 are targeting the same receptor, 
resistant and sensitive strains were compared between the compounds and common 
validated strains were better evaluated, as they were believed to represent the the most 
robust chemical genetic interactions. The common hits between 23 and 54 were 
subjected to a gene ontology analysis and the results are indicated in table 3.4. 
Unfortunately, no enrichment was found for the common resistant strains.  
 
Ontology Enrichment P-value # of hits 
Biological process intra-Golgi vesicle-mediated transport 8.08x10-3 5 
  Macromolecule localisation  1.11x10-2 18 
  Cellular protein localisation 1.53x10-2 14 
  Cellular macromolecule localisation 2.52x10-2 14 
  Protein localisation 2.60x10-2 16 
  Intracellular protein transport 2.84x10-2 12 
  Cellular localisation 3.54x10-2 18 
  Protein transport 4.85x10-2 14 
Cellular component Endomembrane system 9.17x10-8 15 
  Bounding membrane of organelle 1.132x10-5 24 
  Endoplasmic reticulum part 1.31x10-5 15 
  Endoplasmic reticulum membrane 3.87x10-5 3 
  Endoplasmic reticulum 3.96x10-5 16 
  Nuclear outer membrane-endoplasmic reticulum membrane network 6.00x10
-3 14 
  Organelle membrane 9.01x10-4 6 
  Integral component of endoplasmic reticulum membrane 2.82x10
-3 6 
  Intrinsic component of endoplasmic reticulum membrane 2.82x10
-3 21 
  Endoplasmic reticulum membrane protein complex  5.13x10
-3 22 
  Golgi transport complex 1.42x10-2 3 
  Membrane 2.17x10-2 29 
 
Table 3.4: Gene ontology for the common sensitive hits between 23 and 54. 
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A manual analysis of the validated resistant and sensitive hits showed a high number 
of gene involved in specific protein complexes, as shown in table 3.5. For example all 
but one EMC gene of the EMC complex was defined as sensitive after the validations 
indicating a strong interaction with the complex. Similar results were obtained for 
other complexes (table 3.5). Where possible members of the complexes shown in 
table 3.5 that were not tested were all subjected to hypothesis testing in order to assess 
their sensitivity to compounds 23 and 54. This allows for the testing of potential false 
negatives from the high-throughput genetic screening in method 3.8. 
 
3.20 Hypothesis testing of non-validated strains 
 
Where several members of a protein complex had been identified through the initial 
screen and validated, it was hypothesised that these complexes were important in the 
mode of action of the compounds. This hypothesis was tested through assessment of 
further members of each complex. Hypothesis testing was undertaken utilising the 
same methodology as the validation assay in order to reduce any potential variation in 
data. The hypothesis testing was run coherently with randomly selected strains from 
the pdr1∆pdr3∆xxx∆ deletion mutant library, that were previously defined as not 
resistant or sensitive in order remove any potential biases in the results. By utilising 
the same parameters as the validation experiments, several of the genes previously 
untested in the complexes in table 3.5 were validated and defined as sensitive. This 
added further weight for the importance of the complexes in the mechanism of action 
of compounds 23 and 54. Randomly selected strains that were included as a negative 
control showed no sign so sensitivity.  
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Complex Member Validation Hypothesis testing 
EMC EMC1 23   
  EMC2 23 and 54   
  EMC3 23 and 54   
  EMC4 23   
  EMC5 Not tested 23 and 54 
  EMC6 23 and 54   
        
COG COG1 Not tested Not in deletion library 
  COG2 Not tested Null mutant inviable 
  COG3 Not tested Not in deletion library 
  COG4 Not tested Null mutant inviable 
  COG5 23 and 54   
  COG6 Not tested 23 and 54 
  COG7 23 and 54   
  COG8 23 and 54   
        
GARP VPS51 23 and 54   
  VPS52 Not tested Not in deletion library 
  VPS53 23 and 54   
  VPS54 Not tested Not in deletion library 
        
Sec63 Complex SEC62 Not tested  Null mutant inviable 
  SEC66 23 and 54   
  SEC72 Not tested  23 
        
SSH1 complex SSH1 23 and 54   
  SBH2 23 23 and 54 
  SSS1 Not tested Null mutant inviable 
 
 
Table 3.5: Potential complexes involved in the mechanism of action of both 23 and 54 showing 
validated hits and hypothesis tested hits to respective protein complex. 
3.21 Mammalian cell experiments 
 
Compound 23 was subjected to MMT assay by PhD candidate, Richard Little, who 
utilised the HL-60 human promyelocytic leukemia cell line to conduct initial dose-
response assays. As shown in figure 3.7, inhibition of growth was observed over a 
48 hour period with a maximal inhibition dose of 76 µM. Utilising triplicate data and 
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the best fitted sigmoidal curve, the IC50 value was calculated to be 24 µM. Although 
mammalian cells tend to be more sensitive to small molecules due to their lack of 
PDR efflux pumps, these results are consistent with the IC50 value reported in the 
yeast liquid dose-response. It is important to note that the perceived increase in 
survival at a higher concentration of approximately 400 µM is again due to the 
precipitation of compound 23 and not an increase in cell viability. 
 
 
 
 
Figure 3.7: Dose-response assay of HL-60 mammalian cell line to compound 23 measured over a 
48 hour period. The triplicate data was fitted by a sigmoidal curve a. Error bars represent standard error 
of the mean. 
 
 
3.22 Protein isolation and identification via affinity purification 
 
As the dose-response results (section 3.17.1) demonstrated bioactivity of the 
propargyl derivative 61, a chemical proteomic analysis was undertaken in order to 
attempt to elucidate the potential target for the bioactive compounds synthesised in 
chapter 2. Both linear ion trap (LTQ) and MALDI-TOF mass spectroscopic methods 
were used in this study. 
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Analysis of the results from the LTQ mass spectroscopy was undertaken using 
Thermo fisher Proteome Discoverer 1.4.1.14, which yielded several identified 
proteins as shown in table 3.6. However all hits had scores below those considered 
meaningful. These low quality assignments were based off low percentage coverage 
of the protein as identifications were made from a very small number of peptides. For 
example the top result as determined by Thermo fisher Proteome Discoverer was 
Fructose-bisphosphate aldolase, which had the highest score of 31.1 although 
identification was made from two peptides with covered 8.36% of the peptide. This is 
not sufficient to identify the protein as a target, and most likely relates to a small 
amount of contamination in the sample.  
 
 
Analysis of the MALDI results by protein pilot™ program and MASCOT algorithm 
yielded one potential match, the YAL028W-like protein, however this was also 
associated with a low score of 26, with only 4/108 peptide fragment matches. 
Therefore this data is also not significant and no observations were made.  
Description Score Coverage Proteins Unique peptides Peptides #AA 
Fructose-bisphosphate 
aldolase 31.1 8.36% 1 2 2 359 
Glyceraldehyde-3-phosphate 
dehydrogenase 15.55 9.34% 3 1 3 332 
Enolase 14.17 11.90% 2 2 6 437 
60S ribosomal protein 10.43 5.39% 1 1 2 297 
Phosphoglycerate kinase 10.08 8.17% 1 1 3 416 
Heat shock protein SSA2 6.31 9.23% 2 2 3 639 
Phosphoglycerate mutase 5.27 7.29% 1 1 2 247 
Pyruvate kinase 5.26 6.40% 1 2 3 500 
40S ribosomal protein 3.97 11.76% 2 1 1 136 
Elongation factor 2.69 2.40% 1 1 1 458 
 
 
Table 3.6: Results from the LTQ mass spectrometer. Although results were recorded the low score 
and low protein coverage does not make these results significant, therefore no observations were 
made. 
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Discussion 
 
The decision to undergo biological analysis utilising the pdr1∆pdr3∆ DMA library 
was made based on the previous findings reported by Davies,2 which indicated 1,2-
cyclopropyl carbohydrates were potentially active substrates for ATP-binding cassette 
(ABC) efflux transporters. The general amphiphilicity of the 1,2-cyclopropyl 
carbohydrates synthesised by Davies was consistent with that of efflux substrates. To 
this end, Davies screened a small library of 1,2-cyclopropyl carbohydrates against the 
yeast wild-type strain BY4741, which resulted in no bioactivity, however, identical 
test runs against the pdr1∆pdr3∆ deletion library yielded toxicity in the mid to low 
micromolar concentration range, which was promising.  
 
3.23 Dose response in relation to chemical structure 
 
As stated in section 1.4.1, it was proposed that due to the high ring and torsional strain 
of the cyclopropane moiety and its sp2-like characteristics, 1,2-cyclopropyl 
carbohydrates would undergo either a ring opening or expansion reaction if exposed 
to an enzymatic nucleophile, allowing for a mechanism-based inhibition of a putative 
target enzyme. Through a number of SAR assays with a small library of 1,2-
cyclopropyl carbohydrates, Davies2  was able to postulate a potential mechanism of 
inhibition. For example, positioning good leaving groups at either the C-7 or C-3 
position resulted in very little to no bioactivity, deeming ring expansion reactions 
shown in scheme 3.1 to be unlikely.  
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In contrast, synthesised compounds with the ability to stabilise a C-7 carbanion 
consistently showed bioactivity, suggesting ring opening reactions as a mechanism of 
inhibition as shown in scheme 3.2. This led to the proposed design of the new lead 
compound 54, where the formation of an enolate anion (81b) was envisaged to occur 
leading to an increase stabilisation through resonance with 81a and favoring the ring 
opening reaction. As expected, the synthesised target compounds in chapter 2 
exhibited inhibition of pdr1∆pdr3∆ yeast strain in the low micromolar concentration 
range, adding further weight that the compounds undergo a ring opening reaction and 
formation of a carbanion. Disappointingly, however, the IC50 values of the newly 
synthesised compounds were higher then the original compound 23. This was 
envisaged to be due to unfavourable non-covalent interactions within the binding 
pocket. Moreover, the substitution of the electronegative chlorine for an alkyl chain 
could result in unfavourable hydrophobic interactions within the binding pocket, 
resulting in the increased IC50 value. Nonetheless, observed bioactivity of all 
synthesised compounds was consistent with ring opening and carbanion stabilisation. 
The proposed mechanism shown in scheme 3.2 is thought to be the most likely 
mechanism of inhibition.  
 
 
 
 
 
 
 
 
Scheme 3.1: Unlikely ring expansion mechanisms. 
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Scheme 3.2: Proposed mechanism of inhibition of compound 54. 
 
 
As demonstrated by Davies2, the stereochemistry of the cyclopropane ring also has an 
important effect on the biological activity of the compounds, with bioactivity being 
reported only for the compounds with the cyclopropyl ring on the α-face on the 
pyranose ring. Although in this study bioactivity was reported for both the α- and β 
cyclopropyl compounds synthesised in chapter 2, a substantial reduction in bioactivity 
was observed in the β diastereoisomers compared to the α diastereoisomers. This 
suggested that either a steric interaction reduces the ability of the β diastereoisomers 
to access the active site of the target leading to a lower bioactivity, or that the 
stereochemistry of the β diastereoisomers interferes with either the enzymatic 
nucleophilic attack or the ability for the enzyme to aid in the stabilisation of the C-7 
carbanion. As shown in figure 3.8, if an enzymatic nucleophile attacks the anomeric 
carbon from the β-face on the pyranose ring, the steric bulk of the cyclopropane and 
the attached substituents in the β isomer may hinder the nucleophilic attack from 
occurring, leading to a reduced affinity of the compound. Much like the positioning of 
the enzymatic nucleophile preference may also be imposed through the positioning of 
a catalytic residue within the binding site, which aids in the stabilisation of the C-7 
carbanion. Irrespective of which of these effects underlies the facial preference, it is 
clear that a diastereoselective preference is consistent with a target based activation of 
O
OBn
BnO
HO
Nu
O
OBn
BnO
HO
Nu
O
OBn
BnO
HO
NuO
OBn
BnO
HO
Nu
1
234
5
6
7
1
234
5
6
7
1
234
5
6
7
1
234
5
6
7
54 81a
83 82
O
O
O
O
O
OBn
BnO
HO
Nu
1
234
5
6
7
81b
O
O
O
O
O
O
11
12 11
12
11
12
11
12
11
12
H
	 109	
the compound. An example demonstrating a similar situation was reported by 
Todoroki and colleagues,135 where the correct stereochemistry cyclopropane ring on 
the plant hormone abscisic acid was essential in eliciting bioactivity. Through the 
synthesis of several derivatives of abscisic acid and extensive biological testing, they 
conclude that the cyclopropane must be in the ‘down’ orientation due to the tight 
sterics of the binding site.135 
 
 
 
 
Figure 3.8:  Enzymatic nucleophilic attack from the β face, as a proposed reason for decreased 
bioactivity of the β diastereoisomers. 
 
 
 
As expected, the dose response of compound 56 gave no bioactivity, which was 
consistent with the results reported by Davies.2 This negative result adds further 
weight that the C-6 OH is an essential pharmacophores element for the bioactivity of 
the synthesised compounds. This suggests that non-covalent interactions such as a 
hydrogen bond acceptor may be present within the binding pocket in close proximity 
to the C-6 OH. However, the lack of bioactivity may also be due to the larger steric 
bulk of the formate ester, preventing the compound from accessing the enzyme’s 
active site.  
 
It is important to note that although the results are consistent with the possibility that 
the synthesised 1,2-cyclopropyl carbohydrates are substrates for an enzymatic 
nucleophilic attack, it remains conceivable that the inhibition could be occurring 
through strictly non-covalent interactions or that nucleophilic attack is occurring via 
an activated water molecule.136 
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3.24 Chemical genetic analysis 
 
Investigation into the potential mechanism of compounds 23 and 54 through the use 
of chemical genetic profiling resulted in some fascinating outcomes, which allowed 
for the speculation of potential pathways and even targets involved in the activity of 
both compounds. The initial chemical genetic screen using the pdr1∆pdr3∆xxx∆ 
DMA library125 yielded a total of 132 resistant strain and 67 sensitive strains for 
compound 23 and 87 resistant and 106 sensitive strain for compound 54. However 
due to the potential errors that can arise from high-throughput screening all identified 
strain were subjected to validation in order to identify potential false positive results. 
As stated in section 3.19, it was assumed that both compounds had a common target 
due the similarities in the resulting chemical genetic profiles. Therefore all genes 
identified as a ’hit’ in the chemical genetic screens were combined in the validation 
and run against compounds 23 and 54. The validation screens included randomly 
selected strains, which were not identified as a ‘hit’ in the high-throughput screens as 
negative controls.  
 
Identification of the sensitive and resistant strains allowed for the analysis of 
biological and cellular enrichment through gene ontology. Although no enrichment 
was found for the common resistant genes, several processes were found to be 
significant for the sensitive strains with the general theme for protein localisation and 
trafficking associated with the endoplasmic reticulum and golgi (for the full ontology 
enrichments see, table 3.4). The common validated results also underwent further 
analysis with the Biological Networks Gene Ontology (BiNGO) tool which is an 
open-source Java application that determines which gene ontologies are significantly 
overexpressed.137 This allowed for further analysis of the data indicating over 
representation of genes in specific pathways along with the graphical representation 
of the data (figure 3.9). As shown in figure 3.9, although significant enrichment is 
associated with such processes as protein folding in the endoplasmic reticulum and 
cellular calcium ion homeostasis, the overwhelming majority of enrichment is in 
protein localisation and intracellular transport, verifying the results from the initial 
ontological screens. 
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Figure 3.9: BiNGO analysis of the common validated sensitive strains indicated an over representation 
of genes involved in protein localisation and intracellular transport. 
 
 
However although both gene ontology and BiNGO analysis indicated the potential 
mechanism of action of compounds 23 and 54 being involved in protein localisation 
and intracellular transport, further work needed to be done to narrow the parameters 
in which inhibition may be occurring. Therefore a manual analysis of the common 
validated hits was undertaken in order to identify the potential involvement of specific 
protein complexes in the mechanism of compounds 23 and 54. As shown in table 3.5, 
five protein complexes were found to display sensitivity to both compounds. 
 
Analysis of the complexes shown in table 3.5 leads to a speculative hypothesis of a 
potential mechanism of action of compounds 23 and 54. The initial aim was to 
attempt to identify a set of essential genes that are not in the deletion library with a 
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paralog complex that would be identified as sensitive. With chemical genetic 
interactions, partial inhibition of the essential complex at a low concentration, i.e IC50, 
level would lead to reduced growth of all colonies however the strain with the gene 
deletion in the paralog complex or associated pathways would exhibit hypersensitivity 
to the compound indicating the essential complex as a potential target. 
 
Of the complexes shown in table 3.5 this was the case of the Sec61 complex. The 
Sec61 complex is essential for yeast viability, hence it is not in the deletion library, 
however, Sec61 is known to have a physical interaction with the Sec63 complex and 
it also has a paralog, the Ssh1 complex, both of which were found to be 
hypersensitive. The Sec61 complex is essential in protein translocation into the 
endoplasmic reticulum (ER) for both co- and post-translational translocation of 
protein. During co-translational translocation a signal recognising particle receptor 
(SRPR) recognises a specific signal recognising particle (SRP) at the amino terminal 
of the peptide within the translating ribosome. The SRPR transfers the ribosome to 
the Sec61 complex allowing he two complexes to directly bind in turn allowing 
translocation of the polypeptide through the Sec61 complex concurrently with the 
peptide synthesis (figure 3.10A).138,139 In contrast to co-translational translocation, 
post-translational translocation is the translocation of previously synthesised peptide 
from the cytosol to the ER. This requires the recruitment of the additional complex 
Sec63 and the Hsp70 chaperone protein BiP,140 to aid in the unidirectional movement 
of the proteins into the ER form the cytosol. Upon Sec61 recognition of the SRP on 
the polypepide, Sec63 recruits the BiP chaperone, which essentially pulls the 
polypeptide through the Sec61 complex and into the ER (Figure 3.10B).139 
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Figure 3.10: A) Co-translational translocation: SRPR binds to SRP on the ribosome. Binding of the 
ribosome directly to Sec61 releases the SRP-induced break on translation and allows translocation to 
occur concurrently with translation, B) posttranslational translocation: Translated polypeptide binds to 
Sec61 which recruits the Sec63 complex. The polypeptide is pulled through via Hsp70 chaperone 
protein BiP. Figure adopted from Park et al with permission from the publisher.139 
 
 
In light of these results and findings Sec61 was identified as a potential target for 
compounds 23 and 54. The results from the chemical genetic screens and the 
validations also seem to match that reported by Junne and colleagus,141 who reported 
the isolation and discovery of a new natural product that directly inhibited the 
translocation complex Sec61. Due to only a small amount of their chemical genetic 
profile being published, the authors were contacted directly to see if similarities were 
present between both their data set and that presented in this thesis. However after 
examination of their data and correspondence with the authors few similarities were 
found reducing the probability of Sec61 as a potential target for 23 and 54. Consistent 
with this, analysis of the strains resistant to compound 23 shown enrichment in the 
cytosolic ribosome, suggesting that the reduction of translation into the ER causes 
resistance, most likely through reducing the build up of protein in the ER. This 
contradicts the suggestion of Sec61 complex as a potential target, as inhibition Sec61 
would also slow translation and reduce the build up of protein in the ER giving 
similar results.  
 
Analysis of the literature identified the use of both the GARP and the COG 
complexes in the process of vesicle tethering. Vesicle fusion to the plasma membrane 
is known to be mediated through the attachment of proteins known as target N-
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ethylmaleimide sensitive factor attachment protein receptors (t-SNARE) located on 
the target plasma membrane and vesicle N-ethylmaleimide sensitive factor attachment 
protein receptor (v-SNARES) located on the vesicle plasma membrane.142 However, 
although it is well known that attachment of both t-SNARES and v-SNARES is 
essential for the fusion of the vesicles to the plasma membrane, the fidelity of a 
specific vesicle to the desired target has been debated.143 The wide distribution of 
SNAREs on vesicle and target plasma membranes is not enough to account for the 
specific localised distribution of vesicles to their target. An example of this was 
demonstrated by Brennwald and colleagues144 in which they found that the yeast 
SNAREs Sso1p and Sso2p were widely distributed  over the plasma membrane of 
both vesicles and target, however vesicles still arrived at specific destinations. This 
specificity is now thought to be attributed to the tether complexes such as the 
conserved oligomeric golgi (COG) and the golgi-associated retrograde protein 
(GARP), which have been demonstrated to form the first initial link between the 
vesicle and the plasma membrane aiding in the recognition of the vesicle and 
facilitating v-SNARE and t-SNARE binding.142,143,145   
 
The GOG tethering complex is apart of a class of tethering factors along with GARP 
and the exocyst complex known as the CATCHR (complexes associated with 
tethering containing helical rods). Although these tethering complexes belong to the 
same family they share few sequence similarities with the exception of a conserved 
helical bundle.142 As shown in figure 3.11A the COG complex consists of 8 subunits, 
which are organised in two to distinct lobes that have few structural and functional 
similarities.146 The essential COG4 is proposed to bind directly to the v-SNARE, Syl1 
and Vps45 through N-terminal helical coiled-coil mediating and stabilising the 
interaction with the vesicle. COG domains 6 and 7 also bind directly to the SNAREs 
via the same mechanism further aiding in stabilisation.142 The COG tethering complex 
has been stated to regulate the intra-golgi and endosome-to-golgi trafficking.143, 
147,146,142 All four non essential subunits were among the genes that defined as 
sensitive to both compounds 23 and 54 (see table 3.5).  
 
Although the GARP complex is less extensively characterised than the remanding two 
members of the CATCHR family, the COG and exocyst complex, it is still known to 
facilitate retrograde trafficking of vesicles from the late endosome to the golgi.148,148 
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An example of this was demonstrated by Fröhlich and colleauges,149 who were 
investigating the importance of retrograde trafficking from the endosome to the golgi 
for sphingolipid homeostasis. Upon a quantitative genome-wide synthetic lethality 
assay in yeast they found one of the strongest hypersensitivity was towards genes of 
the GARP complex. This later allowed them to propose that the GARP complex was 
essential for retrograde trafficking of sphingolipid from the endosome to the golgi. As 
shown in figure 3.11B the GARP complex consists of 4 subunits of which Vps51 has 
been shown to be essential in the tethering process. It has been shown that in the 
absence of Vsp51 the remaining GARP complex can still form however no binding to 
Stx6 occurs. However lack of one of the remaining subunits in the presence of Vps51 
only slightly reduces binding.148 As shown in figure 3.11, Vsp52 and 53 also bind 
directly with the yeast SNARE stx6. With the exception of Vsp52 and Vps53, which 
are not in the pdr1∆pdr3∆xxx∆ deletion library, deletion of the other members of the 
GARP complex led to sensitivity.  
 
 
 
The final member of the tethering CATCHR family, the excoyst complex is an 
essential gene in the viability of yeast. Much like the COG and the GARP complex 
 
Figure 3.11: Multi subunit tethering complexes COG and GARP interacting with membrane bound 
SNAREs, allowing for the stabilisation of vesicles. A) Indicting the 8 subunits of COG with the 
interactions of COG4, COG7 and COG6 directly with the SNAREs. B) The GARP complex, Vps51 is 
essential in the function of the GARP complex as lack of Vps51 has been shown to inhibit GARP 
tethering. Figure adopted from Hong and colleagues with rights from the publisher.142  
	116	
the exocyst complex aids in vesicle tethering indirectly facilitating SNARE 
docking.142,145 As shown in figure 3.12 the exocyst complex consists of 8 subunits, of 
which Sec3 and Sec70 have been shown to interact strongly with the plasma 
membrane via electronic interactions and Sec4 interacts with the vesicle. 
Establishment of these interactions facilitates the interaction of the v-SNARE and the 
t-SNARE.142, 145 As stated above, partial inhibition of an essential gene with a low 
drug concentration would lead to a reduced growth in all viable strains however stains 
with coinciding deletions is related processes would lead to hypersensitivity. As 
hypersensitivity was seen in the in strains which contained deletions in either the 
COG or GARP complex, which are closely related to the exocyst system, this allowed 
for the speculation of potential inhibition of a component of the exocyst complex or a 
protein closely associated with the exocyst complex. Interestingly the exocyst 
complex has also been shown to interact both physically and functionally with the 
Sec61 complex.150,151 Toikkanen and colleagues150 showed that through 
overexpression of the Sec61β gene they were able to suppress the growth defects of 
all excocyst mutants. Therefore, by expansion of this, Sec61 mutants should cause 
hypersensitivity and reduced growth in yeast when the exocyst complex is been 
inhibited. This is exactly what is observed in the chemical genetic screens further 
adding weight to potential inhibition of an aspect of the exocyst system or associated 
proteins.   
 
 
 
Figure 3.12: The exocyst multi subunit tethering complex. indirectly facilitating the docking of t-
SNAREs and v-SNAREs. Figure adopted from Hong and colleagues with rights from the publisher.142 
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The final protein complex that was identified in the chemical screens as being 
sensitive to compounds 23 and 54 is the ER membrane protein complex (EMC). The 
EMC was initially proposed to be associated with the unfolded protein response 
(UPR),152,153 which would explain the gene ontology enrichment in protein folding 
(table 3.2, figure 3.9), however, new studies suggest that the complex is more likely 
involved in the process of retrograde and anterograde transport154 with more recent 
publications proposing that the EMC complex directly aids in ER to mitochondrial 
vesicle tethering.155 This adds further weight to the hypothesis that compound 23 and 
54 are involved in the inhibition of protein tethering.  
 
Although no enrichment was found in the common resistant strains, analysis of the 
strains resistant to compound 54 showed enrichment in SNARE complex and SNAP 
receptor activity. SNAP is one of the four essential α-helices that make up the 
SNARE complex. Although the exact interaction and involvement of 23 and 54 
remains unknown resistance in both the SNAREs and the SNAPs reinforces the idea 
that the compounds are closely associated with vesicle tethering and the exocyst 
system.  
 
3.25 Affinity purification of target protein 
 
As the target of the synthesised 1,2-cyclopropyl carbohydrates remains unknown, 
attempts to isolate the target were undertaken through the use of an affinity 
purification resin. Although Davies2 was unsuccessful in his attempts of isolating the 
target protein he did report potential involvement of the compounds in transcription 
and translation. It was therefore assumed that, like the majority of drugs, the target of 
the 1,2-cyclopropyl carbohydrates was a protein. 
 
The unsuccessful attempts at target isolation by Davies2 was found to be due the 
inactivity of his probe modified compounds which contained p-azidobenzyl 
substituents at carbons C-3 and C-4 position. This indicated a potential essential 
interaction with the target at these positions, therefore we hypothesised that 
attachment of a propargyl probe at the C-7 position might extend out of the binding 
pocket and allow of a copper-assisted azide-alkyne cycloaddition reaction to occur 
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with an azide modified resin. In order to test this hypothesis compound 61 was 
successfully synthesised and an initial biological analysis was conducted on the 61 
which indicated bioactivity in the low micromolar concentration similar to that of 54. 
However due to the addition of only 5 atoms onto the C-7 carbon speculation still 
remained whether the propargyl probe would be long enough to extend out of the 
binding pocket and interact with the azide modified resin.  
 
Whole cell lysate from S. cerevisiae was treated with 61 followed by the addition of 
the azide modified agarose resin. Following the removal of the supernatant the resin 
was washed with a low salt solution removing any unbound proteins followed by a 
high salt concentration wash. Utilisation of both the low and the high salt wash had 
been shown to remove any non-specific bound protein.156 A final wash using LDS-
page was undertaken to remove any specific but non-covalently associated protein as 
it was assumed that the compound was covalently binding to the target. Finally the 
resin was then subjected to a trypsin digest followed by mass spec analysis.  
 
As reported (section 3.22) no significant results were obtained from either the LTQ 
mass spectroscopy of the MALDI mass spectroscopy analysis. After analysis of the 
chemical genetic screens indicated a potential mechanism of action in protein 
trafficking, it was assumed that the target protein may be membrane bound therefore 
it would not be possible to isolate the target through an affinity purification as the 
insoluble membrane is removed in the first stage of preparing the cell lysate.  
Summary  
 
The initial dose-responses conducted on the compounds synthesised in chapter 2 
showed pleasing results with bioactivity being recorded in the mid to low micromolar 
concentrations range. An SAR analysis confirmed that the mechanism of inhibition 
was most likely occurring through a cyclopropane ring opening reaction and 
formation of a carbanion. Variation in bioactivity between the α and β 
diastereoisomers suggest a that either a potential steric interactions of the binding 
pocket or the position of the catalytic residue or nucleophile favors α diastereoisomers 
(figure 3.8). The chemical genetic analysis preformed indicated involvement of the 
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compound in protein trafficking and translocation, with further analysis of specific 
complexes, suggesting involvement in vesicle tethering. Consistent with this, no 
cytosolic target could be isolated and identified by mass spectroscopy; however, lack 
of target identification could also be due to other factors such as steric bulk of the 
target protein inhibition the interaction of the azide and alkyne. Although no target 
was isolated through an affinity purification process, the exocyst complex was found 
to be an essential complex central to the identified sensitive strains, therefore future 
work would revolve around the exocyst system to better understand its involvement in 
the mechanism of action of the synthesised 1,2-cyclopropyl carbohydrates.   
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Chapter 4 
Conclusion 
 
4.1 Future directions 
 
Although much work has been done throughout this thesis towards the elucidation of 
the mechanism of action of 1,2-cyclopropyl carbohydrates, many areas of 
investigation still remain. While the target 1,2-cyclopropyl carbohydrates 23, 54 and 
61 were successfully synthesised, it would be valuable to further increase the library 
of 1,2-cyclopropyl carbohydrate derivatives in order to better understand the 
structure-activity relationship needed for bioactivity and in turn increasing the overall 
biological activity. Further work to identify the target through affinity purification 
and/or better understand the mechanism of action would also be needed as the next 
essential step in the development the 1,2-cyclopropyl carbohydrates derivatives 
towards their use as pharmaceutical compounds.  
 
4.1.1 Structure-activity relationship 
 
As previous SAR assays conducted by Davies2 identified several essential 
pharmacophore elements around the pyranose ring, such as benzyl groups at the C-3 
and C-4 position along with a hydroxyl group at the C-6 position, the limitations of 
the binding pocket around the ethyoxy- and propargyloxycarbonyl substituent of 54 
and 61 remain largely unknown. Extension of the alkyl chain would allow 
investigation as to whether the chain is orientated such that it protrudes out of the 
binding pocket and in turn potentially eluding to the depth of the binding pocket. This 
would be indicated by either a constant bioactivity in the mid to low micro molar 
concentration, or, if the alkane chain does not protrude out of the binding pocket a 
decrease in bioactivity will be observed with an increasing chain length. Extending 
the alkane chain will also increase the LogP (The logarithm of the partition coefficient 
between water and 1-octanol).  Increasing lipophilicity of the compound might allow 
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for easier access into the cell, alternatively use of a more polar substituent at this 
position may reduce the sensitivity of the compound to the action of efflux pumps. If 
extension of the alkane chain is successful and bioactivity is retained this may address 
previous concerns that the propargyl group on compound 61 was not protruding out of 
the binding pocket limiting its ability to interact with the derivatised matrix. Therefore 
addition of an alkyne group onto an extended alkane chain would overcome this issue 
increasing the ability for the copper-assisted azide-alkyne cycloaddition.  
 
The use of alternative stereochemistry around the pyranose ring should also be 
investigated though a SAR assay. Use of galactose, mannose and allose would 
provide alternative stereochemistry around the pyranose ring, which may affect the 
bioactivity of the 1,2-cylopropyl carbohydrate derivatives. Use of these alternatives 
substrates will also give vital information about the 1,2-cyclopropyl carbohydrates 
binding site.  
 
4.1.2 Elucidation of the mechanism of action and target identification 
 
Despite great progress being made in the identification of the mechanism of action, 
the exact mechanism and target of the 1,2-cyclopropyl carbohydrates still remains 
unknown. Use of yeast library tagged with green fluorescent protein (GFP) would 
allow for the visualisation of any changes in protein localisation in response to the 
1,2-cyclopropyl carbohydrates. As the 1,2-cyclopropyl carbohydrate derivatives have 
indicated to be involved in post-translational protein trafficking this would indicate 
where protein trafficking is been stopped.157 Alternatively attachment of a GFP to a 
propargyloxycarbonyl substituted 1,2-cyclopropyl carbohydrate like 61 and 62, could 
allow for the visualisation of where the compounds are going within the cell.  
 
Isolation and identification of the biological target may prove to be the most 
important next stage in understanding the potential pharmaceutical benefit of these 
1,2-cyclopropyl carbohydrates. Unsuccessful target isolation and identification in this 
thesis was thought to be due to either the propargyl probe on compound 61 not 
extending out of the binding pocket or that the target was a membrane bound protein. 
To overcome these issues future work should initially focus on a membrane affinity 
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purification, which would isolate the target if it is membrane bound protein. If no 
target is isolated then the second attempt should focus on the derivatisation of the 
propargyloxycarbonyl in attempt to extend the alkane chain. This would potentially 
allow for the extension of the propargyl out of the binding pocket allowing it to 
interact with the modified matrix. 
 
4.2 Conclusion 
 
The initial aim of this Masters project was to synthesise a small library of 1,2-
cyclopropyl carbohydrates in order to test whether these compound were undergoing 
mechanism-based covalent binding through a cyclopropane ring opening reaction. 
This hypothesis was tested through the preparation of compounds 23 and the 
carboxyalky 1,2-cyclopropyl carbohydrate derivatives 54 and 61, which if subjected 
to an enzymatic nucleophilic attack at C-1 leading to a cyclopropane ring opening 
would be able to stabilise the carbanion formation through the electronegative 
chlorines of 23 and enolate stabilisation of 54 and 61. Successful synthesis of 23, 54 
and 61 was achieved in yields of 32%, 22% and 9% respectively over 7 steps. 
Chemical genetic profiling of compounds 23, 54 and 61 against a pdr1∆pdr3∆ yeast 
strain resulted in bioactivity in the low macromolar concentration indicating 
cyclopropane ring opening and carbanion formation as the likely mechanism of 
inhibition. 
 
As these compounds were found to be bioactive identification of the mechanism of 
action was undertaken with compound 23 and 54 through a chemical genetic analysis 
utilising a PDR-deficient yeast deletion strain, pdr1∆pdr3∆xxx∆ library. A high-
throughput assay identified a total of 132 resistant and 67 sensitive strains for 
compound 23 with 83 resistant and 106 sensitive strains for compound 54, which 
were all subjected further validation. Validated genes were subjected to a gene 
ontology analysis and enrichment was found in protein trafficking and localisation 
with notable involvement in vesicle tethering, revealed through chemical genetic 
interactions with the GARP, GOG, Sec63, Ssh1 and EMC complexes. Although no 
target protein was isolated through affinity purification the impressive specificity of 
chemical genetic screens strongly indicate the mechanism of action of the 1,2-
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cyclopropyl carbohydrates in protein localisation and vesicle tethering. A potential 
role for the exocyst complex in the mechanism of action of these compounds is 
proposed for future evaluation.  
 
Although much work still needs to be done through the chemical synthesis of more 
1,2-cyclopropyl carbohydrates derivatives and further biological analysis to better 
understand their mechanism of action, the use of 1,2-cyclopropyl carbohydrates as 
potential pharmaceuticals or probes of protein trafficking functions shows much 
promise.  
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Spectra 
 
1H NMR of the cyclopropane substrate 40 (500 MHz, CDCl3) 
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13C NMR of the cyclopropane substrate 40 (500 MHz, CDCl3) 
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1H NMR of the C-6 protected 1,2-cyclopropyl carbohydrate 41 (500 MHz, CDCl3) 
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13C NMR of the C-6 protected 1,2-cyclopropyl carbohydrate 41 (500 MHz, CDCl3) 
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1H NMR of the C-6 protected 1,2-cyclopropyl carbohydrate 41 (500 MHz, CDCl3) 
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13C NMR of the C-6 protected 1,2-cyclopropyl carbohydrate 42 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 23 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 23 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 43 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 43 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 54 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 54 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 55 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 55 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 56 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 56 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 61 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 61 (500 MHz, CDCl3) 
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1H NMR of the 1,2-cyclopropyl carbohydrate 62 (500 MHz, CDCl3) 
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13C NMR of the 1,2-cyclopropyl carbohydrate 62 (500 MHz, CDCl3) 
 
  
O OB
n
OH
Bn
O
1 2
3
45
6
7
8
O
O
9
10
11
62
pp
m
20
40
60
80
10
0
12
0
14
0
16
0
  
	158	
Chemical genetic hits 
Resistant Validations 
Compound 23 Compound 54 
ORF Gene ORF Gene 
YBL027W RPL19B YGL212W VAM7 
YBR089C-A NHP6B YHL033C RPL8A 
YBR161W CSH1 YML058W SML1 
YBR181C RPS6B YMR017W SPO20 
YBR266C SLM6 YMR085W YMR085W 
YBR267W REI1 YNL147W LSM7 
YDL082W RPL13A YOR106W VAM3 
YDL121C YDL121C YPL086C ELP3 
YDL128W VCX1 YPL120W VPS30 
YDR005C MAF1 YPL178W CBC2 
YDR250C YDR250C YPR043W RPL43A 
YDR375C BCS1 YGR055W MUP1 
YDR435C PPM1   
YEL013W VAC8   
YFL023W BUD27   
YFL036W RPO41   
YFR048W RMD8   
YGL024W YGL024W   
YGL174W BUD13   
YGL175C SAE2   
YGR037C ACB1   
YGR206W MVB12   
YHL033C RPL8A   
YHR081W LRP1   
YHR203C RPS4B   
YIL138C TPM2   
YIR005W IST3   
YJR032W CPR7   
YJR050W ISY1   
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YLL045C RPL8B   
YLR185W RPL37A   
YLR234W TOP3   
YLR345W YLR345W   
YLR346C YLR346C   
YLR371W ROM2   
YML010C-B YML010C-B   
YML035C AMD1   
YML058W SML1   
YML107C PML39   
YML129C COX14   
YMR017W SPO20   
YMR256C COX7   
YMR269W TMA23   
YMR269W YMR269W   
YMR282C AEP2   
YNL147W LSM7   
YNL169C PSD1   
YNL171C YNL171C   
YNL242W ATG2   
YNL246W VPS75   
YNL316C PHA2   
YOL089C HAL9   
YOL160W YOL160W   
YOR085W OST3   
YPL080C YPL080C   
YPL090C RPS6A   
YPL157W TGS1   
YPL178W CBC2   
YPL222W FMP40   
YPR043W RPL43A   
YPR191W QCR2   
 
Table 4.0: Resistant validated strain 1 
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Sensitive Validations 
  
Sesistant strains  
Compound 23 Compound 54 
ORF Gene ORF Gene 
YAL027W SAW1 YAL010C MDM10 
YAL028W FRT2 YAL027W SAW1 
YBL028C YBL028C YBL048W RRT1 
YBL047C EDE1 YBR022W POA1 
YBL048W RRT1 YBR036C CSG2 
YBR022W POA1 YBR089C-A NHP6B 
YBR023C CHS3 YBR171W SEC66 
YBR036C CSG2 YBR283C SSH1 
YBR042C CST26 YDL006W PTC1 
YBR043C QDR3 YDL020C RPN4 
YBR150C TBS1 YDR058C TGL2 
YBR171W SEC66 YDR074W TPS2 
YBR175W SWD3 YDR127W ARO1 
YBR194W AIM4 YDR207C UME6 
YBR283C SSH1 YEL031W SPF1 
YCL045C EMC1 YER090W TRP2 
YCL046W YCL046W YFL032W YFL032W 
YCR020C-A MAK31 YGL005C COG7 
YDL006W PTC1 YGL023C PIB2 
YDL020C RPN4 YGL133W ITC1 
YDL199C YDL199C YGR028W MSP1 
YDR056C YDR056C YGR080W TWF1 
YDR057W YOS9 YGR157W CHO2 
YDR058C TGL2 YGR188C BUB1 
YDR072C IPT1 YIL030C SSM4 
YDR074W TPS2 YIL036W CST6 
YDR123C INO2 YJL029C VPS53 
YDR127W ARO1 YJL192C SOP4 
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YDR183W PLP1 YJR040W GEF1 
YDR199W YDR199W YJR059W PTK2 
YDR294C DPL1 YJR087W YJR087W 
YDR297W SUR2 YJR088C EMC2 
YDR304C CPR5 YKL081W TEF4 
YDR305C HNT2 YKL207W EMC3 
YDR326C YSP2 YKR020W VPS51 
YEL031W SPF1 YKR072C SIS2 
YER002W NOP16 YKR082W NUP133 
YER019C-A SBH2 YLL014W EMC6 
YFL032W YFL032W YLR262C YPT6 
YFR024C-A LSB3 YLR338W OPI9 
YFR039C OSW7 YML013W UBX2 
YGL005C COG7 YML071C COG8 
YGL051W MST27 YML097C VPS9 
YGL085W LCL3 YMR123W PKR1 
YGL132W YGL132W YNL051W COG5 
YGL133W ITC1 YNL231C PDR16 
YGL230C YGL230C YNL257C SIP3 
YGL231C EMC4 YNR019W ARE2 
YGL261C PAU11 YNR021W YNR021W 
YGR017W YGR017W YOR026W BUB3 
YGR028W MSP1 YOR216C RUD3 
YGR079W YGR079W YPR060C ARO7 
YGR080W TWF1 YPR170C YPR170C 
YGR093W DRN1   
YGR100W MDR1   
YGR111W YGR111W   
YGR123C PPT1   
YGR157W CHO2   
YGR188C  BUB1   
YIR007W EGH1   
YJL029C VPS53   
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YJL095W BCK1   
YJL134W LCB3   
YJL135W YJL135W   
YJL150W YJL150W   
YJL192C SOP4   
YJR040W GEF1   
YJR073C OPI3   
YJR087W YJR087W   
YJR088C EMC2   
YJR108W ABM1   
YJR110W YMR1   
YJR145C RPS4A   
YKL063C YKL063C   
YKL081W TEF4   
YKL207W EMC3   
YKR020W VPS51   
YKR029C SET3   
YKR082W NUP133   
YLL014W EMC6   
YLR058C SHM2   
YLR262C YPT6   
YLR337C VRP1   
YLR338W OPI9   
YLR374C YLR374C   
YLR415C YLR415C   
YLR454W FMP27   
YML013W UBX2   
YML052W SUR7   
YML071C  COG8   
YML097C VPS9   
YML106W URA5   
YMR102C YMR102C   
YMR123W PKR1   
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YMR304W UBP15   
YNL051W COG5   
YNL079C TPM1   
YNL162W RPL42A   
YNL231C PDR16   
YNL238W KEX2   
YNL257C SIP3   
YNR019W ARE2   
YNR021W YNR021W   
YNR031C SSK2   
YOL087C DUF1   
YOR006C TSR3   
YOR026W BUB3   
YOR216C RUD3   
YOR265W RBL2   
YPL108W YPL108W   
YPL171C OYE3   
YPR170C YPR170C   
 
Table 4.1: Sensitive validated strain 1 
  
